Annual Report 2012Caring for the world, one person at a time…
inspires and unites the people of
Johnson & Johnson.
ONTHECOVER:
Michelle,anemployeewiththeJohnson&JohnsonFamilyof
Scan thisQR code toview
Companies,enjoystimewithheryoungdaughter,Alexis,while
adigital version of the 2012
grandmother,Jacqueline,lookson.Johnson&Johnsonhelpspeople
Johnson & Johnson Annual Report
allovertheworldcareforthehealthandwell-beingofthosethey
love,andtolivelonger,healthier,happierlives.CHAIRMAN’S LETTER
To Our Shareholders
A
sIbegantocomposethisletter,Irealizedhowquicklymyfirstyearhas
passedasChiefExecutiveOfficerofJohnson&Johnson.Ithasbeena
yearwithmanyrewardingmoments,aswellassomechallenges.Though
ayearoftransition,wemadesolidprogressonmanyfronts,including
buildingoutstrategicplatforms,whileestablishingexcitingnewones.
IamhonoredtobejusttheseventhCEOinourlonghistory.Thislegacyof
leadershipisatributetothesuccessandstabilityofJohnson&Johnson,andtothe
beliefintheimportanceofourpurposeheldincommonwithusbyourshareholders
oversomanydecades.Personally,Iamtrulyhumbledtoleadtheincrediblytalented
anddedicatedpeoplewhoworkforJohnson&Johnson.
Onechallengeallofusintheworldtodayfacetogetherishealthandhealthcare.
Thisistrueinbothdevelopedandemergingmarkets.Whencombinedwiththe
rapidlychangingdemographicsofanagingpopulation,agrowingmiddleclassand
thepersistenceofchronicdisease,thescaleandcomplexityoftheissueismagnified.
Itismybeliefthatprovidinghigh-qualityhealthcaretopatientsandconsumers
ALEXGORSKY
aroundtheworldinasustainablemannerissociety’sgreatestchallenge.Butitisalso
Chairman,BoardofDirectors,and
thegreatesthopeforabetterfutureforeveryindividual,everyfamily,every
ChiefExecutiveOfficer
communityandeverycountry.
Johnson&Johnsonworksattheverycenterofthischallenge,acrossthebroadestbaseofanycompanyinglobalhealthcare.Every
day,weareworkingtohelppeopleeverywherelivelonger,healthier,andhappierlives.Werecognizethatwithourgloballeadership
comesaresponsibility;oneweconsideraprivilege.I’mpleasedwithhowwearemeetingthatresponsibility,butI’mfarfromsatisfied.
ThepassinglastfallofformerCEOJamesBurkeremindedusallthatthesimplesetofbeliefsdefinedinOurCredocanguideour
Companythroughallthechallengesandcomplexitiesoftheseoranytime.MyoverarchinggoalasCEOistoensurethatournearly
128,000employeesinmorethan275operatingcompaniesaroundtheworldwillalwaysbeunitedbyOurCredoandoursingle
purpose:Caringfortheworld,onepersonatatime.
LEGACYOFCARING
ThatpurposewasatworkhereinNewJersey,thehomestateofJohnson&Johnson,whenHurricaneSandyroaredthroughsomany
communitieslastyear.ImmediatelypartneringwiththeAmericanRedCross,SavetheChildren,AmeriCaresandotherdisaster-
assistancegroups,Johnson&Johnsonwasabletohelpprovideaidandrelief.Weprovidedmorethan20,000first-aidkitsthatwere
usedbyemergencyresponders.Weprovidedtheblanketsthatwarmedfamiliesinshelters.Weweretherewithmorethan$5million
infunding,respondingtothegovernorsofthreestatesinthisregion.Mostimportantly,ourpeoplewerethereintheirown
communities.Immediatelyandwithouthesitation,theywereonthefrontlinesofresponseandreliefeffortswhereverandhowever
theycould.
Itisthisexampleofcaringbyindividualsthatinspirescaringinthewholecommunity,andremindsmeofhowfirmlyand
fundamentallycompassioniswovenintothefabricofourculture.Thislegacyofcaringcontinuesaswerenewourcommitmentto
philanthropyandcitizenshipallovertheworld.Wewilllooktogobeyondreliefandrebuilding,andexploreprogramsthatwillmake
communitiesmoreresilientandpreparethemtoendureanykindofdisaster,beitnaturaloreconomic.
2012BUSINESSRESULTS
Oursolidbusinessresultsin2012wereachievedwhilecontinuingtodelivermeaningfulinnovationinhealthcaretopatientsand
customers.
• WegeneratedsignificantcashflowandmaintainedourAAAcreditrating.Importantly,wecontinuedourtrackrecordof
consistentperformance,with29straightyearsofadjustedearnings*increasesand50consecutiveyearsofdividendincreases.
Johnson&JohnsonisoneofonlysixcompaniesintheStandard&Poor’s100Indextoachievethatrecord.
• InourPharmaceuticalsbusinesssegment,ourresultsincludedstronggrowthofkeyproductsandsuccessfulnewlaunches.
Asaresultofourcontinuingcommitmenttoresearchanddevelopment,collaborationandinnovation,weexpectto
maintainstrongmomentum.Wecontinuetomakeimportantinvestmentsinbuildingstrategicpartnershipsandadvancing
ourpipeline,positioninguswelltodeliversustainablegrowthin2013andbeyond.
CHAIRMAN’SLETTER• TheadditionofSynthes,Inc.toourfamilyofcompaniesmarkedthelargestacquisitioninourhistoryand,combined
withDePuy,createstheworld’slargest,mostcomprehensiveorthopaedicsandneurologicsbusiness,theDePuySynthes
Companies.WewillcontinuetheexcitingintegrationofSynthesintoourMedicalDevicesandDiagnosticsbusiness
segmentinthecomingyear.
• InourConsumerbusinesssegment,wewillcontinuerestoringareliablesupplyofourMcNeilover-the-counter
medicines.Theworktobringourplantsfullyonlineisprogressing.Weexpecttoreturnaconsistentsupplyofkey
productstothemarketoverthecourseof2013.Wearedefinitelymakinggoodprogress;however,wemustmovefrom
goodtogreatthisyear.
MoredetailsontheprogressofourthreebusinesssegmentscanbefoundintheBusinessSegmentHighlightssectionofthis
AnnualReport.
ENSURINGROBUSTGROWTH
WithinthecontextofOurCredoandstrategicframeworktherearespecificareasoffocusforJohnson&Johnson—ourGrowth
Drivers—thatwillhelpensurerobustgrowthforthefuture.
• Firstisourcommitmenttoinnovationtocreatevalue;notjustinnovationinproductsandservices,butineverythingwe
doandeverywhereweoperate.Weneedaconstantflowofnewideasanddifferentapproachestomeetthechallengesand
opportunitiesofthefuture.
• Second,ourglobalreachmustbebroughttolifewithalocalfocus.Thatputscriticaldecision-makingwheretheneedsare
andwhereourglobalresourceslive.Webelieveourcommitmenttodecentralizedmanagementprovidesacompetitive
advantageinallofourbusinessesandallofourmarkets.
• Third,wewillhavealaserfocusonexcellenceinexecution.Acrossourenterprise,wehavebuiltgreateraccountabilityfor
qualityintotherequirementsforallofourleaders.Thishasstrengthenedqualityandcomplianceattheenterpriselevelby
takingspecificstepstoreducevariationandincreasegovernance.We’veredefinedstandardsandprocessesinoursupply
chainto,mostimportantly,improvethelevelofexecution,andtodeliverefficienciesthatcanfreeresourcesfor
investment.
• Fourth,wewillcontinuetofosterapurpose-drivenorganizationanddevelopleadershipateverylevelofourCompany.
Thisisessentialforustodeliverontheresponsibilitiesthatcomealongwithourgloballeadership.
ADDRESSINGAGLOBALCHALLENGE
Ourbroadbaseinhealthcaregivesusauniqueperspectiveontheneeds,fears,frustrationsandhopesofconsumers,patients,their
familiesandhealthprofessionalsworldwide.Ibelievethatahealthierworldisnotjustahappierworld,butalsoonethathasmuch
greatereconomicstabilityandprovidesafoundationforindividualandsocietaladvancement.I’mveryproudoftheprogresswe
havemadetowardourpurposeofcaringfortheworld,onepersonatatime.Butallofusarekeenlyawareofthegapsthatstillexist
intheworld.
Forexample,thereisagapinaccesstobasichealthcare.Whetherbecauseofalackoftrainedprofessionals,inadequate
infrastructureorculturalobstacles,addressingthisgapisakeylong-termgoalforusastheleaderinglobalhealthcare.
Thereisagapinadequatementalhealthcareservices.Thishascometopublicattentioninglaringexamplesofrecenttragediesin
theUnitedStates.Again,thisgapmaybearesultofalackoftrainedprofessionalsorthestigmathattoooftenpreventspeoplefrom
seekinghelp.
Thereisagapinpreventivemedicinethatoftenfocusessocietieson“sickcare”ratherthanhealthcare.Thisisaparticularfocus
forme,andforallofusatJohnson&Johnson,notonlybecauseofthedepthoftheproblem,butalsobecauseofthescopeofthe
opportunity.
Canweclosethesegaps?Wearecommittedtoconveningadialoguethatrecognizesandaddressesthesesignificantgapsin
caring.Wewillworkwithcommunitiesandlocalpartnersaroundtheworldtotakemeaningfulactiontoimprovepeople’slives.
That’saglobalchallengeweaimtoaddress.Workingtogetherwecan…andwemust.
OURINSPIRATION
Thechallengeswefaceinthisever-changinghealthcarelandscapewillrequiretime,vigilanceanddedicationtosolve.Allofushere
atJohnson&Johnsonrealizeweareonajourney.Everyday,though,Iaminspiredbyyetanotherstoryofhowwehavedeliveredon
OurCredo.
JOHNSON&JOHNSON2012ANNUALREPORTThisyearwe’vecreatedafullyinteractive,digital,onlineannualreportwhereyoucanfindourStoriesofCaring.Hereareafew
examplestogiveyouanideaofthebreadthofthismosaic:
• AshaisamotherraisingchildreninBangladesh,wherereliablehealthinformationcansometimesbehardtofind.After
strugglingwiththehealthofherfirstchild,Ashaisnowbetterpreparedtotakecareofhernewdaughterthankstovital
®
healthmessagesdeliveredbytexttohermobilephone.Johnson&JohnsonandBabyCenter arefoundingpartnersina
uniquecollaborationtoimprovethelivesofpregnantwomen,newmothersandtheirfamiliesindevelopingcountries.
• ForBill,reachinghis80thbirthdaywasmorethanamilestone.Afteradiagnosisofprostatecancerseveralyearsagoanda
®
seriesoftreatments,hedidn’tknowwhatwouldlieahead.Nowhe’sonZYTIGA (abirateroneacetate),andhe’s
spendingcherishedtimewiththepeopleheloves—andtrulycelebratingthat80thbirthday.
• Braydonisanormalteenagerinmanyways.Helovestohangoutwithhisfriends,playgolf,doworkwithhisdad.Allthis
despitebeingbornwithseverescoliosisthatcausedhisspinetocurve,fusedhisribsandthreatenedtoleavehim
®
wheelchair-boundandunabletobreathewithouthelp.ThankstotheinnovativeVEPTR procedure,fromDePuy
SynthesSpine,Braydoncangoaboutlivinglifetothefullest.
YoucanfindtheseandotherStoriesofCaring,aswellasmuchmore,atwww.2012annualreport.jnj.com.Ihopeyou’lllikethese
storiessomuchthatyou’lldecidetosharethem,andourdigitalannualreport,withfamilyandfriends.
MYCOMMITMENTTOYOU
Ourleadershipinhealthcarehasbeenmadepossiblebythebeliefinourmissionthatyousharewithus.Iamcommittedto
continuingtheproudtraditionofJohnson&Johnsonasapurpose-ledorganization,callingonthegreatrangeanddiversityofour
worldwidetalentandcapabilities.WewillfurtherdedicateourselveseverydaytotheresponsibilitiesdefinedinOurCredo,thefirst
beingourresponsibilityto“thedoctors,nursesandpatients,themothersandfathersandallwhouseourproducts”everyday.We’ll
alsocontinueourcommitmenttoouremployees,andtothecommunitiesinwhichweoperateandproudlycallhome.Andtoyou,
ourvaluedshareholders,whohaveplaceyourconfidenceandtrustinus.
ThisisourlegacyatJohnson&Johnson.Atlastyear’sannualshareholdermeeting,Idescribedmyselfasarealisticoptimist,and
despiteourchallenges,Ifirmlybelievethereisnocompanybetterpositionedtoberecognizedastheworld’sleaderinhealthcare.
Sincerely,
AlexGorsky
Chairman,BoardofDirectors,andChiefExecutiveOfficer
March13,2013
* Excludesspecialitems
CHAIRMAN’SLETTER2012 Business Segment Highlights
Johnson&Johnsondeliveredsolidresultsin2012,reflectingcontinuedsalesmomentuminmanypartsofourbusiness
drivenbyourfocusondeliveringmeaningfulinnovationinhealthcaretopatientsandcustomers.Ourresultsincluded
stronggrowthofkeyproducts,successfulnewproductlaunches,andtheadditionofSynthestoourfamilyofcompanies.
Inaddition,wecontinuedtomakeimportantinvestmentsbuildingstrategicpartnershipsandinadvancingourpipeline,
positioninguswellfordeliveringsustainablegrowth.
Pharmaceutical Segment Sales Medical Devices and Diagnostics Consumer Segment Sales
Sales by Therapeutic Area (in billions of dollars) Segment Sales Sales by Major Franchise (in billions of dollars)
2012 Sales: $25.4 billion Sales by Major Franchise (in billions of dollars) 2012 Sales: $14.4 billion
Sales Change: 2012 Sales: $27.4 billion Sales Change:
Total: 4.0% Sales Change:1 Total: (2.9%)
Operational*: 6.8% Total: 6.4% Operational*: 0.5%
$ (O 5 8T .. 3H 0 %ER )** Operational*: 8.7% VI $S IO 3 2.7N .
%
0CARE
CARD $I O C 2V AA .R 0S ECULAR WOMEN’S HEALTH
WO $U O
(
3N 1T .8D .H %0 EC )RARE/ B
$
A (2B 3Y
.. 7 2
%CA )*R *E
(13.2%) $ 1.6
ONCOLOGY SURGICAL CARE (9.3%)
$ 2.6 $ 6.5
28.4% (2.3%) DIABETES CARE
$ 2.6 ORAL CARE
$ 1.6
IMM $ U 7N .O 9LOGY (1.4%) 0.0%
15.8%
DIAGNOSTICS
$ 2.1
NEU $R 6OS .C 7IENCE SPECI $A L 2TY . 5SURGERY (4.4%) S $K IN 3 C .6ARE
(3.3%) 4.9% PREVIENNFTECIOTNIO/ONT HER (2.6%)
$ 0.9**
5.1%
OTC AND
INFECT $I O 3U .S 2 DISEASES ORT $H O 7P .A 8EDICS1 NU $T R 4IT .IO 4NALS
0.2% 34.3% (1.1%)
* Operational excludes the impact of currency. (1) Excluding the net impact of the Synthes acquisition, MD&D
** Rounded for visual accuracy. total change = (1.5%) and Orthopaedics total change = (0.4%)
PHARMACEUTICALS
With$25.4billioninworldwidesalesin2012,wearetheeighth-largestpharmaceuticalsbusinessintheworldandthe
®
sixth-largestbiotechbusiness.Primarycontributorstostrongoperationalgrowthof6.8percentincludeREMICADE
(infliximab),abiologicapprovedforthetreatmentofanumberofimmune-mediatedinflammatorydiseases;
® ®
VELCADE (bortezomib),atreatmentformultiplemyeloma;PREZISTA (darunavir),atreatmentforHIV;anda
numberofrecentlylaunchedproducts.
Weareacceleratinggrowthwhileensuringgreateraccessandreimbursementbyimplementingstronglaunch
®
programsforrecentlyapprovedproductsincludingZYTIGA (abirateroneacetate),anoral,once-dailymedicationfor
®
useincombinationwithprednisoneforthetreatmentofmetastatic,castration-resistantprostatecancer;INVEGA
® ®
SUSTENNA /XEPLION (paliperidonepalmitate),aonce-monthly,long-acting,injectableatypicalantipsychoticfor
®
treatmentofschizophreniainadults;INCIVO (telaprevir),adirect-actingantiviralproteaseinhibitorforthetreatment
®
ofgenotype-1chronichepatitisCvirus,incombinationwithpeginterferonalfaandribavirin,inadults;STELARA
®
(ustekinumab),abiologicapprovedforthetreatmentofadultswithmoderatetosevereplaquepsoriasis;XARELTO
®
(rivaroxaban),anoralanticoagulant;andSIMPONI (golimumab),abiologicapprovedtotreatadultswithmoderately
toseverelyactiverheumatoidarthritis(RA),activepsoriaticarthritisandactiveankylosingspondylitis.
2012 BUSINESS SEGMENTHIGHLIGHTS®
SalesresultswerenegativelyimpactedbygenericcompetitionforLEVAQUIN (levofloxacin),atreatmentfor
®
bacterialinfections,andthemanufacturingsuspensionatathird-partysupplierforDOXIL (doxorubicinHCl
®
liposomeinjection)/CAELYX (pegylatedliposomaldoxorubicinhydrochloride),amedicationtotreatovarian
andothercancers.
™
InDecember,theU.S.FoodandDrugAdministration(FDA)grantedacceleratedapprovalforSIRTURO
(bedaquiline)tabletsforthetreatmentofpulmonarymulti-drug-resistanttuberculosisaspartofcombinationtherapy
inadults.ItiscurrentlyunderreviewbythreeregulatorybodiesincludingtheEuropeanMedicinesAgency(EU),State
FoodandDrugAdministration(China)andMedicinesControlCouncil(SouthAfrica).TheFDAandtheEuropean
®
CommissionalsoapprovedanexpandedindicationforZYTIGA (abirateroneacetate),incombinationwith
prednisone,allowingfortheusebeforechemotherapyinthetreatmentofmetastaticcastration-resistantdisease.
®
InNovember,theFDAapprovedadditionalindicationsforXARELTO (rivaroxaban)forthetreatmentofdeep
veinthrombosis(DVT)and/orpulmonaryembolism(PE),andtoreducetheriskofrecurrenceofDVTandPE
®
followinginitialtreatment.Inaddition,theFDAapprovedanew800mgtabletofPREZISTA (darunavir)for
once-dailyoraladministrationforthetreatmentofhumanimmunodeficiencyvirus(HIV-1)intreatment-naive
andtreatment-experiencedadultpatientswithnodarunavirresistance-associatedmutations.
®
InAugust,theFDAapprovedthesupplementalNewDrugApplicationforNUCYNTA ER(tapentadol)
extended-releasetabletsforthemanagementofneuropathicpainassociatedwithdiabeticperipheralneuropathy
®
inadults.InSeptember,theEuropeanCommissionapprovedthemarketingauthorizationforDACOGEN
(decitabine)forthetreatmentofadultpatients(age65yearsandabove)withnewlydiagnoseddenovoor
®
secondaryacutemyeloidleukemia,andforthesubcutaneousadministrationofVELCADE (bortezomib)forthe
treatmentofmultiplemyeloma.
Wehaveanexcitingandlate-stagepipelineofdifferentiatedmedicines.NewDrugApplicationsarepresently
underreviewintheUnitedStatesandintheEuropeanUnionseekingapprovalforINVOKANA*(canagliflozin),
ourfirstpharmaceuticaltreatmentforpatientswithtype2diabetes.Additionalsubmissionsincludeda
supplementalBiologicsLicenseApplicationtotheFDAandaTypeIIVariationtotheEuropeanMedicines
®
AgencyrequestingapprovalofSTELARA (ustekinumab)forthetreatmentofadultswithactivepsoriaticarthritis
®
andofSIMPONI (golimumab)forthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitis.A
BiologicsLicenseApplicationwasalsosubmittedtotheFDAseekingapprovalofintravenous(I.V.)golimumab
forthetreatmentofmoderatelytoseverelyactiveRA.
*Proposedtradename
MEDICALDEVICESANDDIAGNOSTICS
With$27.4billioninworldwidesalesin2012,ourMedicalDevicesandDiagnostics(MD&D)businessisthelargest
medicaltechnologybusinessintheworld.Operationalgrowthwas8.7percent.Salesincludedtheimpactofthe
recentlycompletedacquisitionofSynthes,Inc.,whichcontributed7.9percenttoworldwideMD&Dsegment
operationalsalesgrowth,netofthedivestitureoftheDePuytraumabusiness.Primarycontributorstooperational
growthweresalesfromtherecentlycompletedacquisitionofSynthes,Inc.intheOrthopaedicsbusiness;anumberof
productsintheSpecialtySurgerybusiness;electrophysiologyproductsintheCardiovascularCarebusinessof
BiosenseWebster,Inc.;disposablecontactlensesfromVistakonDivisionofJohnson&JohnsonVisionCare,Inc.
Whileoverallmarketgrowthhasslowed,we’vebeenfocusingonbuildingourmarketleadershippositionand
weholdNo.1orNo.2positionsin80percentofourkeyplatforms.
Wecontinuetoinvestforlong-termsustainablegrowthandcompletedthelargestacquisitioninourhistory
withSynthes.InJune,DePuyandSynthesjoinedtoformtheworld’slargest,mostcomprehensiveorthopaedics
andneurologicsorganization.Atotalsolutionsbusiness,DePuySynthesoffersanunparalleledbreadthanddepth
ofproducts,servicesandprogramsintheareasofjointreconstruction,trauma,spine,sportsmedicine,
neurological,craniomaxillofacial,powertoolsandbiomaterials,andhastheopportunitytocontributeingreater
waystomeettheneedsoftoday’sdynamichealthcareenvironment.
™
In2012,theFDAapprovedEVARREST FibrinSealantPatch,anovelproductthatrapidlyandreliablyaidsin
® ®
stoppingproblematicbleedingduringsurgery.TheFDAalsoapprovedtheS.M.A.R.T. CONTROL Vascular
StentSystemsforuseinthesuperficialfemoralarteryand/ortheproximalpoplitealartery.TheHARMONIC
®
ACE +ShearswithAdaptiveTissueTechnology,strengtheningourpositioninthefast-growingEnergymarket,
wasalsoapprovedbytheFDAin2012.
JOHNSON&JOHNSON2012 ANNUAL REPORT®
Earlierintheyear,EthiconEndo-Surgery,Inc.receivedanapprovableletterfortheSEDASYS System,a
computer-assistedpersonalizedsedationsystem,fromtheFDA’sCenterforDevicesandRadiologicalHealth.In
® ™
addition,BiosenseWebster’sTHERMOCOOL SMARTTOUCH ContactForceSensingCatheterreceivedCE
MarkclearanceinEurope.Thecatheterprovidesreal-timeinformationaboutthepreciseamountanddirectionof
theforcebeingappliedduringcardiacablationprocedures.
We’reexpandingourglobalpresencewithstronggrowthinemergingmarkets.Andaswelooktothefuture,
we’readvancinginnovativenewproductsinourpipeline,continuingtotakeadisciplinedapproachtomanaging
ourportfolioandadaptingourbusinesstothechangingmarketplace.
CONSUMER
With$14.4billioninworldwidesalesin2012,ourConsumerbusinessisthesixth-largestconsumerhealthcare
businessintheworld.Operationalgrowthwas0.5percent.WeremaincommittedtostrengtheningtheConsumer
businessstartingbycontinuingtorestoreareliablesupplyofourMcNeilover-the-counter(OTC)productstothe
U.S.market.
Meanwhile,positivecontributorstooperationalresultsweresalesofupperrespiratoryOTCproductsoutside
® ®
theU.S.;internationalsalesofLISTERINE oralcareproducts;andU.S.salesofNEUTROGENA skincare
products.
OurinvestmentsforgrowthinConsumerwillbepredicatedonafocusedproductportfolioapproachtodeliver
science-basedproductswithlocalmarketinsights,professionalendorsementsandcommercialexcellence.
Wehavetakenstepstoreshapeourportfolioandhavedivestednon-strategicproductsorbrands.Wearealso
investingingrowthandexpansioninemergingmarketsthroughtheacquisitionofmarket-specificbrandslike
®
DOKTORMOM coughcoldproductsinRussiaandShanghaiElskerMother&BabyCo.Ltd.inChina.We’re
® ®
alsocontinuingtoleveragethestrengthofouriconicbrandslikeJOHNSON’S BabyandNEUTROGENA .
RegardingMcNeil,we’recontinuingtooperateinaccordancewiththeconsentdecree.We’veachievedall
commitmentstodateundertheremediationworkplan,whichwasapprovedbytheFDAin2012.Theworkto
bringourplantsfullyonlineisprogressing.Weexpecttoreturntoaconsistentsupplyofkeyproductstothe
marketoverthecourseof2013.Oureffortscontinuetobeintheinterestofservingcustomers,consistentwiththe
responsibilitiesoutlinedinOurCredo.
NOTEONFORWARD-LOOKINGSTATEMENTS
ThisAnnualReportcontains“forward-lookingstatements”asdefinedinthePrivateSecuritiesLitigationReformActof1995.
Thereaderiscautionednottorelyontheseforward-lookingstatements.Thesestatementsarebasedoncurrentexpectationsof
futureevents.Ifunderlyingassumptionsproveinaccurateorunknownrisksoruncertaintiesmaterialize,actualresultscould
varymateriallyfromtheexpectationsandprojectionsofJohnson&Johnson.Risksanduncertaintiesinclude,butarenotlimited
to,generalindustryconditionsandcompetition;economicfactors,suchasinterestrateandcurrencyexchangeratefluctuations;
technologicaladvances,newproductsandpatentsattainedbycompetitors;challengesinherentinnewproductdevelopment,
includingobtainingregulatoryapprovals;significantadverselitigationorgovernmentaction;impactofbusinesscombinations;
changesinbehaviorandspendingpatternsorfinancialdistressofpurchasersofhealthcareproductsandservices;changesto
governmentallawsandregulationsanddomesticandforeignhealthcarereforms;trendstowardhealthcarecostcontainment;
increasedscrutinyofthehealthcareindustrybygovernmentagencies;manufacturingdifficultiesordelays;andproductefficacy
orsafetyconcernsresultinginproductrecallsorregulatoryaction.Afurtherlistanddescriptionoftheserisks,uncertaintiesand
otherfactorscanbefoundinExhibit99ofJohnson&Johnson’sAnnualReportonForm10-Kforthefiscalyearended
December30,2012.CopiesofthisForm10-K,aswellassubsequentfilings,areavailableon-lineatwww.sec.gov,
www.investor.jnj.comoronrequestfromJohnson&Johnson.Johnson&Johnsondoesnotundertaketoupdateany
forward-lookingstatementsasaresultofnewinformationorfutureeventsordevelopments.
2012 BUSINESS SEGMENTHIGHLIGHTSMANAGEMENT’SDISCUSSIONANDANALYSIS OFRESULTS
OFOPERATIONSANDFINANCIALCONDITION
OrganizationandBusinessSegments 2
ResultsofOperations 3
AnalysisofSalesbyBusinessSegments 4
AnalysisofConsolidatedEarningsBeforeProvisionforTaxesonIncome 8
LiquidityandCapitalResources 11
OtherInformation 14
CautionaryFactorsThatMayAffectFutureResults 19
AUDITEDCONSOLIDATEDFINANCIALSTATEMENTS
ConsolidatedBalanceSheets 20
ConsolidatedStatementsofEarnings 21
ConsolidatedStatementsofComprehensiveIncome 22
ConsolidatedStatementsofEquity 23
ConsolidatedStatementsofCashFlows 24
NotestoConsolidatedFinancialStatements 25
ReportofIndependentRegisteredPublicAccountingFirm 69
Management’sReportonInternalControlOverFinancialReporting 70
SUPPORTINGSCHEDULES
SummaryofOperationsandStatisticalData2002–2012 71
ShareholderReturnPerformanceGraphs 72
Johnson&Johnson2012AnnualReport • 1Management’s Discussion and Analysis of
Results of Operations and Financial Condition
Organization and Business Segments
DescriptionoftheCompanyandBusinessSegments
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately127,600employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevicesand
Diagnostics.TheConsumersegmentincludesabroadrangeofproductsusedinthebabycare,skincare,oralcare,
woundcareandwomen’shealthfields,aswellasnutritionalandover-the-counterpharmaceuticalproductsandwellness
andpreventionplatforms.Theseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutletsand
distributorsthroughouttheworld.ThePharmaceuticalsegmentincludesproductsinthefollowingareas:anti-infective,
antipsychotic,contraceptive,gastrointestinal,hematology,immunology,infectiousdiseases,neurology,oncology,pain
management,thrombosisandvaccines.Theseproductsaredistributeddirectlytoretailers,wholesalersandhealthcare
professionalsforprescriptionuse.TheMedicalDevicesandDiagnosticssegmentincludesabroadrangeofproducts
distributedtowholesalers,hospitalsandretailers,usedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals
andclinics.Theseincludeproductstotreatcardiovasculardisease;orthopaedicandneurologicalproducts;bloodglucose
monitoringandinsulindeliveryproducts;generalsurgery,biosurgicalandenergyproducts;professionaldiagnostic
products;infectionpreventionproducts;anddisposablecontactlenses.
TheCompany’sstructureisbasedupontheprincipleofdecentralizedmanagement.TheExecutiveCommitteeof
Johnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategicoperationsandallocationofthe
resourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesoftheConsumer,Pharmaceuticaland
MedicalDevicesandDiagnosticsbusinesssegments.
Inallofitsproductlines,theCompanycompeteswithcompaniesbothlocallyandglobally,throughouttheworld.
Competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.
Competitioninresearch,involvingthedevelopmentandtheimprovementofnewandexistingproductsandprocesses,is
particularlysignificant.ThedevelopmentofnewandinnovativeproductsisimportanttotheCompany’ssuccessinall
areasofitsbusiness.ThisalsoincludesprotectingtheCompany’sportfolioofintellectualproperty.Thecompetitive
environmentrequiressubstantialinvestmentsincontinuingresearchandinmaintainingsalesforces.Inaddition,the
developmentandmaintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvessignificant
expendituresforadvertisingandpromotion.
Management’sObjectives
TheCompanymanageswithinastrategicframeworkaimedatachievingsustainablegrowth.Toaccomplishthis,the
Company’smanagementoperatesthebusinessconsistentwithcertainstrategicprinciplesthathaveprovensuccessful
overtime.Tothisend,theCompanyparticipatesingrowthareasinhumanhealthcareandiscommittedtoattaining
leadershippositionsinthesegrowthareasthroughthedevelopmentofhighquality,innovativeproductsandservices.New
productsintroducedwithinthepastfiveyearsaccountedforapproximately25%of2012sales.In2012,$7.7billion,or
11.4%ofsales,wasinvestedinresearchanddevelopment.Thisinvestmentreflectsmanagement’scommitmenttothe
importanceofongoingdevelopmentofnewanddifferentiatedproductsandservicestosustainlong-termgrowth.
Withmorethan275operatingcompanieslocatedin60countries,theCompanyviewsitsprincipleofdecentralized
managementasanassetandfundamentaltothesuccessofabroadlybasedbusiness.Italsofostersanentrepreneurial
spirit,combiningtheextensiveresourcesofalargeorganizationwiththeabilitytoanticipateandreactquicklytolocal
marketchangesandchallenges.
2 • Johnson&Johnson2012AnnualReportTheCompanyiscommittedtodevelopingglobalbusinessleaderswhocanachievegrowthobjectives.Businessesare
managedforthelong-terminordertosustainleadershippositionsandachievegrowththatprovidesanenduringsourceof
valuetoourshareholders.
OurCredounifiesthemanagementteamandtheCompany’sdedicatedemployeesinachievingtheseobjectives,and
providesacommonsetofvaluesthatserveasaconstantreminderoftheCompany’sresponsibilitiestoitscustomers,
employees,communitiesandshareholders.TheCompanybelievesthatthesebasicprinciples,alongwithitsoverall
missionofimprovingthequalityoflifeforpeopleeverywhere,willenableJohnson&Johnsontocontinuetobeamongthe
leadersinthehealthcareindustry.
Results of Operations
AnalysisofConsolidatedSales
In2012,worldwidesalesincreased3.4%to$67.2billion,comparedtoanincreaseof5.6%in2011andadecreaseof
0.5%in2010.Thesesaleschangesconsistedofthefollowing:
Salesincrease/(decrease)dueto: 2012 2011 2010
Volume 5.7% 3.1 (0.5)
Price 0.4 (0.3) (0.8)
Currency (2.7) 2.8 0.8
Total 3.4% 5.6 (0.5)
SalesbyU.S.companieswere$29.8billionin2012,$28.9billionin2011and$29.5billionin2010.Thisrepresentsan
increaseof3.2%in2012,anddecreasesof1.8%in2011and4.7%in2010.Salesbyinternationalcompanieswere
$37.4billionin2012,$36.1billionin2011and$32.1billionin2010.Thisrepresentsincreasesof3.5%in2012,12.4%
in2011and3.6%in2010.TheacquisitionofSynthes,Inc.,netoftherelateddivestiture,increasedbothtotalworldwide
salesgrowthandoperationalgrowthby3.1%.
Thefive-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere1.9%,(1.7)%and5.5%,
respectively.Theten-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere6.4%,2.9%and
10.4%,respectively.
SalesinEuropeexperiencedadeclineof1.1%ascomparedtotheprioryear,includingoperationalgrowthof5.8%offset
byanegativecurrencyimpactof6.9%.SalesintheWesternHemisphere(excludingtheU.S.)achievedgrowthof12.3%
ascomparedtotheprioryear,includingoperationalgrowthof19.0%andanegativecurrencyimpactof6.7%.Salesinthe
Asia-Pacific,Africaregionachievedgrowthof5.3%ascomparedtotheprioryear,includingoperationalgrowthof6.7%
andanegativecurrencyimpactof1.4%.
In2012,2011and2010,theCompanydidnothaveacustomerthatrepresented10%ormoreoftotalconsolidated
revenues.
U.S.HealthCareReform
UndertheprovisionsofthePatientProtectionandAffordableCareActandtheHealthCareandEducationReconciliation
Actof2010,beginningin2011,companiesthatsoldbrandedprescriptiondrugstospecifiedU.S.Governmentprograms
payanannualnon-taxdeductiblefeebasedonanallocationofeachcompany’smarketshareoftotalbrandedprescription
drugsalesfromtheprioryear.Thefull-yearimpacttoselling,marketingandadministrativeexpenseswasapproximately
$115millionin2012and$140millionin2011.Underthecurrentlaw,beginningin2013,theCompanywillberequired
topayataxdeductible2.3%excisetaximposedonthesaleofcertainmedicaldevices.The2013excisetaxisestimated
tobebetween$200-$300millionandwillberecordedincostofproductssoldwithinthestatementofearnings.
Thenettradesalesimpactofthehealthcarereformlegislationwasanannualreductionofapproximately$450millionand
$425millionin2012and2011,respectively,duetoanincreaseinsalesrebatesanddiscounts.
Johnson&Johnson2012AnnualReport • 3Analysis of Sales by Business Segments
ConsumerSegment
Consumersegmentsalesin2012were$14.4billion,adecreaseof2.9%from2011,whichincluded0.5%operational
growthoffsetbyanegativecurrencyimpactof3.4%.U.S.Consumersegmentsaleswere$5.0billion,adecreaseof
2.0%.Internationalsaleswere$9.4billion,adecreaseof3.4%,whichincluded1.9%operationalgrowthoffsetbya
negativecurrencyimpactof5.3%.
MajorConsumerFranchiseSales:
%Change
(DollarsinMillions) 2012 2011 2010 ’12vs.’11 ’11vs.’10
OTCPharmaceuticals&Nutritionals $4,354 4,402 4,549 (1.1)% (3.2)
SkinCare 3,618 3,715 3,452 (2.6) 7.6
BabyCare 2,254 2,340 2,209 (3.7) 5.9
Women’sHealth 1,625 1,792 1,844 (9.3) (2.8)
OralCare 1,624 1,624 1,526 0.0 6.4
WoundCare/Other 972 1,010 1,010 (3.8) 0.0
TotalConsumerSales $14,447 14,883 14,590 (2.9)% 2.0
TheOver-the-Counter(OTC)PharmaceuticalsandNutritionalsfranchisesaleswere$4.4billion,adecreaseof1.1%from
2011.SalesintheU.S.decreasedprimarilyduetolowersalesofanalgesicsasaresultofsupplyconstraintsand
competitivepressuresinnutritionalproducts.Stronggrowthofupperrespiratory,digestivehealthandanalgesicsproducts
outsidetheU.S.wasoffsetbynegativecurrency.
McNEIL-PPC,Inc.,continuestooperateunderaconsentdecreesignedin2011,withtheU.S.FoodandDrug
Administration(FDA),whichgovernscertainMcNeilConsumerHealthcaremanufacturingoperations.McNeilcontinuesto
operatethemanufacturingfacilitiesinLasPiedras,PuertoRicoandLancaster,Pennsylvania;however,productionvolumes
fromthesefacilitiescontinuetobeimpactedbyadditionalreviewandapprovalprocessesrequiredundertheconsent
decree.TheCompanyexpectsthistocontinuethroughoutmostof2013.Plantsoperatingundertheconsentdecreewill
produceasimplifiedportfoliofocusedonkeybrands.TheFortWashington,Pennsylvaniamanufacturingsiteisnotin
operationatthistime.McNeilcontinuestoworkonthere-sitingoftheproductspreviouslyproducedattheFort
Washingtonfacilitytootherfacilities.
TheSkinCarefranchisesaleswere$3.6billionin2012,adecreaseof2.6%from2011.Increasedsalesof
NEUTROGENA®productsintheU.S.wereoffsetbycompetitionandeconomicconditionsoutsidetheU.S.TheBaby
Carefranchisesaleswere$2.3billion,adecreaseof3.7%from2011.ThedeclineinU.S.salesandtheimpactof
negativecurrencywaspartiallyoffsetbyincreasedsalesofhaircareandwipesoutsidetheU.S.TheWomen’sHealth
franchisesaleswere$1.6billion,adecreaseof9.3%primarilyduetotheimpactofthedivestitureofcertainbrands.The
OralCarefranchisesaleswereflatascomparedtotheprioryear.IncreasedsalesofLISTERINE®productsoutsidethe
U.S.werepartiallyoffsetbycompetitivepressuresintheU.S.TheWoundCare/Otherfranchisesaleswere$1.0billionin
2012,adecreaseof3.8%from2011duetodivestituresandcompetitivepressures.Negativecurrencyimpactedallofthe
franchises.
Consumersegmentsalesin2011were$14.9billion,anincreaseof2.0%from2010,a0.7%operationaldeclinewas
offsetbyapositivecurrencyimpactof2.7%.U.S.Consumersegmentsaleswere$5.2billion,adecreaseof6.7%.
Internationalsaleswere$9.7billion,anincreaseof7.3%,whichincluded2.9%operationalgrowthandapositivecurrency
impactof4.4%.
4 • Johnson&Johnson2012AnnualReportPharmaceutical Segment
ThePharmaceuticalsegmentachievedsalesof$25.4billionin2012,representinganincreaseof4.0%overtheprioryear,
withoperationalgrowthof6.8%andanegativecurrencyimpactof2.8%.U.S.saleswere$12.4billion,anincreaseof
0.3%.Internationalsaleswere$12.9billion,anincreaseof7.9%,whichincluded13.6%operationalgrowthanda
negativecurrencyimpactof5.7%.
MajorPharmaceutical TherapeuticAreaSales:*
%Change
(DollarsinMillions) 2012 2011 2010 ’12vs.’11 ’11vs.’10
TotalImmunology $7,874 6,798 5,398 15.8% 25.9
REMICADE® 6,139 5,492 4,610 11.8 19.1
SIMPONI® 607 410 226 48.0 81.4
STELARA® 1,025 738 393 38.9 87.8
OtherImmunology 103 158 169 (34.8) (6.5)
TotalInfectiousDiseases 3,194 3,189 3,033 0.2 5.1
INTELENCE® 349 314 243 11.1 29.2
LEVAQUIN®/FLOXIN® 75 623 1,357 (88.0) (54.1)
PREZISTA® 1,414 1,211 857 16.8 41.3
OtherInfectiousDiseases 1,356 1,041 576 30.3 80.7
TotalNeuroscience 6,718 6,948 6,644 (3.3) 4.6
CONCERTA®/methylphenidate 1,073 1,268 1,319 (15.4) (3.9)
INVEGA® 550 499 424 10.2 17.7
INVEGA®SUSTENNA®/XEPLION® 796 378 152 ** **
RISPERDAL®CONSTA® 1,425 1,583 1,500 (10.0) 5.5
OtherNeuroscience 2,874 3,220 3,249 (10.7) (0.9)
TotalOncology 2,629 2,048 1,465 28.4 39.8
DOXIL®/CAELYX® 83 402 320 (79.4) 25.6
VELCADE® 1,500 1,274 1,080 17.7 18.0
ZYTIGA® 961 301 – ** 100.0
OtherOncology 85 71 65 19.7 9.2
TotalOther 4,936 5,385 5,856 (8.3) (8.0)
ACIPHEX®/PARIET® 835 975 1,006 (14.4) (3.1)
PROCRIT®/EPREX® 1,462 1,623 1,934 (9.9) (16.1)
Other 2,639 2,787 2,916 (5.3) (4.4)
TotalPharmaceuticalSales $25,351 24,368 22,396 4.0% 8.8
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
**Percentagegreaterthan100%
Immunologyproductsachievedsalesof$7.9billionin2012,representinganincreaseof15.8%ascomparedtotheprior
year.TheincreasedsalesofSIMPONI®(golimumab)andREMICADE®(infliximab)wereprimarilyduetomarketgrowth
andtheimpactoftheagreementwithMerck&Co.Inc.(Merck).EffectiveJuly1,2011,distributionrightstoREMICADE®
andSIMPONI®incertainterritorieswererelinquishedtotheCompanybyMerck.Additionalcontributorstotheincrease
weresalesofSTELARA®(ustekinumab).
Infectiousdiseaseproductsachievedsalesof$3.2billionin2012,representinganincreaseof0.2%ascomparedtothe
prioryear.MajorcontributorswereINCIVO®(telaprevir),thecontinuedmomentuminmarketsharegrowthofPREZISTA®
(darunavir),EDURANT®(rilpivirine)andINTELENCE®(etravirine)partiallyoffsetbylowersalesofLEVAQUIN®
(levofloxacin)/FLOXIN®(ofloxacin),duetothelossofmarketexclusivityintheU.S.inJune2011.
Johnson&Johnson2012AnnualReport • 5Neuroscienceproductssaleswere$6.7billion,adeclineof3.3%ascomparedtotheprioryear.Growthwasimpactedby
genericcompetitionforCONCERTA®/methylphenidate,RAZADYNE®(galantamine),RISPERDAL®(risperidone)and
DURAGESIC®/FentanylTransdermal(fentanyltransdermalsystem).AdeclineintheCompany’slong-actinginjectable
antipsychotic,RISPERDAL®CONSTA®(risperidone),wasoffsetbystrongsalesofINVEGA®SUSTENNA®/XEPLION®
(paliperidonepalmitate)andINVEGA®(paliperidonepalmitate).TheCompany’sU.S.SupplyandDistributionAgreement
withWatsonLaboratories,Inc.todistributeanauthorizedgenericversionofCONCERTA®becameeffectiveMay1,2011.
TheoriginalCONCERTA®patentexpiredin2004,andthepartieshavereceivedapprovalfromtheFDAtomanufacture
andmarketagenericversionofCONCERTA®.AnothergenericversionofCONCERTA®waslaunchedonDecember31,
2012.ThiswillresultinafurtherreductioninCONCERTA®sales.
Oncologyproductsachievedsalesof$2.6billionin2012,representinganincreaseof28.4%ascomparedtotheprior
year.ThisgrowthwasprimarilyduetosalesofZYTIGA®(abirateroneacetate)andVELCADE®(bortezomib).Thisgrowth
waspartiallyoffsetbylowersalesofDOXIL®(doxorubicinHCIliposomeinjection)/CAELYX®(pegylatedliposomal
doxorubicinhydrochloride),duetosupplyconstraintsfromtheCompany’sthird-partymanufacturer.TheCompanyhas
beenworkingtorestoreareliablesupplyofDOXIL®/CAELYX®.FullaccessintheU.S.hasbeenrestored.Analternate
manufacturingapproachwasapprovedintheEuropeanUnion(EU)andJapanlatein2012andinCanadainJanuaryof
2013.IntheEuropeanUnion,theCAELYX®managedaccessprogramwasputinplacetoensurepatientscancomplete
theirfullcourseoftreatment.ItwillremaininplaceuntilafullsupplyofCAELYX®hasbeenrestored.InFebruary2013,the
FDAapprovedagenericversionofDOXIL®.
OtherPharmaceuticalsaleswere$4.9billion,adeclineof8.3%ascomparedtotheprioryearprimarilyduetodivestitures
andlowersalesofACIPHEX®/PARIET®(rabeprazolesodium)andEPREX®(Epoetinalfa),primarilyduetotheimpactof
genericcompetition.TheseresultswerepartiallyoffsetbysalesgrowthofXARELTO®(rivaroxaban).
During2012,theCompanyreceivedseveralregulatoryapprovalsincluding:U.S.approvalofanew800mgtabletof
PREZISTA®(darunavir)foronce-dailyoraladministrationforthetreatmentofhumanimmunodeficiencyvirus(HIV-1)in
treatment-naiveandtreatment-experiencedadultpatientswithnodarunavirresistance-associatedmutations;FDA
approvalfortheexpandeduseofXARELTO®(rivaroxaban)totreatdeep-veinthrombosis,orDVT,andpulmonary
embolism,orPEandtoreducetheriskofrecurrentDVTandPEfollowinginitialtreatment;andtheFDAgranted
acceleratedapprovalforSIRTURO™(bedaquiline)tabletsforthetreatmentofpulmonarymulti-drugresistanttuberculosis
aspartofcombinationtherapyinadults.TheFDAapprovedthesupplementalNewDrugApplication(NDA)for
NUCYNTA®ER(tapentadol)extended-releasetablets,anoralanalgesictakentwicedaily,forthemanagementof
neuropathicpainassociatedwithdiabeticperipheralneuropathyinadults.TheFDAandtheEuropeanCommissionalso
approvedanexpandedindicationforZYTIGA®(abirateroneacetate),incombinationwithprednisone,allowingfortheuse
beforechemotherapyinthetreatmentofmetastaticcastration-resistantprostatecancer.Inaddition,theEuropean
CommissionapprovedthemarketingauthorizationsforDACOGEN®(decitabine)forthetreatmentofadultpatients(age
65yearsandabove)withnewlydiagnoseddenovoorsecondaryacutemyeloidleukemiawhoarenotcandidatesfor
standardinductionchemotherapy,andforthesubcutaneousadministrationofVELCADE®(bortezomib)forthetreatment
ofmultiplemyeloma.
TheCompanysubmittedseveralNewDrugApplications,includinganNDAtotheFDAandMarketingAuthorization
Application(MAA)totheEuropeanMedicinesAgency(EMA)seekingapprovalfortheuseofcanagliflozin,anoral,once-
daily,selectivesodiumglucoseco-transporter2(SGLT2)inhibitor,forthetreatmentofadultpatientswithtype2diabetes,
andanNDAseekingapprovalforafixed-dosetherapycombiningcanagliflozinandimmediatereleasemetformintotreat
patientswithtype2diabetes.AdditionalsubmissionsincludedasupplementalBiologicsLicenseApplicationtotheFDA
andaTypeIIVariationtotheEMArequestingapprovalofSTELARA®(ustekinumab)forthetreatmentofadultpatients
withactivepsoriaticarthritis,andaBiologicsLicenseApplicationtotheFDArequestingapprovalofaninvestigational
intravenousformulationoftheanti-tumornecrosisfactor(TNF)-alphaSIMPONI®(golimumab)forthetreatmentofadults
withmoderatelytoseverelyactiverheumatoidarthritis.Inaddition,asupplementalBiologicsLicenseApplicationwas
submittedtotheFDAandaTypeIIVariationwassubmittedtotheEMArequestingapprovalofSIMPONI®(golimumab)for
thetreatmentofmoderatelytoseverelyactiveulcerativecolitisinadultpatientswhohavehadaninadequateresponseto
conventionaltherapyincludingcorticosteroidsand6-mercaptopurine(6-MP)orazathioprine(AZA),orwhoareintolerant
toorhavemedicalcontraindicationsforsuchtherapies.Finally,anMAAwassubmittedtotheEMAseekingconditional
approvalfortheuseofbedaquiline(TMC207)asanoraltreatment,tobeusedaspartofcombinationtherapyfor
pulmonary,multi-drugresistanttuberculosisinadults.
Pharmaceuticalsegmentsalesin2011were$24.4billion,anincreaseof8.8%from2010,withoperationalgrowthof
6.2%andapositivecurrencyimpactof2.6%.U.S.saleswere$12.4billion,adecreaseof1.1%.Internationalsaleswere
$12.0billion,anincreaseof21.3%,whichincluded15.5%operationalgrowthandapositivecurrencyimpactof5.8%.
6 • Johnson&Johnson2012AnnualReportMedicalDevicesandDiagnosticsSegment
TheMedicalDevicesandDiagnosticssegmentachievedsalesof$27.4billionin2012,representinganincreaseof6.4%
overtheprioryear,withoperationalgrowthof8.7%andanegativecurrencyimpactof2.3%.U.S.saleswere$12.4billion,
anincreaseof8.7%ascomparedtotheprioryear.Internationalsaleswere$15.1billion,anincreaseof4.5%overthe
prioryear,withoperationalgrowthof8.6%andanegativecurrencyimpactof4.1%.TheacquisitionofSynthes,Inc.,netof
therelateddivestiture,increasedbothtotalsalesgrowthandoperationalgrowthfortheMedicalDevicesandDiagnostics
segmentby7.9%.
MajorMedicalDevicesandDiagnosticsFranchiseSales:*
%Change
(DollarsinMillions) 2012 2011 2010 ’12vs.’11 ’11vs.’10
Orthopaedics $7,799 5,809 5,585 34.3% 4.0
SurgicalCare 6,483 6,637 6,272 (2.3) 5.8
VisionCare 2,996 2,916 2,680 2.7 8.8
DiabetesCare 2,616 2,652 2,470 (1.4) 7.4
SpecialtySurgery 2,526 2,407 2,186 4.9 10.1
Diagnostics 2,069 2,164 2,053 (4.4) 5.4
CardiovascularCare 1,985 2,288 2,552 (13.2) (10.3)
InfectionPrevention/Other 952 906 803 5.1 12.8
TotalMedicalDevicesandDiagnosticsSales $27,426 25,779 24,601 6.4% 4.8
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
TheOrthopaedicsfranchiseachievedsalesof$7.8billionin2012,a34.3%increaseovertheprioryear.Growthwas
primarilyduetosalesofnewlyacquiredproductsfromSynthes,Inc.,andsalesofjointreconstructionandMiteksports
medicineproducts.SaleswereimpactedbythedivestituresofthesurgicalinstrumentsbusinessofCodman&Shurtleff,
Inc.,inthefiscalfourthquarterof2011,andthedivestitureofcertainrightsandassetsrelatedtotheDePuytrauma
business.ThepositiveimpactontheOrthopaedicsfranchisetotalsalesgrowthandoperationalgrowthduetothenewly
acquiredproductsfromSynthes,Inc.netoftherelatedtraumabusinessdivestiturewas34.7%.
TheSurgicalCarefranchisesaleswere$6.5billionin2012,adecreaseof2.3%fromtheprioryear.Lowersalesof
mechanical,breastcareandpelvicfloorproductswerepartiallyoffsetbyincreasedsalesofsuturesandendoscopy
productswiththesuccessoftheECHELONFLEX™poweredENDOPATH®Stapler.
TheVisionCarefranchiseachievedsalesof$3.0billionin2012,a2.7%increaseovertheprioryear.Thegrowthwas
drivenbyACUVUE®TruEye®,1-DAYACUVUE®MOIST®forAstigmatismand1-DAYACUVUE®MOIST®.
TheDiabetesCarefranchisesaleswere$2.6billion,adecreaseof1.4%versustheprioryear.SalesgrowthinAsiaand
LatinAmericawasoffsetbythenegativeimpactofcurrency.
TheSpecialtySurgeryfranchiseachievedsalesof$2.5billionin2012,a4.9%increaseovertheprioryear.Incremental
salesfromtheacquisitionofSterilMedInc.,salesofbiosurgeryproductsandinternationalsalesofenergyproductswere
themajorcontributorstothegrowth.
TheDiagnosticsfranchisesaleswere$2.1billion,adeclineof4.4%versustheprioryear.Thedeclinewasprimarilydueto
lowersalesindonorscreeningduetocompetitivepressures,andthedivestitureoftheRhoGAM®businessduringthe
thirdquarterof2012.InJanuary2013,theCompanyannounceditisexploringstrategicalternativesfortheOrtho-Clinical
Diagnosticsbusiness,includingapossibledivestiture.
TheCardiovascularCarefranchisesaleswere$2.0billion,adeclineof13.2%versustheprioryear.Saleswereimpacted
bytheCompany’sdecisiontoexitthedrug-elutingstentmarketinthesecondquarterof2011,andlowersalesof
endovascularproducts,impactedbycompetitivelaunchesandadisruptioninsupplythatwasresolvedlateinthethird
quarter.ThedeclineinsaleswaspartiallyoffsetbystronggrowthinBiosenseWebster’selectrophysiologybusiness
primarilyduetothesuccessoftheTHERMOCOOL®catheterlaunches.
TheInfectionPrevention/Otherfranchiseachievedsalesof$1.0billionin2012,a5.1%increaseovertheprioryear
primarilyduetogrowthintheadvancedsterilizationbusiness.
Johnson&Johnson2012AnnualReport • 7TheMedicalDevicesandDiagnosticssegmentachievedsalesof$25.8billionin2011,representinganincreaseof4.8%
overtheprioryear,withoperationalgrowthof1.7%andapositivecurrencyimpactof3.1%.U.S.saleswere$11.4billion,
adecreaseof0.4%ascomparedtotheprioryear.Internationalsaleswere$14.4billion,anincreaseof9.2%overthe
prioryear,withoperationalgrowthof3.4%andapositivecurrencyimpactof5.8%.
Analysis of Consolidated Earnings Before Provision for Taxes on
Income
Consolidatedearningsbeforeprovisionfortaxesonincomeincreasedby$1.4billionto$13.8billionin2012as
comparedto$12.4billionin2011,anincreaseof11.4%.Earningsbeforeprovisionfortaxesonincomewerefavorable
duetoincreasedgrossprofitof$0.9billion,a$0.1billiondecreaseinselling,marketingandadministrativeexpensesdue
tocostcontainmentinitiativesacrossmanyofthebusinesses,lowerlitigationexpenseof$2.1billionandlowerchargesof
$0.4billionrelatedtotheDePuyASR™Hipprogramversustheprioryear.Thiswaspartiallyoffsetby$2.1billionof
chargesattributabletoassetwrite-downsandimpairmentofin-processresearchanddevelopment,primarilyrelatedtothe
CrucellvaccinebusinessandthediscontinuationofthePhaseIIIclinicaldevelopmentofbapineuzumabIVand$0.2billion
ofintegrationandcurrencycostsrelatedtotheacquisitionofSynthes,Inc.,versustheprioryear.Includedin2011wasa
$0.6billionrestructuringcharge,netofinventorywrite-offswhichareincludedincostofproductssold,relatedtothe
CardiovascularCarebusiness.Additionally,2011includedhighergainsfromdivestituresandotheritemsof$0.3billion,
recordedinother(income)expense,net.
The2011decreaseof27.1%ascomparedto2010wasprimarilyduetocostsassociatedwithlitigation,whichincludes
productliability,theimpactoftheOTCandDePuyASR™Hiprecallsandtherestructuringexpenserelatedtothe
CardiovascularCarebusiness.Additionally,investmentspending,thefeeonbrandedpharmaceuticalproductsincurred
duetotheU.S.healthcarereformlegislation,andtheintegrationcosts,includinganinventorystep-upcharge,associated
withtheacquisitionofCrucellcontributedtothedecreaseinearnings.Thiswaspartiallyoffsetbygainsfromdivestitures.
Asapercenttosales,consolidatedearningsbeforeprovisionfortaxesonincomein2012was20.5%versus19.0%in
2011.
CostofProductsSoldandSelling,MarketingandAdministrativeExpenses:Costofproductssoldandselling,
marketingandadministrativeexpensesasapercenttosaleswereasfollows:
%ofSales 2012 2011 2010
Costofproductssold 32.2% 31.3 30.5
Percentpointincreaseovertheprioryear 0.9 0.8 0.7
Selling,marketingandadministrativeexpenses 31.0 32.3 31.5
Percentpoint(decrease)/increaseovertheprioryear (1.3) 0.8 (0.5)
In2012,costofproductssoldasapercenttosalesincreasedcomparedtotheprioryear.Thiswasprimarilytheresultof
theamortizationoftheinventorystep-upchargeof$0.4billionandamortizationofintangiblesrelatedtotheSynthes,Inc.,
acquisitionof$0.3billionandongoingremediationcostsintheMcNeilOTCbusiness.Therewasadecreaseinthe
percenttosalesofselling,marketingandadministrativeexpensesin2012comparedtotheprioryearprimarilyduetocost
containmentinitiativesacrossmanyofthebusinesses.Theprioryearperiodincludedhigherinvestmentspendinginthe
Pharmaceuticalbusinessfornewproducts.
In2011,costofproductssoldasapercenttosalesincreasedcomparedtotheprioryear.Thiswasprimarilyattributable
toongoingremediationcostsintheMcNeilOTCbusinessandinventorywrite-offsduetotherestructuringofthe
CardiovascularCarebusiness.Inaddition,lowermarginsandintegrationcosts,includinganinventorystep-upcharge,
associatedwiththeacquisitionofCrucellnegativelyimpactedcostofproductssold.Percenttosalesofselling,marketing
andadministrativeexpensesincreasedin2011comparedtotheprioryearprimarilyduetoinvestmentspending,aswellas
thefeeonbrandedpharmaceuticalproductsincurredduetotheU.S.healthcarereformlegislation.
8 • Johnson&Johnson2012AnnualReportResearchandDevelopmentExpense:Researchanddevelopmentexpensebysegmentofbusinesswasasfollows:
2012 2011 2010
(DollarsinMillions) Amount %ofSales* Amount %ofSales* Amount %ofSales*
Consumer $622 4.3% 659 4.4 609 4.2
Pharmaceutical 5,362 21.2 5,138 21.1 4,432 19.8
MedicalDevicesandDiagnostics 1,681 6.1 1,751 6.8 1,803 7.3
Totalresearchanddevelopmentexpense $7,665 11.4% 7,548 11.6 6,844 11.1
Percentincrease/(decrease)overtheprior
year 1.6% 10.3 (2.0)
*Asapercenttosegmentsales
ResearchanddevelopmentactivitiesrepresentasignificantpartoftheCompany’sbusiness.Theseexpendituresrelateto
theprocessesofdiscovering,testinganddevelopingnewproducts,improvingexistingproducts,aswellasensuring
productefficacyandregulatorycompliancepriortolaunch.TheCompanyremainscommittedtoinvestinginresearchand
developmentwiththeaimofdeliveringhighqualityandinnovativeproducts.In2012,worldwidecostsofresearchand
developmentactivitiesincreasedby1.6%comparedto2011.ThedecreaseintheMedicalDevicesandDiagnostics
segmentwasprimarilyduetothediscontinuationoftheclinicaldevelopmentprogramfortheNEVO™Sirolimus-Eluting
CoronaryStent.
In-ProcessResearchandDevelopment(IPR&D):In2012,theCompanyrecordedachargeof$1.2billion,which
included$0.7billionfortheimpairmentoftheIPR&DrelatedtothediscontinuationofthePhaseIIIclinicaldevelopmentof
bapineuzumabIVandthepartialimpairmentoftheIPR&DrelatedtotheCrucellvaccinebusinessintheamountof$0.4
billion.Ofthe$0.7billionimpairmentoftheIPR&DrelatedtothediscontinuationofthePhaseIIIclinicaldevelopmentof
bapineuzumabIV,$0.3billionisattributabletononcontrollinginterest.Thesechargesrelatetodevelopmentprojects
whichhavebeenrecentlydiscontinuedordelayed.
Other(Income)Expense,Net:Other(income)expense,netincludesroyaltyincome;gainsandlossesrelatedtothe
saleandwrite-downofcertaininvestmentsinequitysecuritiesheldbyJohnson&JohnsonDevelopmentCorporation;
gainsandlossesonthedisposalofproperty,plantandequipment;currencygainsandlosses;andlitigationsettlements.In
2012,thefavorablechangeof$1.1billioninother(income)expense,net,wasprimarilyduetolowerexpensesof$2.1
billionrelatedtolitigation,includingproductliability,and$0.4billionforcostsrelatedtotheDePuyASR™Hipprogram.
Thiswaspartiallyoffsetby$0.9billionattributedtoassetwrite-downs,primarilyrelatedtotheCrucellvaccinebusiness,
and$0.2billionofhigherintegration/transactionandcurrencycostsrelatedtotheacquisitionofSynthes,Inc.
In2011,theunfavorablechangeof$3.5billioninother(income)expense,net,wasprimarilyduetonetlitigation,which
includesproductliabilityof$3.3billionin2011ascomparedtoa$0.4billionnetgainfromlitigationin2010.Additionally,
2011ascomparedto2010includedhigherexpensesof$0.2billionforcostsrelatedtotheDePuyASR™Hipprogram
andanadjustmentof$0.5billiontothevalueofthecurrencyoptionanddealcostsrelatedtotheacquisitionofSynthes,
Inc.Includedin2011werehighergainsonthedivestituresofbusinessesof$0.6billionascomparedto2010.
Restructuring:In2011,CordisCorporation,asubsidiaryofJohnson&Johnson,announcedthediscontinuationofits
clinicaldevelopmentprogramfortheNEVO™Sirolimus-ElutingCoronaryStentandcessationofthemanufactureand
marketingofCYPHER®andCYPHERSELECT®PlusSirolimus-ElutingCoronaryStentsbytheendof2011.The
Companyrecordedapre-taxchargeof$0.7billion,ofwhich$0.1billionwasincludedinthecostofproductssold.There
wasnorestructuringchargein2012.SeeNote22totheConsolidatedFinancialStatementsforadditionaldetailsrelated
totherestructuring.
Interest(Income)Expense:Interestincomein2012decreasedby$27millionascomparedtotheprioryeardueto
lowerratesofinterestearnedandloweraveragecashbalances.Cash,cashequivalentsandmarketablesecuritiestotaled
$21.1billionattheendof2012,andaveraged$26.7billionascomparedtothe$30.0billionaveragecashbalancein
2011.ThedeclineintheaveragecashbalancewasduetotheacquisitionofSynthes,Inc.,partiallyoffsetbycash
generatedfromoperatingactivities.
Interestexpensein2012decreasedby$39millionascomparedto2011duetoaloweraveragedebtbalance.The
averagedebtbalancewas$17.9billionin2012versus$18.2billionin2011.Thetotaldebtbalanceattheendof2012
was$16.2billionascomparedto$19.6billionattheendof2011.Thereductionindebtofapproximately$3.4billionwas
primarilyduetoareductionincommercialpaper.
Johnson&Johnson2012AnnualReport • 9Interestincomein2011decreasedby$16millionascomparedtotheprioryearduetolowerratesofinterestearned
despitehigheraveragecashbalances.Cash,cashequivalentsandmarketablesecuritiestotaled$32.3billionattheendof
2011,andaveraged$30.0billionascomparedtothe$23.6billionaveragecashbalancein2010.Theincreaseinthe
averagecashbalancewasprimarilyduetocashgeneratedfromoperatingactivitiesandnetcashproceedsfrom
divestitures.
Interestexpensein2011increasedby$116millionascomparedto2010duetoahigheraveragedebtbalance.Thetotal
debtbalanceattheendof2011was$19.6billionascomparedto$16.8billionattheendof2010.Thehigheraverage
debtbalanceof$18.2billionin2011versus$15.7billionin2010wasduetoincreasedborrowings.TheCompany
increasedborrowings,capitalizingonfavorabletermsinthecapitalmarkets.Theproceedsoftheborrowingswereused
forgeneralcorporatepurposes.
SegmentPre-TaxProfit
Pre-taxprofitsbysegmentofbusinesswereasfollows:
Percentof
SegmentSales
(DollarsinMillions) 2012 2011 2012 2011
Consumer $1,693 2,096 11.7% 14.1
Pharmaceutical 6,075 6,406 24.0 26.3
MedicalDevicesandDiagnostics 7,187 5,263 26.2 20.4
Total(1) 14,955 13,765 22.2 21.2
Less:Expensesnotallocatedtosegments(2) 1,180 1,404
Earningsbeforeprovisionfortaxesonincome $13,775 12,361 20.5% 19.0
(1) SeeNote18totheConsolidatedFinancialStatementsformoredetails.
(2) Amountsnotallocatedtosegmentsincludeinterest(income)expense,noncontrollinginterests,andgeneralcorporate(income)
expense.A$0.2billionand$0.5billioncurrencyrelatedexpensefortheacquisitionofSynthes,Inc.,wasincludedin2012and2011,
respectively.
ConsumerSegment:In2012,Consumersegmentpre-taxprofitasapercenttosaleswas11.7%versus14.1%in
2011.Pre-taxprofitwasunfavorablyimpactedby$0.3billionattributedtointangibleassetwrite-downsandapproximately
$0.3billionduetounfavorableproductmixandremediationcostsassociatedwiththeMcNEIL-PPC,Inc.,consentdecree.
Thiswaspartiallyoffsetbycostcontainmentinitiativesrealizedinselling,marketingandadministrativeexpenses.In
addition,2011includedhighergainsondivestitures.In2011,Consumersegmentpre-taxprofitdecreased10.5%from
2010.Theprimarydriversofthedeclineinoperatingprofitwereunfavorableproductmixandremediationcostsassociated
withtherecallofcertainOTCproducts,partiallyoffsetbythegainonthedivestitureofMONISTAT®.
PharmaceuticalSegment:In2012,Pharmaceuticalsegmentpre-taxprofitasapercenttosaleswas24.0%versus
26.3%in2011.Pre-taxprofitwasunfavorablyimpactedbychargesof$1.6billionattributedtothewrite-downofassets
andimpairmentofin-processresearchanddevelopmentassets,relatedtotheCrucellvaccinebusiness,andtothe
discontinuationofthePhaseIIIclinicaldevelopmentofbapineuzumabIV.Thiswaspartiallyoffsetbylowerlitigation
expenseof$1.1billionversustheprioryearandfavorableoperatingexpensesof$0.3billion.Additionally,2012included
thegainonthedivestitureofBYSTOLIC®(nebivolol)IPrights.In2011,Pharmaceuticalsegmentpre-taxprofitdecreased
9.6%from2010.Theprimarydriversofthedecreaseinthepre-taxprofitmarginwerehigherlitigationexpensesrecorded
in2011,theimpactoftheU.S.healthcarereformfee,andlowermarginsandintegrationcosts,includinganinventory
step-upcharge,associatedwiththeCrucellacquisition.ThiswaspartiallyoffsetbygainsonthedivestituresoftheAnimal
HealthBusinessandOrthoDermatologics,thegainrelatedtotheCompany’searlierinvestmentinCrucell,andlower
manufacturingcosts.
MedicalDevicesandDiagnosticsSegment:In2012,MedicalDevicesandDiagnosticssegmentpre-taxprofitasa
percenttosaleswas26.2%versus20.4%in2011.TheMedicalDevicesandDiagnosticssegmentpre-taxprofitwas
favorablyimpactedbyprofitsfromSynthessales,lowerexpensesof$1.4billionforlitigation,includingproductliability,
andtheDePuyASR™Hipprogramand$0.1billionforresearchanddevelopmentprimarilyduetothediscontinuationof
itsclinicaldevelopmentprogramfortheNEVO™Sirolimus-ElutingCoronaryStent.Thiswaspartiallyoffsetbyanincrease
inintegrationcostsandamortizationoftheinventorystep-upof$0.8billionassociatedwiththeacquisitionofSynthes,
Inc.,and$0.1billionattributedtothewrite-downofintangibleassets.Inaddition,2012includedhighergainson
10 • Johnson&Johnson2012AnnualReportdivestituresversustheprioryearduetothedivestituresoftheTherakosbusinessandRhoGAM®.Additionally,2011
includeda$0.7billionrestructuringchargerelatedtothediscontinuationoftheclinicaldevelopmentprogramforthe
NEVO™Sirolimus-ElutingCoronaryStent.In2011,MedicalDevicesandDiagnosticssegmentpre-taxprofitdecreased
36.4%from2010.Theprimarydriversofthedeclineinthepre-taxprofitmarginintheMedicalDevicesandDiagnostics
segmentwerelitigationexpenses,includingproductliability,costsassociatedwiththeDePuyASR™Hipprogram,
restructuringexpense,costsincurredrelatedtotheacquisitionofSynthes,Inc.,andincreasedinvestmentspending.
ProvisionforTaxesonIncome:Theworldwideeffectiveincometaxratewas23.7%in2012,21.8%in2011and
21.3%in2010.Theincreaseinthe2012effectivetaxrateof1.9%ascomparedto2011wasduetolowertaxbenefits
ontheimpairmentofin-processresearchanddevelopmentintangibleassetsinlowtaxjurisdictions,increasesintaxable
incomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsandtheexclusionofthebenefitoftheU.S.Research&
Development(R&D)taxcreditandtheCFClook-throughprovisionsfromthe2012fiscalyearfinancialresults.TheR&D
taxcreditandtheCFClook-throughprovisionswereenactedintolawin2013andwereretroactivetoJanuary1,2012.
TheentirebenefitoftheR&DtaxcreditandtheCFClook-throughprovisionswillbereflectedinthe2013fiscalyear
financialresults.
The2011taxrateincreasedascomparedto2010duetocertainU.S.expenseswhicharenotfullytaxdeductibleand
higherU.S.statetaxespartiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictionsrelativetohighertax
jurisdictions.
NoncontrollingInterest:Achargeof$0.7billionfortheimpairmentoftheIPR&Drelatedtothediscontinuationofthe
PhaseIIIclinicaldevelopmentofbapineuzumabIVwasrecordedin2012.Ofthe$0.7billionimpairment,$0.3billionis
attributabletononcontrollinginterest.
Liquidity and Capital Resources
Liquidity&CashFlows
Cashandcashequivalentswere$14.9billionattheendof2012ascomparedwith$24.5billionattheendof2011.The
primaryusesofcashthatcontributedtothe$9.6billiondecreaseversustheprioryearwereapproximately$4.5billionnet
cashusedbyinvestingactivitiesand$20.6billionnetcashusedbyfinancingactivitiespartiallyoffsetby$15.4billionof
cashgeneratedfromoperatingactivities.
Cashflowfromoperationsof$15.4billionwastheresultof$10.5billionofnetearningsand$6.9billionofnon-cash
chargesprimarilyrelatedtodepreciationandamortization,assetwrite-downs(primarilyin-processresearchand
development),stock-basedcompensation,noncontrollinginterestanddeferredtaxprovisionreducedby$2.0billion
relatedtochangesinassetsandliabilities,netofeffectsfromacquisitions.
Investingactivitiesuseof$4.5billionwasprimarilyfor$2.9billionforadditionstoproperty,plantandequipmentand
acquisitions,netofcashacquiredof$4.5billionpartiallyoffsetbynetsalesofinvestmentsinmarketablesecuritiesof
$1.4billionand$1.5billionofproceedsfromthedisposalofassets.
Financingactivitiesuseof$20.6billionwasfortherepurchaseofcommonstockof$12.9billionprimarilyforthe
acquisitionofSynthes,Inc.,dividendstoshareholdersof$6.6billionandnetretirementofshortandlong-termdebtof
$3.7billion,partiallyoffsetby$2.7billionofnetproceedsfromstockoptionsexercised/excesstaxbenefits.
In2012,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Foradditionaldetails
onborrowings,seeNote7totheConsolidatedFinancialStatements.
TheCompanyanticipatesthatoperatingcashflows,existingcreditfacilitiesandaccesstothecommercialpapermarkets
willprovidesufficientresourcestofundoperatingneedsin2013.
ConcentrationofCreditRisk
Globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge
numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimits.Recenteconomicchallengesin
Italy,Spain,GreeceandPortugal(theSouthernEuropeanRegion)haveimpactedcertainpaymentpatterns,whichhave
historicallybeenlongerthanthoseexperiencedintheU.S.andotherinternationalmarkets.Thetotalnettradeaccounts
receivablebalanceintheSouthernEuropeanRegionwasapproximately$2.1billionasofDecember30,2012and
Johnson&Johnson2012AnnualReport • 11approximately$2.4billionasofJanuary1,2012.Approximately$1.2billionasofDecember30,2012andapproximately
$1.4billionasofJanuary1,2012oftheSouthernEuropeanRegionnettradeaccountsreceivablebalancerelatedtothe
Company’sConsumer,VisionCareandDiabetesCarebusinessesaswellascertainPharmaceuticalandMedicalDevices
andDiagnosticscustomerswhichareinlinewithhistoricalcollectionpatterns.
TheremainingbalanceofnettradeaccountsreceivableintheSouthernEuropeanRegionhasbeennegativelyimpacted
bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain
distributorsofthePharmaceuticalandMedicalDevicesandDiagnosticslocalaffiliates.Thetotalnettradeaccounts
receivablebalanceforthesecustomerswereapproximately$0.9billionatDecember30,2012and$1.0billionat
January1,2012.TheCompanycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepayment
premiums.Forcustomerswherepaymentisexpectedoverperiodsoftimelongerthanoneyear,revenueandtrade
receivableshavebeendiscountedovertheestimatedperiodoftimeforcollection.Allowancesfordoubtfulaccountshave
beenincreasedforthesecustomers,buthavebeenimmaterialtodate.TheCompanywillcontinuetoworkcloselywith
thesecustomersonpaymentplans,monitortheeconomicsituationandtakeappropriateactionsasnecessary.
FinancingandMarketRisk
TheCompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows.
Accordingly,theCompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency
assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcosts.Gainsorlosses
onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactions.A10%appreciationoftheU.S.Dollar
fromtheDecember30,2012marketrateswouldincreasetheunrealizedvalueoftheCompany’sforwardcontractsby
$91million.Conversely,a10%depreciationoftheU.S.DollarfromtheDecember30,2012marketrateswoulddecrease
theunrealizedvalueoftheCompany’sforwardcontractsby$112million.Ineitherscenario,thegainorlossontheforward
contractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhavenoimpactonfuture
anticipatedearningsandcashflows.
TheCompanyhedgestheexposuretofluctuationsincurrencyexchangerates,andtheeffectoncertainassetsand
liabilitiesinforeigncurrency,byenteringintocurrencyswapcontracts.A1%changeinthespreadbetweenU.S.and
foreigninterestratesontheCompany’sinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe
unrealizedvalueoftheCompany’sswapcontractsbyapproximately$190million.Ineitherscenario,atmaturity,thegainor
lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhaveno
impactonfutureanticipatedcashflows.
TheCompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposes.Further,theCompanyhasa
policyofonlyenteringintocontractswithpartiesthathaveatleastan“A”(orequivalent)creditrating.Thecounter-parties
tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone
counter-party.Managementbelievestheriskoflossisremote.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2012,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember19,2013.Interestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementarenotmaterial.
Totalborrowingsattheendof2012and2011were$16.2billionand$19.6billion,respectively.Thereductionindebtin
2012ofapproximately$3.4billionwasprimarilyduetoareductionincommercialpaper.
In2012,netcash(cashandcurrentmarketablesecurities,netofdebt)was$4.9billioncomparedtonetcashof
$12.6billionin2011.Totaldebtrepresented20.0%oftotalcapital(shareholders’equityandtotaldebt)in2012and
25.6%oftotalcapitalin2011.Shareholders’equitypershareattheendof2012was$23.33comparedto$20.95at
year-end2011,anincreaseof11.4%.
AsummaryofborrowingscanbefoundinNote7totheConsolidatedFinancialStatements.
12 • Johnson&Johnson2012AnnualReportContractualObligationsandCommitments
TheCompany’scontractualobligationsareprimarilyforleases,debtandunfundedretirementplans.Therearenoother
significantobligations.Tosatisfytheseobligations,theCompanywillusecashfromoperations.Thefollowingtable
summarizestheCompany’scontractualobligationsandtheiraggregatematuritiesasofDecember30,2012(seeNotes7,
10and16totheConsolidatedFinancialStatementsforfurtherdetails):
Long-Term Intereston Unfunded
Debt Debt Retirement Operating
(DollarsinMillions) Obligations Obligations Plans Leases Total
2013 $1,512 497 68 251 2,328
2014 1,789 483 66 192 2,530
2015 – 477 71 149 697
2016 898 471 76 115 1,560
2017 1,000 436 80 90 1,606
After2017 7,802 4,232 502 128 12,664
Total $13,001 6,596 863 925 21,385
Fortaxmatters,seeNote8totheConsolidatedFinancialStatements.
ShareRepurchase andDividends
OnJuly9,2007,theCompanyannouncedthatitsBoardofDirectorsapprovedastockrepurchaseprogramauthorizing
theCompanytobuybackupto$10.0billionoftheCompany’sCommonStock.AsofJanuary2,2011,theCompany
repurchasedanaggregateof158.3millionsharesofJohnson&JohnsonCommonStockatacostof$10.0billionandthe
stockrepurchaseprogramwascompleted.TheCompanyfundedthesharerepurchaseprogramthroughacombinationof
availablecashanddebt.
PursuanttotheacceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofSynthes,Inc.,the
CompanyhasnotmadeanypurchasesofCommonStockontheopenmarketduringthefiscalthirdandfourthquartersof
2012.
TheCompanyincreaseditsdividendin2012forthe50thconsecutiveyear.Cashdividendspaidwere$2.40persharein
2012comparedwithdividendsof$2.25persharein2011,and$2.11persharein2010.Thedividendsweredistributed
asfollows:
2012 2011 2010
Firstquarter $0.57 0.54 0.49
Secondquarter 0.61 0.57 0.54
Thirdquarter 0.61 0.57 0.54
Fourthquarter 0.61 0.57 0.54
Total $2.40 2.25 2.11
OnJanuary2,2013,theBoardofDirectorsdeclaredaregularquarterlycashdividendof$0.61pershare,payableon
March12,2013,toshareholdersofrecordasofFebruary26,2013.TheCompanyexpectstocontinuethepracticeof
payingregularcashdividends.
Johnson&Johnson2012AnnualReport • 13Other Information
CriticalAccountingPoliciesandEstimates
Management’sdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedontheCompany’s
consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin
theU.S.(GAAP).Thepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand
assumptionsthataffecttheamountsreportedforrevenues,expenses,assets,liabilitiesandotherrelateddisclosures.
Actualresultsmayormaynotdifferfromtheseestimates.TheCompanybelievesthattheunderstandingofcertainkey
accountingpoliciesandestimatesareessentialinachievingmoreinsightintotheCompany’soperatingresultsand
financialcondition.Thesekeyaccountingpoliciesincluderevenuerecognition,incometaxes,legalandself-insurance
contingencies,valuationoflong-livedassets,assumptionsusedtodeterminetheamountsrecordedforpensionsandother
employeebenefitplansandaccountingforstockoptions.
RevenueRecognition:TheCompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordelivered,and
titleandriskoflosspasstothecustomer.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,
productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsales
arerecorded.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingpriceschargedbycompetitors.Rebates,thelargestbeingtheMedicaidrebate
provision,areestimatedbasedoncontractualterms,historicalexperience,trendanalysisandprojectedmarketconditions
inthevariousmarketsserved.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarily
throughtheanalysisofwholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternally
generatedinformation.
Salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibit
unusualsalesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedand
analyzedaspartoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa
percenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescreditto
customersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsfor
certainfranchisesintheMedicalDevicesandDiagnosticssegmentaretypicallyresalablebutarenotmaterial.The
Companyrarelyexchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompany
hasrangedbetween1.0%and1.2%ofannualnettradesalesduringthefiscalreportingyears2012,2011and2010.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
yearincurred.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentiveprograms.The
redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.Volume-based
incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold.
TheCompanyalsoearnsservicerevenueforco-promotionofcertainproducts.Forallyearspresented,servicerevenues
werelessthan2%oftotalrevenuesandareincludedinsalestocustomers.Thesearrangementsareevaluatedto
determinetheappropriateamountstobedeferred.
Inaddition,theCompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities.
Amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered,
basedontherelativefairvalue.Upfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedoverthe
performanceperiod.SeeNote1totheConsolidatedFinancialStatementsforadditionaldisclosuresoncollaborations.
Reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebates,returnsandpromotionsarenot
anticipatedtohaveamaterialeffectonthefinancialstatements.TheCompanycurrentlydisclosestheimpactofchanges
toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact.
14 • Johnson&Johnson2012AnnualReportBelowaretablesthatshowtheprogressionofaccruedrebates,returns,promotions,reservefordoubtfulaccountsand
reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedDecember30,2012andJanuary1,2012.
ConsumerSegment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2012
Accruedrebates(1) $127 438 (433) 132
Accruedreturns 114 131 (137) 108
Accruedpromotions 240 1,392 (1,351) 281
Subtotal $481 1,961 (1,921) 521
Reservefordoubtfulaccounts 43 6 (11) 38
Reserveforcashdiscounts 22 214 (215) 21
Total $546 2,181 (2,147) 580
2011
Accruedrebates(1) $131 346 (350) 127
Accruedreturns 145 103 (134) 114
Accruedpromotions 294 1,520 (1,574) 240
Subtotal $570 1,969 (2,058) 481
Reservefordoubtfulaccounts 57 3 (17) 43
Reserveforcashdiscounts 21 226 (225) 22
Total $648 2,198 (2,300) 546
(1) Includesreserveforcustomerrebatesof$33millionatDecember30,2012and$34millionatJanuary1,2012,recordedasacontra
asset.
Pharmaceutical Segment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2012
Accruedrebates(1) $1,591 4,732 (4,556) 1,767
Accruedreturns 384 49 (36) 397
Accruedpromotions 83 142 (131) 94
Subtotal $2,058 4,923 (4,723) 2,258
Reservefordoubtfulaccounts 157 47 (13) 191
Reserveforcashdiscounts 45 425 (408) 62
Total $2,260 5,395 (5,144) 2,511
2011
Accruedrebates(1) $1,520 4,732 (4,661) 1,591
Accruedreturns 294 105 (15) 384
Accruedpromotions 83 187 (187) 83
Subtotal $1,897 5,024 (4,863) 2,058
Reservefordoubtfulaccounts 145 20 (8) 157
Reserveforcashdiscounts 54 392 (401) 45
Total $2,096 5,436 (5,272) 2,260
(1) Includesreserveforcustomerrebatesof$269millionatDecember30,2012and$298millionatJanuary1,2012,recordedasa
contraasset.
Johnson&Johnson2012AnnualReport • 15MedicalDevicesandDiagnosticsSegment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2012
Accruedrebates(1) $497 3,803 (3,733) 567
Accruedreturns 184 369 (348) 205
Accruedpromotions 73 49 (62) 60
Subtotal $754 4,221 (4,143) 832
Reservefordoubtfulaccounts 161 74 2 237
Reserveforcashdiscounts 32 371 (381) 22
Total $947 4,666 (4,522) 1,091
2011
Accruedrebates(1) $495 3,253 (3,251) 497
Accruedreturns 201 352 (369) 184
Accruedpromotions 50 67 (44) 73
Subtotal $746 3,672 (3,664) 754
Reservefordoubtfulaccounts 138 54 (31) 161
Reserveforcashdiscounts 35 342 (345) 32
Total $919 4,068 (4,040) 947
(1) Includesreserveforcustomerrebatesof$340millionatDecember30,2012and$324millionatJanuary1,2012,recordedasa
contraasset.
IncomeTaxes:Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe
resultsofanydifferencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.
TheCompanyestimatesdeferredtaxassetsandliabilitiesbasedoncurrenttaxregulationsandrates.Changesintaxlaws
andratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
AtDecember30,2012andJanuary1,2012,thecumulativeamountsofundistributedinternationalearningswere
approximately$49.0billionand$41.6billion,respectively.AtDecember30,2012andJanuary1,2012,theCompany’s
foreignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsof$14.8billionand$24.5billion,
respectively.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational
subsidiarieswheretheearningsareconsideredtobepermanentlyreinvested.TheCompanyintendstocontinueto
reinvesttheseearningsininternationaloperations.IftheCompanydecidedatalaterdatetorepatriatetheseearningsto
theU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectsontheseamounts.TheCompanydoesnot
determinethedeferredtaxliabilityassociatedwiththeseundistributedearnings,assuchdeterminationisnotpractical.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
LegalandSelfInsuranceContingencies:TheCompanyrecordsaccrualsforvariouscontingenciesincludinglegal
proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusiness.Theaccrualsarebasedon
management’sjudgmentastotheprobabilityoflossesand,whereapplicable,actuariallydeterminedestimates.The
Companyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompanyandisinsureduptocertainlimits.In
additiontoaccrualsintheselfinsuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesare
probableandamountscanbereasonablyestimated.Additionally,theCompanyrecordsinsurancereceivableamounts
fromthird-partyinsurerswhenrecoveryisprobable.Asappropriate,reservesagainstthesereceivablesarerecordedfor
estimatedamountsthatmaynotbecollectedfromthird-partyinsurers.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
16 • Johnson&Johnson2012AnnualReportLong-LivedandIntangibleAssets:TheCompanyassesseschangesineconomicconditionsandmakesassumptions
regardingestimatedfuturecashflowsinevaluatingthevalueoftheCompany’sproperty,plantandequipment,goodwill
andintangibleassets.Astheseassumptionsandestimatesmaychangeovertime,itmayormaynotbenecessaryforthe
Companytorecordimpairmentcharges.
EmployeeBenefitPlans:TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,
definedcontributionandterminationindemnityplans,whichcovermostemployeesworldwide.Theseplansarebasedon
assumptionsforthediscountrate,expectedreturnonplanassets,expectedsalaryincreasesandhealthcarecosttrend
rates.SeeNote10totheConsolidatedFinancialStatementsforfurtherdetailsontheseratesandtheeffectaratechange
wouldhaveontheCompany’sresultsofoperations.
StockBasedCompensation:TheCompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity
instrumentstoemployeesfortheirservices.ThefairvalueofeachawardisestimatedonthedateofgrantusingtheBlack-
Scholesoptionvaluationmodelandisexpensedinthefinancialstatementsoverthevestingperiod.Theinputassumptions
usedindeterminingfairvaluearetheexpectedlife,expectedvolatility,risk-freerateandthedividendyield.SeeNote17to
theConsolidatedFinancialStatementsforadditionalinformation.
NewAccountingPronouncements
RefertoNote1totheConsolidatedFinancialStatementsforrecentlyadoptedaccountingpronouncementsandrecently
issuedaccountingpronouncementsnotyetadoptedasofDecember30,2012.
EconomicandMarketFactors
TheCompanyisawarethatitsproductsareusedinanenvironmentwhere,formorethanadecade,policymakers,
consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcare.Inresponsetotheseconcerns,
theCompanyhasalong-standingpolicyofpricingproductsresponsibly.Fortheperiod2002-2012,intheUnited
States,theweightedaveragecompoundannualgrowthrateoftheCompany’snetpriceincreasesforhealthcareproducts
(prescriptionandover-the-counterdrugs,hospitalandprofessionalproducts)wasbelowtheU.S.ConsumerPriceIndex
(CPI).
Inflationratescontinuetohaveaneffectonworldwideeconomiesand,consequently,onthewaycompaniesoperate.The
CompanyaccountedforoperationsinVenezuelaashighlyinflationaryin2010,2011and2012,asthepriorthree-year
cumulativeinflationratesurpassed100%.Inthefaceofincreasingcosts,theCompanystrivestomaintainitsprofit
marginsthroughcostreductionprograms,productivityimprovementsandperiodicpriceincreases.
OnFebruary8,2013,theVenezuelangovernmentannounceda32%devaluationofitscurrency.Theeffectofthe
devaluationisnotexpectedtohaveamaterialimpactontheCompany’s2013fullyearresults.
TheCompanyisexposedtofluctuationsincurrencyexchangerates.A1%changeinthevalueoftheU.S.Dollaras
comparedtoallforeigncurrenciesinwhichtheCompanyhadsales,incomeorexpensein2012wouldhaveincreasedor
decreasedthetranslationofforeignsalesbyapproximately$375millionandincomeby$80million.
TheCompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude
healthcarecostcontainmentandgovernmentlegislationrelatingtosales,promotionsandreimbursementofhealthcare
products.
Changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservices,includingdelaying
medicalprocedures,rationingprescriptionmedications,reducingthefrequencyofphysicianvisitsandforegoinghealth
careinsurancecoverage,asaresultofthecurrentglobaleconomicdownturn,maycontinuetoimpacttheCompany’s
businesses.
TheCompanyalsooperatesinanenvironmentwhichhasbecomeincreasinglyhostiletointellectualpropertyrights.
GenericdrugfirmshavefiledAbbreviatedNewDrugApplications(ANDAs)seekingtomarketgenericformsofmostofthe
Company’skeypharmaceuticalproducts,priortoexpirationoftheapplicablepatentscoveringthoseproducts.Intheevent
theCompanyisnotsuccessfulindefendingthepatentclaimschallengedinANDAfilings,thegenericfirmswillthen
introducegenericversionsoftheproductatissue,resultinginthepotentialforsubstantialmarketshareandrevenue
lossesforthatproduct.Forfurtherinformation,seethediscussionon“LitigationAgainstFilersofAbbreviatedNewDrug
Applications”inNote21totheConsolidatedFinancialStatements.
Johnson&Johnson2012AnnualReport • 17LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseofbusiness.
TheCompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount
ofthelosscanbereasonablyestimated.TheCompanyhasaccruedforcertainlitigationmattersandcontinuestomonitor
eachrelatedlegalissueandadjustaccrualsfornewinformationandfurtherdevelopmentsinaccordancewithAccounting
StandardsCodification(ASC)450-20-25.Fortheseandotherlitigationandregulatorymatterscurrentlydisclosedfor
whichalossisprobableorreasonablypossible,theCompanyisunabletodetermineanestimateofthepossiblelossor
rangeoflossbeyondtheamountsalreadyaccrued.Thesematterscanbeaffectedbyvariousfactors,includingwhether
damagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnot
commencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;therearesignificant
factsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutioninanyreportingperiodofone
ormoreofthesematters,eitheraloneorintheaggregate,mayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
SeeNote21totheConsolidatedFinancialStatementsforfurtherinformationregardinglegalproceedings.
CommonStockMarketPrices
TheCompany’sCommonStockislistedontheNewYorkStockExchangeunderthesymbolJNJ.AsofFebruary19,
2013,therewere169,820recordholdersofCommonStockoftheCompany.Thecompositemarketpricerangesfor
Johnson&JohnsonCommonStockduring2012and2011were:
2012 2011
High Low High Low
Firstquarter $66.32 64.02 63.54 57.50
Secondquarter 67.70 61.71 67.37 59.25
Thirdquarter 69.75 66.85 68.05 59.08
Fourthquarter 72.74 67.80 66.32 60.83
Year-endclose $69.48 65.58
18 • Johnson&Johnson2012AnnualReportCautionary Factors That May Affect Future Results
ThisAnnualReportcontainsforward-lookingstatements.Forward-lookingstatementsdonotrelatestrictlytohistoricalor
currentfactsandanticipateresultsbasedonmanagement’splansthataresubjecttouncertainty.Forward-looking
statementsmaybeidentifiedbytheuseofwordssuchas“plans,”“expects,”“will,”“anticipates,”“estimates”andother
wordsofsimilarmeaninginconjunctionwith,amongotherthings,discussionsoffutureoperations,financialperformance,
theCompany’sstrategyforgrowth,productdevelopment,regulatoryapproval,marketpositionandexpenditures.
Forward-lookingstatementsarebasedoncurrentexpectationsoffutureevents.TheCompanycannotguaranteethatany
forward-lookingstatementwillbeaccurate,althoughtheCompanybelievesthatithasbeenreasonableinitsexpectations
andassumptions.Investorsshouldrealizethatifunderlyingassumptionsproveinaccurateorthatunknownrisksor
uncertaintiesmaterialize,actualresultscouldvarymateriallyfromtheCompany’sexpectationsandprojections.Investors
arethereforecautionednottoplaceunduerelianceonanyforward-lookingstatements.TheCompanydoesnotundertake
toupdateanyforward-lookingstatementsasaresultofnewinformationorfutureeventsordevelopments.
Risksanduncertaintiesinclude,butarenotlimitedto,generalindustryconditionsandcompetition;economicfactors,such
asinterestrateandcurrencyexchangeratefluctuations;technologicaladvances,newproductsandpatentsattainedby
competitors;challengesinherentinnewproductdevelopment,includingobtainingregulatoryapprovals;challengesto
patents;significantlitigationorgovernmentactionadversetotheCompany;impactofbusinesscombinations;financial
distressandbankruptciesexperiencedbysignificantcustomersandsuppliers;changestogovernmentallawsand
regulationsandU.S.andforeignhealthcarereforms;trendstowardhealthcarecostcontainment;increasedscrutinyof
thehealthcareindustrybygovernmentagencies;changesinbehaviorandspendingpatternsofpurchasersofhealthcare
productsandservices;financialinstabilityofinternationaleconomiesandsovereignrisk;disruptionsduetonatural
disasters;manufacturingdifficultiesordelays;complexglobalsupplychainswithincreasingregulatoryrequirements;and
productefficacyorsafetyconcernsresultinginproductrecallsorregulatoryaction.
TheCompany’sreportonForm10-KfortheyearendedDecember30,2012includes,inExhibit99,adiscussionof
additionalfactorsthatcouldcauseactualresultstodifferfromexpectations.TheCompanynotesthesefactorsas
permittedbythePrivateSecuritiesLitigationReformActof1995.
Johnson&Johnson2012AnnualReport • 19JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AtDecember30,2012andJanuary1,2012
(DollarsinMillionsExceptShareandPerShareAmounts)(Note1)
2012 2011
Assets
Currentassets
Cashandcashequivalents(Notes1and2) $14,911 24,542
Marketablesecurities(Notes1and2) 6,178 7,719
Accountsreceivabletrade,lessallowancesfordoubtfulaccounts$466(2011,$361) 11,309 10,581
Inventories(Notes1and3) 7,495 6,285
Deferredtaxesonincome(Note8) 3,139 2,556
Prepaidexpensesandotherreceivables 3,084 2,633
Totalcurrentassets 46,116 54,316
Property,plantandequipment,net(Notes1and4) 16,097 14,739
Intangibleassets,net(Notes1and5) 28,752 18,138
Goodwill(Notes1and5) 22,424 16,138
Deferredtaxesonincome(Note8) 4,541 6,540
Otherassets 3,417 3,773
Totalassets $121,347 113,644
LiabilitiesandShareholders’Equity
Currentliabilities
Loansandnotespayable(Note7) $4,676 6,658
Accountspayable 5,831 5,725
Accruedliabilities 7,299 4,608
Accruedrebates,returnsandpromotions 2,969 2,637
Accruedcompensationandemployeerelatedobligations 2,423 2,329
Accruedtaxesonincome 1,064 854
Totalcurrentliabilities 24,262 22,811
Long-termdebt(Note7) 11,489 12,969
Deferredtaxesonincome(Note8) 3,136 1,800
Employeerelatedobligations(Notes9and10) 9,082 8,353
Otherliabilities 8,552 10,631
Totalliabilities 56,521 56,564
Shareholders’equity
Preferredstock–withoutparvalue(authorizedandunissued2,000,000shares) – –
Commonstock–parvalue$1.00pershare(Note12)(authorized4,320,000,000shares;issued
3,119,843,000shares) 3,120 3,120
Accumulatedothercomprehensiveincome(Note13) (5,810) (5,632)
Retainedearnings 85,992 81,251
83,302 78,739
Less:commonstockheldintreasury,atcost(Note12)(341,354,000sharesand395,480,000shares) 18,476 21,659
Totalshareholders’equity 64,826 57,080
Totalliabilitiesandshareholders’equity $121,347 113,644
SeeNotestoConsolidatedFinancialStatements
20 • Johnson&Johnson2012AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(DollarsandSharesinMillionsExceptPerShareAmounts)(Note1)
2012 2011 2010
Salestocustomers $67,224 65,030 61,587
Costofproductssold 21,658 20,360 18,792
Grossprofit 45,566 44,670 42,795
Selling,marketingandadministrativeexpenses 20,869 20,969 19,424
Researchanddevelopmentexpense 7,665 7,548 6,844
In-processresearchanddevelopment(Note5) 1,163 – –
Interestincome (64) (91) (107)
Interestexpense,netofportioncapitalized(Note4) 532 571 455
Other(income)expense,net 1,626 2,743 (768)
Restructuring(Note22) – 569 –
Earningsbeforeprovisionfortaxesonincome 13,775 12,361 16,947
Provisionfortaxesonincome(Note8) 3,261 2,689 3,613
Netearnings 10,514 9,672 13,334
Add:Netlossattributabletononcontrollinginterest 339 – –
NetearningsattributabletoJohnson&Johnson $10,853 9,672 13,334
NetearningspershareattributabletoJohnson&Johnson(Notes1and15)
Basic $3.94 3.54 4.85
Diluted $3.86 3.49 4.78
Cashdividendspershare $2.40 2.25 2.11
Averagesharesoutstanding(Notes1and15)
Basic 2,753.3 2,736.0 2,751.4
Diluted 2,812.6 2,775.3 2,788.8
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2012AnnualReport • 21JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(DollarsinMillions)(Note1)
2012 2011 2010
NetEarnings $10,514 9,672 13,334
OtherComprehensiveIncome(Loss),netoftax
Foreigncurrencytranslation 1,230 (557) (461)
Securities:
Unrealizedholdinggain(loss)arisingduringperiod (248) 565 99
Reclassificationstoearnings (5) (141) (45)
Netchange (253) 424 54
Employeebenefitplans:
Priorservicecostamortizationduringperiod 2 5 4
Priorservicecost–currentyear (8) 15 –
Gain(loss)amortizationduringperiod 370 246 188
Gain(loss)–currentyear (1,643) (1,984) (203)
Effectofexchangerates (52) 18 (10)
Netchange (1,331) (1,700) (21)
Derivatives&hedges:
Unrealizedgain(loss)arisingduringperiod 52 (500) (333)
Reclassificationstoearnings 124 232 288
Netchange 176 (268) (45)
OtherComprehensiveIncome(Loss) (178) (2,101) (473)
ComprehensiveIncome $10,336 7,571 12,861
ComprehensiveLossAttributableToNoncontrollingInterest,netoftax 339 – –
ComprehensiveIncomeAttributableToJohnson&Johnson $10,675 7,571 12,861
Thetaxeffectsinothercomprehensiveincomeforthefiscalyearsended2012,2011and2010respectively:Securities;
$136million,$228millionand$29million,EmployeeBenefitPlans;$653million$915millionand$11million,
Derivatives&Hedges;$95million,$144millionand$25million.
Foreigncurrencytranslationisnotadjustedforincometaxesasitrelatestopermanentinvestmentsininternational
subsidiaries.
SeeNotestoConsolidatedFinancialStatements
22 • Johnson&Johnson2012AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(DollarsinMillions)(Note1)
Accumulated
Other Treasury
Retained Comprehensive CommonStock Stock
Total Earnings Income IssuedAmount Amount
Balance,January3,2010 $50,588 70,306 (3,058) 3,120 (19,780)
NetearningsattributabletoJohnson&Johnson 13,334 13,334
Cashdividendspaid (5,804) (5,804)
Employeecompensationandstockoptionplans 1,731 (63) 1,794
Repurchaseofcommonstock (2,797) (2,797)
Othercomprehensiveincome,netoftax: (473) (473)
Balance,January2,2011 $56,579 77,773 (3,531) 3,120 (20,783)
NetearningsattributabletoJohnson&Johnson 9,672 9,672
Cashdividendspaid (6,156) (6,156)
Employeecompensationandstockoptionplans 1,760 111 1,649
Repurchaseofcommonstock (2,525) (2,525)
Other (149) (149)
Othercomprehensiveincome,netoftax: (2,101) (2,101)
Balance,January1,2012 $57,080 81,251 (5,632) 3,120 (21,659)
NetearningsattributabletoJohnson&Johnson 10,853 10,853
Cashdividendspaid (6,614) (6,614)
Employeecompensationandstockoptionplans 3,269 19 3,250
Issuanceofcommonstockassociatedwiththe
acquisitionofSynthes,Inc. 13,335 483 12,852
Repurchaseofcommonstock(1) (12,919) (12,919)
Othercomprehensiveincome,netoftax: (178) (178)
Balance,December30,2012 $64,826 85,992 (5,810) 3,120 (18,476)
(1) IncludesrepurchaseofcommonstockassociatedwiththeacquisitionofSynthes,Inc.
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2012AnnualReport • 23JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DollarsinMillions)(Note1)
2012 2011 2010
Cashflowsfromoperatingactivities
Netearnings $10,514 9,672 13,334
Adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities:
Depreciationandamortizationofpropertyandintangibles 3,666 3,158 2,939
Stockbasedcompensation 662 621 614
Noncontrollinginterest 339 – –
Assetwrite-downsandimpairments 2,131 160 –
Deferredtaxprovision (39) (836) 356
Accountsreceivableallowances 92 32 12
Changesinassetsandliabilities,netofeffectsfromacquisitions:
Increaseinaccountsreceivable (9) (915) (207)
Increaseininventories (1) (715) (196)
Increaseinaccountspayableandaccruedliabilities 2,768 493 20
Increaseinothercurrentandnon-currentassets (2,172) (1,785) (574)
(Decrease)/increaseinothercurrentandnon-currentliabilities (2,555) 4,413 87
Netcashflowsfromoperatingactivities 15,396 14,298 16,385
Cashflowsfrominvestingactivities
Additionstoproperty,plantandequipment (2,934) (2,893) (2,384)
Proceedsfromthedisposalofassets 1,509 1,342 524
Acquisitions,netofcashacquired(Note20) (4,486) (2,797) (1,269)
Purchasesofinvestments (13,434) (29,882) (15,788)
Salesofinvestments 14,797 30,396 11,101
Other(primarilyintangibles) 38 (778) (38)
Netcashusedbyinvestingactivities (4,510) (4,612) (7,854)
Cashflowsfromfinancingactivities
Dividendstoshareholders (6,614) (6,156) (5,804)
Repurchaseofcommonstock (12,919) (2,525) (2,797)
Proceedsfromshort-termdebt 3,268 9,729 7,874
Retirementofshort-termdebt (6,175) (11,200) (6,565)
Proceedsfromlong-termdebt 45 4,470 1,118
Retirementoflong-termdebt (804) (16) (32)
Proceedsfromtheexerciseofstockoptions/excesstaxbenefits 2,720 1,246 1,226
Other (83) – –
Netcashusedbyfinancingactivities (20,562) (4,452) (4,980)
Effectofexchangeratechangesoncashandcashequivalents 45 (47) (6)
(Decrease)/increaseincashandcashequivalents (9,631) 5,187 3,545
Cashandcashequivalents,beginningofyear(Note1) 24,542 19,355 15,810
Cashandcashequivalents,endofyear(Note1) $14,911 24,542 19,355
Supplementalcashflowdata
Cashpaidduringtheyearfor:
Interest $ 616 576 491
Incometaxes 2,507 2,970 2,442
Supplementalscheduleofnon-cashinvestingandfinancingactivities
IssuanceofcommonstockassociatedwiththeacquisitionofSynthes,Inc. 13,335 – –
Treasurystockissuedforemployeecompensationandstockoptionplans,netofcashproceeds 615 433 673
Conversionofdebt – 1 1
Acquisitions
Fairvalueofassetsacquired $19,025 3,025 1,321
Fairvalueofliabilitiesassumedandnoncontrollinginterests (1,204) (228) (52)
Netfairvalueofacquisitions $17,821 2,797 1,269
Less:IssuanceofcommonstockassociatedwiththeacquisitionofSynthes,Inc. 13,335 – –
Netcashpaidforacquisitions $ 4,486 2,797 1,269
SeeNotestoConsolidatedFinancialStatements
24 • Johnson&Johnson2012AnnualReportNotes to Consolidated Financial Statements
1. SummaryofSignificantAccountingPolicies
PrinciplesofConsolidation
TheconsolidatedfinancialstatementsincludetheaccountsofJohnson&Johnsonanditssubsidiaries(theCompany).
Intercompanyaccountsandtransactionsareeliminated.
DescriptionoftheCompanyandBusinessSegments
TheCompanyhasapproximately127,600employeesworldwideengagedintheresearchanddevelopment,manufacture
andsaleofabroadrangeofproductsinthehealthcarefield.TheCompanyconductsbusinessinvirtuallyallcountriesof
theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwell-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevicesand
Diagnostics.TheConsumersegmentincludesabroadrangeofproductsusedinthebabycare,skincare,oralcare,
woundcareandwomen’shealthfields,aswellasnutritionalandover-the-counterpharmaceuticalproductsandwellness
andpreventionplatforms.Theseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutletsand
distributorsthroughouttheworld.ThePharmaceuticalsegmentincludesproductsinthefollowingareas:anti-infective,
antipsychotic,contraceptive,gastrointestinal,hematology,immunology,infectiousdiseases,neurology,oncology,pain
management,thrombosisandvaccines.Theseproductsaredistributeddirectlytoretailers,wholesalersandhealthcare
professionalsforprescriptionuse.TheMedicalDevicesandDiagnosticssegmentincludesabroadrangeofproducts
distributedtowholesalers,hospitalsandretailers,usedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals
andclinics.Theseincludeproductstotreatcardiovasculardisease;orthopaedicandneurologicalproducts;bloodglucose
monitoringandinsulindeliveryproducts;generalsurgery,biosurgicalandenergyproducts;professionaldiagnostic
products;infectionpreventionproducts;anddisposablecontactlenses.
NewAccountingPronouncements
RecentlyAdoptedAccountingPronouncements
Duringthefiscalfirstquarterof2012,theCompanyadoptedtheFinancialAccountingStandardsBoard(FASB)guidance
andamendmentsissuedrelatedtogoodwillimpairmenttesting.Undertheamendmentsinthisupdate,anentityhasthe
optiontofirstassessqualitativefactorstodeterminewhethertheexistenceofeventsorcircumstancesleadstoa
determinationthatitismorelikelythannotthatthefairvalueofareportingunitislessthanitscarryingamount.If,after
assessingthetotalityofeventsorcircumstances,anentitydeterminesitisnotmorelikelythannotthatthefairvalueofa
reportingunitislessthanitscarryingamount,thenperformingthetwo-stepimpairmenttestisunnecessary.However,ifan
entityconcludesotherwise,thenitisrequiredtoperformthefirststepofthetwo-stepimpairmenttest.Thisupdate
becameeffectiveforannualandinterimgoodwillimpairmenttestsperformedforfiscalyearsbeginningafterDecember15,
2011.TheadoptionofthisstandarddidnothaveamaterialimpactontheCompany’sresultsofoperations,cashflowsor
financialposition.
Duringthefiscalfirstquarterof2012,theCompanyadoptedtheFASBamendmenttothedisclosurerequirementsfor
presentationofcomprehensiveincome.Theamendmentrequiresthatallnon-ownerchangesinstockholders’equitybe
presentedeitherinasinglecontinuousstatementofcomprehensiveincomeorintwoseparatebutconsecutive
statements.Thisguidancebecameeffectiveretrospectivelyfortheinterimperiodsandannualperiodsbeginningafter
December15,2011.
Duringthefiscalfirstquarterof2012,theCompanyadoptedtheFASBamendmentstodisclosurerequirementsforfair
valuemeasurement.Theseamendmentsresultinconvergenceoffairvaluemeasurementanddisclosurerequirements
betweenU.S.GenerallyAcceptedAccountingPrinciples(GAAP)andInternationalFinancialReportingStandards(IFRS).
ThisguidancebecameeffectiveprospectivelyfortheinterimperiodsandannualperiodsbeginningafterDecember15,
2011.TheadoptionofthisstandarddidnothaveamaterialimpactontheCompany’sresultsofoperations,cashflowsor
financialposition.
Johnson&Johnson2012AnnualReport • 25RecentlyIssuedAccountingStandards
NotAdoptedasofDecember30,2012
Duringthefiscalthirdquarterof2012,theFASBissuedguidanceandamendmentsrelatedtotestingindefinitelived
intangibleassetsforimpairment.Undertheamendmentsinthisupdate,anentityhastheoptiontofirstassessqualitative
factorstodeterminewhethertheexistenceofeventsorcircumstancesindicatesthatitismorelikelythannotthatthe
indefinitelivedintangibleassetisimpaired.If,afterassessingthetotalityofeventsandcircumstances,anentityconcludes
thatitisnotmorelikelythannotthattheindefinitelivedintangibleassetisimpaired,thentheentityisnotrequiredto
determinethefairvalue.However,ifanentityconcludesotherwise,thenitisrequiredtodeterminethefairvalueofthe
indefinitelivedintangibleassetandperformthequantitativeimpairmenttest.Anentityalsohastheoptiontobypassthe
qualitativeassessmentforanyindefinitelivedintangibleassetinanyperiodandproceeddirectlytoperformingthe
quantitativeimpairmenttest.Thisupdatebecameeffectiveforannualandinterimimpairmenttestsperformedforfiscal
yearsbeginningafterSeptember15,2012.
However,earlyadoptionispermitted.Theadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthe
Company’sresultsofoperations,cashflowsorfinancialposition.
InFebruary2013,theFASBissuedguidancerelatedtoadditionalreportinganddisclosureofamountsreclassifiedoutof
accumulatedothercomprehensiveincome(OCI).Underthisnewguidance,companieswillberequiredtodisclosethe
amountofincome(orloss)reclassifiedoutofOCItoeachrespectivelineitemontheincomestatementofwherenet
incomeispresented.Theguidanceallowscompaniestoelectwhethertodisclosethereclassificationeitherinthenotesto
thefinancialstatements,oronthefaceoftheincomestatement.Thisupdateiseffectiveforannualandinterimreporting
periodsforfiscalyearsbeginningafterDecember15,2012.Theadoptionofthisstandardisnotexpectedhaveamaterial
impactontheCompany’sresultsofoperations,cashflowsorfinancialposition.
CashEquivalents
TheCompanyconsiderssecuritieswithmaturitiesofthreemonthsorless,whenpurchased,tobecashequivalents.
Investments
Short-termmarketablesecuritiesarecarriedatcost,whichapproximatesfairvalue.Investmentsclassifiedasavailable-for-
salearecarriedatestimatedfairvaluewithunrealizedgainsandlossesrecordedasacomponentofaccumulatedother
comprehensiveincome.Long-termdebtsecuritiesthattheCompanyhastheabilityandintenttoholduntilmaturityare
carriedatamortizedcost.Managementdeterminestheappropriateclassificationofitsinvestmentindebtandequity
securitiesatthetimeofpurchaseandre-evaluatessuchdeterminationateachbalancesheetdate.TheCompany
periodicallyreviewsitsinvestmentsinequitysecuritiesforimpairmentandadjuststheseinvestmentstotheirfairvalue
whenadeclineinmarketvalueisdeemedtobeotherthantemporary.Iflossesonthesesecuritiesareconsideredtobe
otherthantemporary,thelossisrecognizedinearnings.
Property,PlantandEquipmentandDepreciation
Property,plantandequipmentarestatedatcost.TheCompanyutilizesthestraight-linemethodofdepreciationoverthe
estimatedusefullivesoftheassets:
Buildingandbuildingequipment 20-30years
Landandleaseholdimprovements 10-20years
Machineryandequipment 2-13years
TheCompanycapitalizescertaincomputersoftwareanddevelopmentcosts,includedinmachineryandequipment,when
incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternaluse.Capitalizedsoftwarecostsare
amortizedovertheestimatedusefullivesofthesoftware,whichgenerallyrangefrom3to8years.
TheCompanyreviewslong-livedassetstoassessrecoverabilityusingundiscountedcashflows.Whencertaineventsor
changesinoperatingoreconomicconditionsoccur,animpairmentassessmentmaybeperformedontherecoverabilityof
thecarryingvalueoftheseassets.Iftheassetisdeterminedtobeimpaired,thelossismeasuredbasedonthedifference
betweentheasset’sfairvalueanditscarryingvalue.Ifquotedmarketpricesarenotavailable,theCompanywillestimate
fairvalueusingadiscountedvalueofestimatedfuturecashflows.
26 • Johnson&Johnson2012AnnualReportRevenue Recognition
TheCompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss
passtothecustomer.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,productreturnsand
discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorded.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingpriceschargedbycompetitors.Rebates,thelargestbeingtheMedicaidrebate
provision,areestimatedbasedoncontractualterms,historicalexperience,trendanalysisandprojectedmarketconditions
inthevariousmarketsserved.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarily
throughtheanalysisofwholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternally
generatedinformation.
Salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibit
unusualsalesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedand
analyzedaspartoftheaccountingforsalesreturnsaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa
percenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescreditto
customersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewithU.S.GAAP
guidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsalesvalue.Sales
returnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsforcertain
franchisesintheMedicalDevicesandDiagnosticssegmentaretypicallyresalablebutarenotmaterial.TheCompany
rarelyexchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhas
rangedbetween1.0%and1.2%ofannualsalestocustomersduringthefiscalreportingyears2012,2011and2010.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
yearincurred.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentiveprograms.The
redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.Volume-based
incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare
sold.TheCompanyalsoearnsservicerevenueforco-promotionofcertainproductsandincludesitinsalestocustomers.
Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferred.
ShippingandHandling
Shippingandhandlingcostsincurredwere$1,051million,$1,022millionand$945millionin2012,2011and2010,
respectively,andareincludedinselling,marketingandadministrativeexpense.Theamountofrevenuereceivedfor
shippingandhandlingislessthan0.5%ofsalestocustomersforallperiodspresented.
Inventories
Inventoriesarestatedatthelowerofcostormarketdeterminedbythefirst-in,first-outmethod.
IntangibleAssetsandGoodwill
TheauthoritativeliteratureonU.S.GAAPrequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed
annuallyforimpairment.TheCompanycompletedtheannualimpairmenttestfor2012inthefiscalfourthquarter.Future
impairmenttestswillbeperformedannuallyinthefiscalfourthquarter,orsoonerifwarranted,aswasthecaseforcertain
indefinitelivedintangibleassetsinthefiscalsecondandthirdquartersof2012.Purchasedin-processresearchand
developmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted,atwhich
pointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleasset,orabandoned,atwhichpointthe
intangibleassetwillbewrittenofforpartiallyimpaired.
Intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullives,andarereviewedfor
impairmentwhenwarrantedbyeconomicconditions.SeeNote5forfurtherdetailsonIntangibleAssetsandGoodwill.
FinancialInstruments
AsrequiredbyU.S.GAAP,allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Fairvalueistheexit
pricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-basedmeasurement
Johnson&Johnson2012AnnualReport • 27determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.Theauthoritativeliterature
establishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue,withLevel1havingthehighest
priorityandLevel3havingthelowest.Changesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings
orothercomprehensiveincome,dependingonwhetherthederivativeisdesignatedaspartofahedgetransaction,andif
so,thetypeofhedgetransaction.
TheCompanydocumentsallrelationshipsbetweenhedgeditemsandderivatives.Theoverallriskmanagementstrategy
includesreasonsforundertakinghedgetransactionsandenteringintoderivatives.Theobjectivesofthisstrategyare:
(1)minimizeforeigncurrencyexposure’simpactontheCompany’sfinancialperformance;(2)protecttheCompany’scash
flowfromadversemovementsinforeignexchangerates;(3)ensuretheappropriatenessoffinancialinstruments;and
(4)managetheenterpriseriskassociatedwithfinancialinstitutions.SeeNote6foradditionalinformationonFinancial
Instruments.
ProductLiability
Accrualsforproductliabilityclaimsarerecorded,onanundiscountedbasis,whenitisprobablethataliabilityhasbeen
incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformation.Theaccrualsare
adjustedperiodicallyasadditionalinformationbecomesavailable.
Asaresultofcostandavailabilityfactors,effectiveNovember1,2005,theCompanyceasedpurchasingthird-party
productliabilityinsurance.TheCompanyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompanyandis
insureduptocertainlimits.Inadditiontoaccrualsintheselfinsuranceprogram,claimsthatexceedtheinsurance
coverageareaccruedwhenlossesareprobableandamountscanbereasonablyestimated.Basedontheavailabilityof
priorcoverage,receivablesforinsurancerecoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscounted
basis,whenitisprobablethatarecoverywillberealized.Asappropriate,reservesagainstthesereceivablesarerecorded
forestimatedamountsthatmaynotbecollectedfromthird-partyinsurers.
ConcentrationofCreditRisk
Globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge
numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimits.Recenteconomicchallengesin
Italy,Spain,GreeceandPortugal(theSouthernEuropeanRegion)haveimpactedcertainpaymentpatterns,whichhave
historicallybeenlongerthanthoseexperiencedintheU.S.andotherinternationalmarkets.Thetotalnettradeaccounts
receivablebalanceintheSouthernEuropeanRegionwasapproximately$2.1billionasofDecember30,2012and
approximately$2.4billionasofJanuary1,2012.Approximately$1.2billionasofDecember30,2012andapproximately
$1.4billionasofJanuary1,2012oftheSouthernEuropeanRegionnettradeaccountsreceivablebalancerelatedtothe
Company’sConsumer,VisionCareandDiabetesCarebusinessesaswellascertainPharmaceuticalandMedicalDevices
andDiagnosticscustomerswhichareinlinewithhistoricalcollectionpatterns.
TheremainingbalanceofnettradeaccountsreceivableintheSouthernEuropeanRegionhasbeennegativelyimpacted
bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain
distributorsofthePharmaceuticalandMedicalDevicesandDiagnosticslocalaffiliates.Thetotalnettradeaccounts
receivablebalanceforthesecustomerswereapproximately$0.9billionatDecember30,2012and$1.0billionat
January1,2012.TheCompanycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepayment
premiums.Forcustomerswherepaymentisexpectedoverperiodsoftimelongerthanoneyear,revenueandtrade
receivableshavebeendiscountedovertheestimatedperiodoftimeforcollection.Allowancesfordoubtfulaccountshave
beenincreasedforthesecustomers,buthavebeenimmaterialtodate.TheCompanywillcontinuetoworkcloselywith
thesecustomersonpaymentplans,monitortheeconomicsituationandtakeappropriateactionsasnecessary.
ResearchandDevelopment
Researchanddevelopmentexpensesareexpensedasincurred.Upfrontandmilestonepaymentsmadetothirdpartiesin
connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval.
Paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful
lifeoftherelatedproduct.Amountscapitalizedforsuchpaymentsareincludedinotherintangibles,netofaccumulated
amortization.
28 • Johnson&Johnson2012AnnualReportTheCompanyentersintocollaborativearrangements,typicallywithotherpharmaceuticalorbiotechnologycompanies,to
developandcommercializedrugcandidatesorintellectualproperty.Thesearrangementstypicallyinvolvetwo(ormore)
partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe
commercialsuccessoftheactivities.Thesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties,
includingresearchanddevelopment,marketingandsellinganddistribution.Often,thesecollaborationsrequireupfront,
milestoneandroyaltyorprofitsharepayments,contingentupontheoccurrenceofcertainfutureeventslinkedtothe
successoftheassetindevelopment.Amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare
generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract
developmentservicesisnotcentraltotheCompany’soperations.Ingeneral,theincomestatementpresentationforthese
collaborationsisasfollows:
Nature/TypeofCollaboration StatementofEarningsPresentation
Third-partysaleofproduct Salestocustomers
Royalties/milestonespaidtocollaborativepartner Costofgoodssold
(post-regulatoryapproval)*
Royaltiesreceivedfromcollaborativepartner Otherincome(expense),net
Upfrontpayments&milestonespaidtocollaborativepartner Researchanddevelopmentexpense
(pre-regulatoryapproval)
Researchanddevelopmentpaymentstocollaborative Researchanddevelopmentexpense
partner
Researchanddevelopmentpaymentsreceivedfrom ReductionofResearchanddevelopmentexpense
collaborativepartner
* Milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife.
Forallyearspresented,therewasnoindividualprojectthatrepresentedgreaterthan5%ofthetotalannualconsolidated
researchanddevelopmentexpense.
Advertising
Costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinselling,marketingand
administrativeexpenses.Advertisingexpensesworldwide,whichcomprisedtelevision,radio,printmediaandInternet
advertising,were$2.3billion,$2.6billionand$2.5billionin2012,2011and2010,respectively.
IncomeTaxes
Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany
differencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.TheCompany
estimatesdeferredtaxassetsandliabilitiesbasedoncurrenttaxregulationsandrates.Changesintaxlawsandratesmay
affectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
AtDecember30,2012andJanuary1,2012,thecumulativeamountsofundistributedinternationalearningswere
approximately$49.0billionand$41.6billion,respectively.AtDecember30,2012andJanuary1,2012,theCompany’s
foreignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsof$14.8billionand$24.5billion,
respectively.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational
subsidiarieswheretheearningsareconsideredtobepermanentlyreinvested.TheCompanyintendstocontinueto
reinvesttheseearningsininternationaloperations.IftheCompanydecidedatalaterdatetorepatriatetheseearningsto
theU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectsontheseamounts.TheCompanydoesnot
determinethedeferredtaxliabilityassociatedwiththeseundistributedearnings,assuchdeterminationisnotpracticable.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
Johnson&Johnson2012AnnualReport • 29NetEarningsPerShare
Basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage
numberofcommonsharesoutstandingfortheperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcould
occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod.
UseofEstimates
Thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe
U.S.requiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreported.Estimatesareusedwhen
accountingforsalesdiscounts,rebates,allowancesandincentives,productliabilities,incometaxes,depreciation,
amortization,employeebenefits,contingenciesandintangibleassetandliabilityvaluations.Actualresultsmayormaynot
differfromthoseestimates.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
AnnualClosingDate
TheCompanyfollowstheconceptofafiscalyear,whichendsontheSundaynearesttotheendofthemonthof
December.Normallyeachfiscalyearconsistsof52weeks,buteveryfiveorsixyearsthefiscalyearconsistsof53weeks,
aswasthecasein2009,andwillbethecaseagainin2015.
Reclassification
Certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
2. Cash,CashEquivalentsandCurrentMarketableSecurities
Attheendof2012and2011,cash,cashequivalentsandcurrentmarketablesecuritieswerecomprisedof:
(DollarsinMillions) 2012 2011
Cash $3,032 2,709
Governmentsecuritiesandobligations 15,323 27,017
Corporatedebtsecurities 622 489
Moneymarketfunds 1,406 1,590
Timedeposits 706 456
Totalcash,cashequivalentsandcurrentmarketablesecurities $21,089 32,261
TheestimatedfairvaluewasthesameastheamortizedcostasofDecember30,2012.Theestimatedfairvaluewas
$32,262millionasofJanuary1,2012reflectinga$1millionunrealizedgainingovernmentsecuritiesandobligations.
AsofDecember30,2012,currentmarketablesecuritiesconsistedof$5,726millionand$452millionofgovernment
securitiesandobligations,andcorporatedebtsecurities,respectively.
AsofJanuary1,2012,currentmarketablesecuritiesconsistedof$7,545millionand$174millionofgovernment
securitiesandobligations,andcorporatedebtsecurities,respectively.
Fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker
pricesandsignificantotherobservableinputs.
TheCompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhigh-quality
moneymarketinstruments.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat
leastanA(orequivalent)creditrating.
30 • Johnson&Johnson2012AnnualReport3. Inventories
Attheendof2012and2011,inventorieswerecomprisedof:
(DollarsinMillions) 2012 2011
Rawmaterialsandsupplies $1,416 1,206
Goodsinprocess 2,262 1,637
Finishedgoods 3,817 3,442
Totalinventories $7,495 6,285
AsofDecember30,2012,theremaininginventorystep-uprelatedtotheSynthes,Inc.,acquisitionisapproximately
$150million.
4. Property,PlantandEquipment
Attheendof2012and2011,property,plantandequipmentatcostandaccumulateddepreciationwere:
(DollarsinMillions) 2012 2011
Landandlandimprovements $793 754
Buildingsandbuildingequipment 10,046 9,389
Machineryandequipment 21,075 19,182
Constructioninprogress 2,740 2,504
Totalproperty,plantandequipment,gross $34,654 31,829
Lessaccumulateddepreciation 18,557 17,090
Totalproperty,plantandequipment,net $16,097 14,739
TheCompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipment.Interestexpense
capitalizedin2012,2011and2010was$115million,$84millionand$73million,respectively.
Depreciationexpense,includingtheamortizationofcapitalizedinterestin2012,2011and2010,was$2.5billion,$2.3
billionand$2.2billion,respectively.
Uponretirementorotherdisposalofproperty,plantandequipment,thecostsandrelatedamountsofaccumulated
depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccounts,respectively.The
difference,ifany,betweenthenetassetvalueandtheproceedsarerecordedinearnings.
5. IntangibleAssetsandGoodwill
Attheendof2012and2011,thegrossandnetamountsofintangibleassetswere:
(DollarsinMillions) 2012 2011
Intangibleassetswithdefinitelives:
Patentsandtrademarks–gross $8,890 7,947
Lessaccumulatedamortization 3,416 2,976
Patentsandtrademarks–net $5,474 4,971
Customerrelationshipsandotherintangibles–gross $18,755 8,716
Lessaccumulatedamortization 4,030 3,432
Customerrelationshipsandotherintangibles–net $14,725 5,284
Intangibleassetswithindefinitelives:
Trademarks $7,648 6,034
Purchasedin-processresearchanddevelopment 905 1,849
Totalintangibleassetswithindefinitelives $8,553 7,883
Totalintangibleassets–net $28,752 18,138
Johnson&Johnson2012AnnualReport • 31GoodwillasofDecember30,2012andJanuary1,2012,asallocatedbysegmentofbusiness,wasasfollows:
MedDevices
and
(DollarsinMillions) Consumer Pharmaceuticals Diagnostics Total
GoodwillatJanuary2,2011 $8,144 1,225 5,925 15,294
Acquisitions 251 538 198 987
Currencytranslation/other (97) (42) (4) (143)
GoodwillatJanuary1,2012 $8,298 1,721 6,119 16,138
Acquisitions 10 46 6,045 6,101
Currencytranslation/other 211 25 (51) 185
GoodwillatDecember30,2012 $8,519 1,792 12,113 22,424
Theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible
assetsare17yearsand24years,respectively.Theamortizationexpenseofamortizableassetswas$1,146million,
$852millionand$748millionbeforetax,forthefiscalyearsendedDecember30,2012,January1,2012andJanuary2,
2011,respectively.Theestimatedamortizationexpenseforthefivesucceedingyearsapproximates$1,350millionbefore
tax,peryear.Amortizationexpenseisincludedincostofproductssold.
Intangibleassetsandgoodwillincreasedby$12.9billionand$6.0billion,respectively,basedonthepurchaseprice
allocationfortheSynthes,Inc.,acquisition.SeeNote20totheConsolidatedFinancialStatementsforadditionaldetailson
theSynthes,Inc.,acquisition.Theincreaseinintangibleassetswaspartiallyoffsetby$0.8billioninintangibleassetwrite-
downsanda$1.2billionimpairmentofpurchasedin-processresearchanddevelopment,primarilyrelatedtothe
discontinuationofthePhaseIIIclinicaldevelopmentofbapineuzumabIVandthepartialimpairmentrelatedtotheCrucell
vaccinebusiness.
6. FairValueMeasurements
TheCompanyusesforwardexchangecontractstomanageitsexposuretothevariabilityofcashflows,primarilyrelatedto
theforeignexchangeratechangesoffutureintercompanyproductandthird-partypurchasesofrawmaterials
denominatedinforeigncurrency.TheCompanyalsousescrosscurrencyinterestrateswapstomanagecurrencyrisk
primarilyrelatedtoborrowings.Bothtypesofderivativesaredesignatedascashflowhedges.TheCompanyalsouses
forwardexchangecontractstomanageitsexposuretothevariabilityofcashflowsforrepatriationofforeigndividends.
Thesecontractsaredesignatedasnetinvestmenthedges.Additionally,theCompanyusesforwardexchangecontractsto
offsetitsexposuretocertainforeigncurrencyassetsandliabilities.Theseforwardexchangecontractsarenotdesignated
ashedgesandtherefore,changesinthefairvaluesofthesederivativesarerecognizedinearnings,therebyoffsettingthe
currentearningseffectoftherelatedforeigncurrencyassetsandliabilities.TheCompanydoesnotenterintoderivative
financialinstrumentsfortradingorspeculativepurposes,orcontaincreditriskrelatedcontingentfeaturesorrequirements
topostcollateral.Onanongoingbasis,theCompanymonitorscounterpartycreditratings.TheCompanyconsiderscredit
non-performancerisktobelow,becausetheCompanyentersintoagreementswithcommercialinstitutionsthathaveat
leastanA(orequivalent)creditrating.AsofDecember30,2012,theCompanyhadnotionalamountsoutstandingfor
forwardforeignexchangecontractsandcrosscurrencyinterestrateswapsof$26.0billionand$2.4billion,respectively.
Allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Changesinthefairvalueofderivativesare
recordedeachperiodincurrentearningsorothercomprehensiveincome,dependingonwhetherthederivativeis
designatedaspartofahedgetransaction,andifso,thetypeofhedgetransaction.
Thedesignationasacashflowhedgeismadeattheentrancedateintothederivativecontract.Atinception,allderivatives
areexpectedtobehighlyeffective.Changesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis
highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings,
andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransaction.Gains/lossesonnetinvestment
hedgesareaccountedforthroughthecurrencytranslationaccountandareinsignificant.Onanongoingbasis,the
Companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesinthecashflowsof
hedgeditems.Ifandwhenaderivativeisnolongerexpectedtobehighlyeffective,hedgeaccountingisdiscontinued.
Hedgeineffectiveness,ifany,isincludedincurrentperiodearningsinOther(income)expense,net.
AsofDecember30,2012,thebalanceofdeferrednetgainsonderivativesincludedinaccumulatedothercomprehensive
incomewas$8millionafter-tax.Foradditionalinformation,seetheConsolidatedStatementsofComprehensiveIncome
andNote13.TheCompanyexpectsthatsubstantiallyalloftheamountrelatedtoforeignexchangecontractswillbe
32 • Johnson&Johnson2012AnnualReportreclassifiedintoearningsoverthenext12monthsasaresultoftransactionsthatareexpectedtooccuroverthatperiod.
ThemaximumlengthoftimeoverwhichtheCompanyishedgingtransactionexposureis18months,excludinginterest
rateswaps.Theamountultimatelyrealizedinearningswilldifferasforeignexchangerateschange.Realizedgainsand
lossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative.
ThefollowingtableisasummaryoftheactivityrelatedtodesignatedderivativesforthefiscalyearsendedDecember30,
2012andJanuary1,2012:
Gain/(Loss) Gain/(Loss)
Gain/(Loss) Reclassifiedfrom Recognizedin
Recognizedin AccumulatedOCI Other
CashFlowHedgesbyIncomeStatementCaption AccumulatedOCI(1) intoIncome(1) Income/Expense(2)
(DollarsinMillions) 2012 2011 2012 2011 2012 2011
Salestocustomers(3) $45 (60) (58) (9) (1) (1)
Costofproductssold(3) 103 (103) (98) (154) (4) 2
Researchanddevelopmentexpense(3) (42) 24 19 (22) (1) (1)
Interest(income)/Interestexpense,net(4) 11 (406) (16) (45) – –
Other(income)expense,net(3) (65) 45 29 (2) – 1
Total $52 (500) (124) (232) (6) 1
Allamountsshowninthetableabovearenetoftax.
(1) Effectiveportion
(2) Ineffectiveportion
(3) Foreignexchangecontracts
(4) Crosscurrencyinterestrateswaps
ForthefiscalyearsendedDecember30,2012andJanuary1,2012,againof$48millionandalossof$23million,
respectively,wasrecognizedinOther(income)expense,net,relatingtoforeignexchangecontractsnotdesignatedas
hedginginstruments.
Fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-based
measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.The
authoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedbelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Thefairvalueofaderivativefinancialinstrument(i.e.,forwardexchangecontract,currencyswap)istheaggregationby
currencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesandsubsequently
convertedtotheU.S.Dollaratthecurrentspotforeignexchangerate.TheCompanydoesnotbelievethatfairvaluesof
thesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementormaturity,orthat
thechangesinfairvaluewillhaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
TheCompanyalsoholdsequityinvestmentsthatareclassifiedasLevel1astheyaretradedinanactiveexchangemarket.
TheCompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequirerevisedvaluationsunder
thisstandardthatarerecognizedatfairvalue.
Thefollowingthreelevelsofinputsareusedtomeasurefairvalue:
Level1–Quotedpricesinactivemarketsforidenticalassetsandliabilities.
Level2–Significantotherobservableinputs.
Level3–Significantunobservableinputs.
Johnson&Johnson2012AnnualReport • 33TheCompany’ssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofDecember30,2012andJanuary1,
2012wereasfollows:
2012 2011
(DollarsinMillions) Level1 Level2 Level3 Total Total(1)
Derivativesdesignatedashedginginstruments:
Assets:
Foreignexchangecontracts $ – 423 – 423 442
Crosscurrencyinterestrateswaps(2) – 98 – 98 15
Total – 521 – 521 457
Liabilities:
Foreignexchangecontracts – 252 – 252 452
Crosscurrencyinterestrateswaps(3) – 10 – 10 594
Total – 262 – 262 1,046
Derivativesnotdesignatedashedginginstruments:
Assets:
Foreignexchangecontracts – 75 – 75 29
SwissFrancOption(4) – – – – 17
Total – 75 – 75 46
Liabilities:
Foreignexchangecontracts – 23 – 23 34
Otherinvestments(5) $1,247 – – 1,247 1,563
(1) 2011assetsandliabilitiesareallclassifiedasLevel2withtheexceptionofOtherinvestmentsof$1,563million,whichareclassified
asLevel1.
(2) Includes$96millionand$15millionofnon-currentassetsforthefiscalyearsendingDecember30,2012andJanuary1,2012,
respectively.
(3) Includes$4millionand$594millionofnon-currentliabilitiesforthefiscalyearsendingDecember30,2012andJanuary1,2012,
respectively.CrosscurrencyinterestrateswapsrelatedtooutstandingEURandGBPnotes,maturedinNovember2012.Theswaps
weresettledatfairmarketvalueandreplacedwithnewswaps.
(4) CurrencyoptionrelatedtotheacquisitionofSynthes,Inc.,whichexpiredinJanuary2012.
(5) Classifiedasnon-currentotherassets.
SeeNotes2and7forfinancialassetsandliabilitiesheldatcarryingamountontheConsolidatedBalanceSheet.
34 • Johnson&Johnson2012AnnualReport7. Borrowings
Thecomponentsoflong-termdebtareasfollows:
Effective Effective
(DollarsinMillions) 2012 Rate% 2011 Rate%
5.15%Debenturesdue2012 $ – –% 599 5.18
0.70%Notesdue2013 500 0.75 500 0.75
3.80%Debenturesdue2013 500 3.82 500 3.82
3monthLIBOR+0%FRNdue2013 500 0.31 500 0.46
3monthLIBOR+0.09%FRNdue2014 750 0.40 750 0.55
1.20%Notesdue2014 999 1.24 999 1.24
2.15%Notesdue2016 898 2.22 898 2.22
5.55%Debenturesdue2017 1,000 5.55 1,000 5.55
5.15%Debenturesdue2018 898 5.15 898 5.15
4.75%Notesdue2019(1BEuro1.3275)(2)/(1BEuro1.2892)(3) 1,321(2) 5.83 1,282(3) 5.35
3%ZeroCouponConvertibleSubordinatedDebenturesdue2020 205 3.00 199 3.00
2.95%Debenturesdue2020 542 3.15 541 3.15
3.55%Notesdue2021 446 3.67 446 3.67
6.73%Debenturesdue2023 250 6.73 250 6.73
5.50%Notesdue2024(500MMGBP1.6169)(2)/(500MMGBP1.5421)(3) 803(2) 6.75 765(3) 5.71
6.95%Notesdue2029 296 7.14 294 7.14
4.95%Debenturesdue2033 500 4.95 500 4.95
5.95%Notesdue2037 995 5.99 995 5.99
5.85%Debenturesdue2038 700 5.86 700 5.86
4.50%Debenturesdue2040 539 4.63 539 4.63
4.85%Notesdue2041 298 4.89 298 4.89
Other 61 – 132 –
13,001(4) 4.14(1) 13,585(4) 4.08(1)
Lesscurrentportion 1,512 616
$11,489 12,969
(1) Weightedaverageeffectiverate.
(2) TranslationrateatDecember30,2012.
(3) TranslationrateatJanuary1,2012.
(4) Theexcessofthefairvalueoverthecarryingvalueofdebtwas$2.2billionin2012and$2.0billionin2011.
Fairvalueofthenon-currentdebtwasestimatedusingmarketprices,whichwerecorroboratedbyquotedbrokerprices
andsignificantotherobservableinputs.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2012,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember19,2013.Interestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementsarenotmaterial.
Throughout2012,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Short-term
borrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$4.7billionattheendof2012,ofwhich
$2.4billionwasborrowedundertheCommercialPaperProgram.Theremainderprincipallyrepresentslocalborrowingby
internationalsubsidiaries.
TheCompanyhasashelfregistrationwiththeU.S.SecuritiesandExchangeCommissionthatenablestheCompanyto
issuedebtsecuritiesandwarrantstopurchasedebtsecuritiesonatimelybasis.
Johnson&Johnson2012AnnualReport • 35Aggregatematuritiesoflong-termobligationscommencingin2012are:
(DollarsinMillions)
After
2013 2014 2015 2016 2017 2017
$1,512 1,789 – 898 1,000 7,802
8. IncomeTaxes
Theprovisionfortaxesonincomeconsistsof:
(DollarsinMillions) 2012 2011 2010
Currentlypayable:
U.S.taxes $2,023 2,392 2,063
Internationaltaxes 1,277 1,133 1,194
Totalcurrentlypayable 3,300 3,525 3,257
Deferred:
U.S.taxes (120) (690) (4)
Internationaltaxes 81 (146) 360
Totaldeferred (39) (836) 356
Provisionfortaxesonincome $3,261 2,689 3,613
AcomparisonofincometaxexpenseattheU.S.statutoryrateof35%in2012,2011and2010,totheCompany’s
effectivetaxrateisasfollows:
(DollarsinMillions) 2012 2011 2010
U.S. $4,664 3,634 6,392
International 9,111 8,727 10,555
Earningsbeforetaxesonincome: $13,775 12,361 16,947
Taxrates:
U.S.statutoryrate 35.0% 35.0 35.0
InternationaloperationsexcludingIreland (9.8) (14.0) (7.5)
IrelandandPuertoRicooperations (3.9) (1.8) (5.1)
Researchandorphandrugtaxcredits — (0.8) (0.6)
U.S.stateandlocal 1.3 2.1 1.0
U.S.manufacturingdeduction (0.9) (0.8) (0.5)
U.S.taxoninternationalincome 1.1 (0.4) (0.6)
Allother(1) 0.9 2.5 (0.4)
Effectivetaxrate 23.7% 21.8 21.3
(1) IncludesU.S.expensesnotfullytaxdeductibleprimarilyrelatedtolitigationexpense.
Theincreaseinthe2012effectivetaxrateascomparedto2011wasduetolowertaxbenefitsontheimpairmentofin-
processresearchanddevelopmentintangibleassetsinlowtaxjurisdictions,increasesintaxableincomeinhighertax
jurisdictionsrelativetolowertaxjurisdictionsandtheexclusionofthebenefitoftheU.S.Research&Development(R&D)
taxcreditandtheCFClook-throughprovisionsfromthe2012fiscalyearfinancialresults.TheR&DtaxcreditandtheCFC
look-throughprovisionswereenactedintolawin2013andwereretroactivetoJanuary1,2012.Theentirebenefitofthe
R&DtaxcreditandtheCFClook-throughprovisionswillbereflectedinthe2013fiscalyearfinancialresults.Theincrease
inthe2011taxrateascomparedto2010wasprimarilyduetocertainU.S.expenseswhicharenotfullytaxdeductible
andhigherU.S.statetaxespartiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictionsrelativetohighertax
jurisdictions.
36 • Johnson&Johnson2012AnnualReportTemporarydifferencesandcarryforwardsfor2012and2011wereasfollows:
2012 2011
DeferredTax DeferredTax
(DollarsinMillions) Asset Liability Asset Liability
Employeerelatedobligations $3,343 3,028
Stockbasedcompensation 1,199 1,358
Depreciation (933) (865)
Non-deductibleintangibles (6,261) (2,997)
InternationalR&Dcapitalizedfortax 1,599 1,509
Reserves&liabilities 1,908 1,527
Incomereportedfortaxpurposes 726 903
Netoperatinglosscarryforwardinternational 1,117 1,183
Miscellaneousinternational 1,291 (371) 1,261 (422)
MiscellaneousU.S. 915 817
Totaldeferredincometaxes $12,098 (7,565) 11,586 (4,284)
Thedifferencebetweenthenetdeferredtaxonincomeperthebalancesheetandthenetdeferredtaxaboveisincludedin
taxesonincomeonthebalancesheet.TheCompanyhaswholly-ownedinternationalsubsidiariesthathavecumulativenet
losses.TheCompanybelievesthatitismorelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincome
sufficienttoutilizethesedeferredtaxassets.
Thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits:
(DollarsinMillions) 2012 2011 2010
Beginningofyear $2,699 2,307 2,403
Increasesrelatedtocurrentyeartaxpositions 538 402 465
Increasesrelatedtopriorperiodtaxpositions 57 87 68
Decreasesrelatedtopriorperiodtaxpositions (41) (77) (431)
Settlements (120) (16) (186)
Lapseofstatuteoflimitations (79) (4) (12)
Endofyear $3,054 2,699 2,307
Theunrecognizedtaxbenefitsof$3.1billionatDecember30,2012,ifrecognized,wouldaffecttheCompany’sannual
effectivetaxrate.TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits
inprogresswithanumberoftaxauthorities.TheU.S.InternalRevenueService(IRS)hascompleteditsauditforthetax
yearsthrough2005;however,therearealimitednumberofissuesremainingopenforpriortaxyearsgoingbackto1999.
InothermajorjurisdictionswheretheCompanyconductsbusiness,theyearsremainopengenerallybacktotheyear
2003.TheCompanybelievesitispossiblethatauditsmaybecompletedbytaxauthoritiesinsomejurisdictionsoverthe
nexttwelvemonths.However,theCompanyisnotabletoprovideareasonablyreliableestimateofthetimingofanyother
futuretaxpaymentsrelatingtouncertaintaxpositions.
TheCompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslong-termliabilities.
Interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpense.TheCompany
recognizedaftertaxinterestof$41millionexpense,$47millionexpenseand$34millionincomein2012,2011and2010,
respectively.Thetotalamountofaccruedinterestwas$422millionand$350millionin2012and2011,respectively.
Johnson&Johnson2012AnnualReport • 379. EmployeeRelatedObligations
Attheendof2012and2011,employeerelatedobligationsrecordedontheConsolidatedBalanceSheetswere:
(DollarsinMillions) 2012 2011
Pensionbenefits $4,488 3,937
Postretirementbenefits 2,789 2,843
Postemploymentbenefits 1,452 1,129
Deferredcompensation 747 863
Totalemployeeobligations 9,476 8,772
Lesscurrentbenefitspayable 394 419
Employeerelatedobligations–non-current $9,082 8,353
Prepaidemployeerelatedobligationsof$194millionand$249millionfor2012and2011,respectively,areincludedin
otherassetsontheConsolidatedBalanceSheets.
10. PensionsandOtherBenefitPlans
TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,definedcontributionand
terminationindemnityplans,whichcovermostemployeesworldwide.TheCompanyalsoprovidespost-retirement
benefits,primarilyhealthcare,toalleligibleU.S.retiredemployeesandtheirdependents.
Manyinternationalemployeesarecoveredbygovernment-sponsoredprogramsandthecosttotheCompanyisnot
significant.
Retirementplanbenefitsareprimarilybasedontheemployee’scompensationduringthelastthreetofiveyearsbefore
retirementandthenumberofyearsofservice.Internationalsubsidiarieshaveplansunderwhichfundsaredepositedwith
trustees,annuitiesarepurchasedundergroupcontracts,orreservesareprovided.
TheCompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture.
TheCompanyusesthedateofitsconsolidatedfinancialstatements(December30,2012andJanuary1,2012,
respectively)asthemeasurementdateforallU.S.andinternationalretirementandotherbenefitplans.
NetperiodicbenefitcostsfortheCompany’sdefinedbenefitretirementplansandotherbenefitplansfor2012,2011and
2010includethefollowingcomponents:
RetirementPlans OtherBenefitPlans
(DollarsinMillions) 2012 2011 2010 2012 2011 2010
Servicecost $722 638 550 175 149 134
Interestcost 878 853 791 165 188 202
Expectedreturnonplanassets (1,236) (1,108) (1,005) (4) (1) (1)
Amortizationofpriorservicecost(credit) 6 9 10 (3) (3) (4)
Amortizationofnettransitionobligation 1 1 1 – – –
Recognizedactuariallosses 494 388 236 76 45 48
Curtailmentsandsettlements – – 1 – – –
Netperiodicbenefitcost $865 781 584 409 378 379
AmountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearfortheCompany’sdefinedbenefit
retirementplansandotherpost-retirementplans:
(DollarsinMillions)
Amortizationofnettransitionobligation $1
Amortizationofnetactuariallosses 775
Amortizationofpriorservicecost 6
38 • Johnson&Johnson2012AnnualReportUnrecognizedgainsandlossesfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceforeach
plan.Forplanswithnoactiveemployees,theyareamortizedovertheaveragelifeexpectancy.Theamortizationofgains
andlossesfortheotherU.S.benefitplansisdeterminedbyusinga10%corridorofthegreaterofthemarketvalueof
assetsortheprojectedbenefitobligation.Totalunamortizedgainsandlossesinexcessofthecorridorareamortizedover
theaverageremainingfutureservice.
Priorservicecosts/benefitsfortheU.S.pensionplansareamortizedovertheremainingfutureserviceofplanparticipants
atthetimeoftheplanamendment.Priorservicecost/benefitfortheotherU.S.benefitplansisamortizedovertheaverage
remainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment.
Theweighted-averageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalue
ofprojectedbenefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear.
RetirementPlans OtherBenefitPlans
2012 2011 2010 2012 2011 2010
WorldwideBenefitPlans
Discountrate 4.25% 5.13% 5.71% 4.55% 5.25% 6.00%
Expectedlong-termrateofreturnonplanassets 8.45% 8.62% 8.68%
Rateofincreaseincompensationlevels 4.08% 4.19% 4.19% 4.28% 4.28% 4.29%
TheCompany’sdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighquality,long-term
fixedincomeinstruments.Theresultingdiscountratesareconsistentwiththedurationofplanliabilities.
TheexpectedratesofreturnonplanassetassumptionsrepresenttheCompany’sassessmentoflong-termreturnson
diversifiedinvestmentportfoliosglobally.Theassessmentisdeterminedusingprojectionsfromexternalfinancialsources,
long-termhistoricalaverages,actualreturnsbyassetclassandthevariousassetclassallocationsbymarket.
Thefollowingtabledisplaystheassumedhealthcarecosttrendrates,forallindividuals:
HealthCarePlans 2012 2011
Healthcarecosttrendrateassumedfornextyear 6.50% 7.50%
Ratetowhichthecosttrendrateisassumedtodecline(ultimatetrend) 4.50% 5.00%
Yeartheratereachestheultimatetrendrate 2032 2018
Aone-percentage-pointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect:
One-Percentage- One-Percentage-
(DollarsinMillions) PointIncrease PointDecrease
HealthCarePlans
Totalinterestandservicecost $42 $(33)
Post-retirementbenefitobligation 496 (394)
Johnson&Johnson2012AnnualReport • 39Thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyear-end
2012and2011fortheCompany’sdefinedbenefitretirementplansandotherpost-retirementplans:
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2012 2011 2012 2011
ChangeinBenefitObligation
Projectedbenefitobligation–beginningofyear $17,424 14,993 3,790 3,572
Servicecost 722 638 175 149
Interestcost 878 853 165 188
Planparticipantcontributions 35 54 – –
Amendments 12 (24) – –
Actuariallosses 2,662 1,698 459 213
Divestitures&acquisitions 629 14 – –
Curtailments&settlements&restructuring (6) (6) – –
Benefitspaidfromplan (697) (659) (432) (320)
Effectofexchangerates 170 (137) 2 (12)
Projectedbenefitobligation–endofyear $21,829 17,424 4,159 3,790
ChangeinPlanAssets
Planassetsatfairvalue–beginningofyear $13,736 13,433 8 14
Actualreturn(loss)onplanassets 1,926 (102) 3 (1)
Companycontributions 1,838 1,135 543 315
Planparticipantcontributions 35 54 – –
Settlements (2) (2) – –
Divestitures&acquisitions 593 (2) – –
Benefitspaidfromplanassets (697) (659) (432) (320)
Effectofexchangerates 107 (121) – –
Planassetsatfairvalue–endofyear $17,536 13,736 122 8
Fundedstatus–endofyear $(4,293) (3,688) (4,037) (3,782)
AmountsRecognizedintheCompany’sBalanceSheetconsistofthefollowing:
Non-currentassets $194 249 – –
Currentliabilities (65) (59) (307) (346)
Non-currentliabilities (4,422) (3,878) (3,730) (3,436)
Totalrecognizedintheconsolidatedbalancesheet–endofyear $(4,293) (3,688) (4,037) (3,782)
AmountsRecognizedinAccumulatedOtherComprehensiveIncomeconsistof
thefollowing:
Netactuarialloss $7,586 6,030 1,601 1,218
Priorservicecost(credit) 9 6 (14) (18)
Unrecognizednettransitionobligation 2 3 – 1
Totalbeforetaxeffects $7,597 6,039 1,587 1,201
AccumulatedBenefitObligations–endofyear $19,267 15,452
ChangesinPlanAssetsandBenefitObligationsRecognizedinOther
ComprehensiveIncome
Netperiodicbenefitcost $865 781 409 378
Netactuarialloss 2,007 2,903 458 197
Amortizationofnetactuarial(loss)gain (494) (388) (76) 8
Priorservicecost 12 (24) – –
Amortizationofpriorservice(cost)credit (6) (9) 3 3
Effectofexchangerates 79 (25) 1 (3)
Totalrecognizedinothercomprehensiveincome,beforetax $1,598 2,457 386 205
Totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome $2,463 3,238 795 583
40 • Johnson&Johnson2012AnnualReportTheCompanyplanstocontinuetofunditsU.S.QualifiedPlanstocomplywiththePensionProtectionActof2006.
InternationalPlansarefundedinaccordancewithlocalregulations.Additionaldiscretionarycontributionsaremadewhen
deemedappropriatetomeetthelong-termobligationsoftheplans.Forcertainplans,fundingisnotacommonpractice,as
fundingprovidesnoeconomicbenefit.Consequently,theCompanyhasseveralpensionplansthatarenotfunded.
In2012,theCompanycontributed$1,399millionand$439milliontoitsU.S.andinternationalpensionplans,
respectively.
ThefollowingtabledisplaysthefundedstatusoftheCompany’sU.S.Qualified&Non-Qualifiedpensionplansand
internationalfundedandunfundedpensionplansatDecember30,2012andJanuary1,2012,respectively:
U.S.Plans InternationalPlans
QualifiedPlans Non-QualifiedPlans FundedPlans UnfundedPlans
(DollarsinMillions) 2012 2011 2012 2011 2012 2011 2012 2011
PlanAssets $11,464 9,132 – – 6,072 4,604 – –
ProjectedBenefitObligation 12,420 10,283 1,343 1,155 7,586 5,626 480 360
AccumulatedBenefitObligation 11,001 9,147 1,070 903 6,774 5,078 422 324
Over(Under)FundedStatus
ProjectedBenefitObligation $(956) (1,151) (1,343) (1,155) (1,514) (1,022) (480) (360)
AccumulatedBenefitObligation 463 (15) (1,070) (903) (702) (474) (422) (324)
Planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligation,projected
benefitobligationandplanassetsof$6.5billion,$7.4billionand$4.0billion,respectivelyattheendof2012and$13.8
billion,$15.4billionand$11.7billion,respectively,attheendof2011.
ThefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromtheCompany’sretirementandotherbenefitplans:
(DollarsinMillions) 2013 2014 2015 2016 2017 2018-2022
Projectedfuturebenefitpayments
Retirementplans $695 715 736 775 820 4,934
Otherbenefitplans–gross 327 221 220 220 220 1,121
Medicarerebates (11) – – – – –
Otherbenefitplans–net $316 221 220 220 220 1,121
ThefollowingtabledisplaystheprojectedfutureminimumcontributionstotheCompany’sU.S.andinternationalunfunded
retirementplans.TheseamountsdonotincludeanydiscretionarycontributionsthattheCompanymayelecttomakeinthe
future.
(DollarsinMillions) 2013 2014 2015 2016 2017 2018-2022
Projectedfuturecontributions
UnfundedU.S.retirementplans $43 46 49 52 56 354
Unfundedinternationalretirementplans $25 20 22 24 24 148
Eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand
investmentofthepensionplans.Indetermininginvestmentpolicies,strategiesandgoals,eachcommitteeorboard
considersfactorsincluding,localpensionrulesandregulations;localtaxregulations;availabilityofinvestmentvehicles
(separateaccounts,commingledaccounts,insurancefunds,etc.);fundedstatusoftheplans;ratioofactivestoretirees;
durationofliabilities;andotherrelevantfactorsincluding;diversification,liquidityoflocalmarketsandliquidityofbase
currency.AmajorityoftheCompany’spensionfundsareopentonewentrantsandareexpectedtobeon-goingplans.
Permittedinvestmentsareprimarilyliquidand/orlisted,withlittlerelianceonilliquidandnon-traditionalinvestmentssuch
ashedgefunds.
Johnson&Johnson2012AnnualReport • 41TheCompany’sretirementplanassetallocationattheendof2012and2011andtargetallocationsfor2013areas
follows:
Percentof
Target
PlanAssets
Allocation
2012 2011 2013
WorldwideRetirementPlans
Equitysecurities 75% 70% 71%
Debtsecurities 25 30 29
Totalplanassets 100% 100% 100%
DeterminationofFairValueofPlanAssets
ThePlanhasanestablishedandwell-documentedprocessfordeterminingfairvalues.Fairvalueisbaseduponquoted
marketprices,whereavailable.Iflistedpricesorquotesarenotavailable,fairvalueisbaseduponmodelsthatprimarily
use,asinputs,market-basedorindependentlysourcedmarketparameters,includingyieldcurves,interestrates,volatilities,
equityordebtprices,foreignexchangeratesandcreditcurves.
WhilethePlanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipants,theuseof
differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent
estimateoffairvalueatthereportingdate.
ValuationHierarchy
Theauthoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedinthetablebelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Afinancialinstrument’scategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis
significanttothefairvaluemeasurement.
Followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue.
• Short-terminvestments–Cashandquotedshort-terminstrumentsarevaluedattheclosingpriceortheamountheld
ondepositbythecustodianbank.OtherinvestmentsarethroughinvestmentvehiclesvaluedusingtheNetAssetValue
(NAV)providedbytheadministratorofthefund.TheNAVisbasedonthevalueoftheunderlyingassetsownedbythe
fund,minusitsliabilities,andthendividedbythenumberofsharesoutstanding.TheNAVisaquotedpriceinamarket
thatisnotactiveandclassifiedasLevel2.
• Governmentandagencysecurities–Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon
themajormarketonwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,
theinvestmentsareclassifiedwithinLevel1ofthevaluationhierarchy.Ifquotedmarketpricesarenotavailableforthe
specificsecurity,thenfairvaluesareestimatedbyusingpricingmodels,quotedpricesofsecuritieswithsimilar
characteristicsordiscountedcashflows.Whenquotedmarketpricesforasecurityarenotavailableinanactivemarket,
theyareclassifiedasLevel2.
• Debtinstruments–Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket
onwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,theinvestmentsare
classifiedasLevel1.Ifquotedmarketpricesarenotavailableforthespecificsecurity,thenfairvaluesareestimatedby
usingpricingmodels,quotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified
asLevel2.Level3debtinstrumentsarepricedbasedonunobservableinputs.
• Equitysecurities–Commonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual
securitiesaretraded.SubstantiallyallcommonstockisclassifiedwithinLevel1ofthevaluationhierarchy.
• Commingledfunds–TheinvestmentsarepublicinvestmentvehiclesvaluedusingtheNAVprovidedbythefund
administrator.TheNAVisbasedonthevalueoftheunderlyingassetsownedbythefund,minusitsliabilities,andthen
dividedbythenumberofsharesoutstanding.AssetsintheLevel2categoryhaveaquotedmarketpriceinamarketthat
isnotactive.
• Insurancecontracts–Theinstrumentsareissuedbyinsurancecompanies.Thefairvalueisbasedonnegotiatedvalue
andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe
issuer.Theunderlyinginvestmentsaregovernment,asset-backedandfixedincomesecurities.Ingeneral,insurance
contractsareclassifiedasLevel3astherearenoquotedpricesnorotherobservableinputsforpricing.
42 • Johnson&Johnson2012AnnualReport• Otherassets–Otherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestments,aswellas
commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebt.Otherassetsthatareexchange
listedandactivelytradedareclassifiedasLevel1,whileinactivelytradedassetsareclassifiedasLevel2.Mostlimited
partnershipsrepresentinvestmentsinprivateequityandsimilarfundsthatarevaluedbythegeneralpartners.These,as
wellasanyotherassetsvaluedusingunobservableinputs,areclassifiedasLevel3.
ThefollowingtablesetsforththeRetirementPlans’trustinvestmentsmeasuredatfairvalueasofDecember30,2012and
January1,2012:
QuotedPrices Significant
inActive Other Significant
Marketsfor Observable Unobservable
IdenticalAssets Inputs Inputs
(Level1) (Level2) (Level3) TotalAssets
(DollarsinMillions) 2012 2011 2012 2011 2012 2011 2012 2011
Short-terminvestmentfunds $155 161 627 632 – – 782 793
Governmentandagencysecurities 53 59 1,706 1,528 – – 1,759 1,587
Debtinstruments 2 1 1,641 1,106 3 9 1,646 1,116
Equitysecurities 8,104 6,682 1 2 4 16 8,109 6,700
Commingledfunds 11 8 4,985 3,375 50 33 5,046 3,416
Insurancecontracts – – – – 24 25 24 25
Otherassets – 1 101 33 69 65 170 99
Trustinvestmentsatfairvalue $8,325 6,912 9,061 6,676 150 148 17,536 13,736
TheCompany’sOtherBenefitPlansareunfundedexceptforU.S.commingledfunds(Level2)of$67millionand$8
millionatDecember30,2012andJanuary1,2012,respectively,and$55millionofU.S.short-term-investmentfunds
(Level2)atDecember30,2012.
ThefairvalueofJohnson&JohnsonCommonStockdirectlyheldinplanassetswas$512million(2.9%oftotalplan
assets)atDecember30,2012and$476million(3.5%oftotalplanassets)atJanuary1,2012.
Level3GainsandLosses
ThetablebelowsetsforthasummaryofchangesinthefairvalueofthePlan’sLevel3assetsfortheyearsended
December30,2012andJanuary1,2012:
Debt Equity Commingled Insurance Other Total
(DollarsinMillions) Instruments Securities Funds Contracts Assets Level3
BalanceJanuary2,2011 $13 24 35 29 82 183
Realizedgains(losses) – 3 – 1 – 4
Unrealizedgains(losses) 1 (2) (6) (2) (17) (26)
Purchases,sales,issuancesandsettlements,net (5) (9) 4 (3) – (13)
BalanceJanuary1,2012 9 16 33 25 65 148
Realizedgains(losses) – (1) – – (5) (6)
Unrealizedgains(losses) – – – – – –
Purchases,sales,issuancesandsettlements,net (6) (11) 17 (1) 9 8
BalanceDecember30,2012 $3 4 50 24 69 150
Johnson&Johnson2012AnnualReport • 4311. SavingsPlan
TheCompanyhasvoluntary401(k)savingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible
employees.TheCompanymatchesapercentageofeachemployee’scontributionsconsistentwiththeprovisionsofthe
planforwhichhe/sheiseligible.TotalCompanymatchingcontributionstotheplanswere$160million,$157millionand
$157millionin2012,2011and2010,respectively.
12. CapitalandTreasuryStock
Changesintreasurystockwere:
TreasuryStock
(AmountsinMillionsExceptTreasuryStockSharesinThousands) Shares Amount
BalanceatJanuary3,2010 365,522 $19,780
Employeecompensationandstockoptionplans (28,866) (1,794)
Repurchaseofcommonstock 45,090 2,797
BalanceatJanuary2,2011 381,746 20,783
Employeecompensationandstockoptionplans (26,007) (1,649)
Repurchaseofcommonstock 39,741 2,525
BalanceatJanuary1,2012 395,480 21,659
Employeecompensationandstockoptionplans (55,170) (3,250)
IssuanceofcommonstockassociatedwiththeacquisitionofSynthes,Inc. (203,740) (12,852)
Repurchaseofcommonstock(1) 204,784 12,919
BalanceatDecember30,2012 341,354 $18,476
AggregatesharesofCommonStockissuedwereapproximately3,119,843,000sharesattheendof2012,2011and
2010.
Cashdividendspaidwere$2.40persharein2012,comparedwithdividendsof$2.25persharein2011,and$2.11per
sharein2010.
(1) IncludesrepurchaseofcommonstockassociatedwiththeacquisitionofSynthes,Inc.
13. AccumulatedOtherComprehensiveIncome
Componentsofothercomprehensiveincome/(loss)consistofthefollowing:
Gains/ Total
Gains/ (Losses) Accumulated
Foreign (Losses) Employee on Other
Currency on Benefit Derivatives Comprehensive
(DollarsinMillions) Translation Securities Plans &Hedges Income/(Loss)
January3,2010 $(508) (30) (2,665) 145 (3,058)
Net2010changes (461) 54 (21) (45) (473)
January2,2011 (969) 24 (2,686) 100 (3,531)
Net2011changes (557) 424 (1,700) (268) (2,101)
January1,2012 (1,526) 448 (4,386) (168) (5,632)
Net2012changes 1,230 (253) (1,331) 176 (178)
December30,2012 $(296) 195 (5,717) 8 (5,810)
Amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpact.Foreigncurrency
translationisnotadjustedforincometaxesasitrelatestopermanentinvestmentsininternationalsubsidiaries.For
additionaldetailsoncomprehensiveincomeseetheConsolidatedStatementsofComprehensiveIncome.
44 • Johnson&Johnson2012AnnualReport14. InternationalCurrencyTranslation
Fortranslationofitssubsidiariesoperatinginnon-U.S.Dollarcurrencies,theCompanyhasdeterminedthatthelocal
currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomies,which
aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationof100%ormoreduringthepastthreeyears,
orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency.
Inconsolidatinginternationalsubsidiaries,balancesheetcurrencyeffectsarerecordedasacomponentofaccumulated
othercomprehensiveincome.Thisequityaccountincludestheresultsoftranslatingallbalancesheetassetsandliabilities
atcurrentexchangerates,exceptforthoselocatedinhighlyinflationaryeconomies.Thetranslationofbalancesheet
accountsforhighlyinflationaryeconomiesarereflectedintheoperatingresults.
Arollforwardofthechangesduring2012,2011and2010forforeigncurrencytranslationadjustmentsisincludedin
Note13.
NetcurrencytransactiongainsandlossesincludedinOther(income)expensewerelossesof$58million,$10millionand
$130millionin2012,2011and2010,respectively.
15. EarningsPerShare
Thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended
December30,2012,January1,2012andJanuary2,2011:
(InMillionsExceptPerShareAmounts) 2012 2011 2010
BasicnetearningspershareattributabletoJohnson&Johnson $3.94 3.54 4.85
Averagesharesoutstanding–basic 2,753.3 2,736.0 2,751.4
Potentialsharesexercisableunderstockoptionplans 164.6 158.3 156.1
Less:sharesrepurchasedundertreasurystockmethod (128.2) (122.6) (122.3)
Convertibledebtshares 3.6 3.6 3.6
Acceleratedsharerepurchaseprogram 19.3 – –
Adjustedaveragesharesoutstanding–diluted 2,812.6 2,775.3 2,788.8
DilutednetearningspershareattributabletoJohnson&Johnson $3.86 3.49 4.78
Thedilutednetearningspersharecalculationincludesthedilutiveeffectofconvertibledebtthatisoffsetbytherelated
reductionininterestexpenseof$4millionafter-taxforyears2012,2011and2010.
Dilutednetearningspershareexcludes0.2million,50.7millionand66.3millionsharesunderlyingstockoptionsfor2012,
2011and2010,respectively,astheexercisepriceoftheseoptionswasgreaterthantheiraveragemarketvalue,which
wouldresultinananti-dilutiveeffectondilutedearningspershare.
ThedilutedearningspersharecalculationforthefiscalyearendedDecember30,2012includedthedilutiveeffectof
19.3millionsharesrelatedtotheacceleratedsharerepurchaseprogram,associatedwiththeacquisitionofSynthes,Inc.
SeeNote20totheConsolidatedFinancialStatementsforadditionaldetails.A$1increase/decreaseinthevolume
weightedaveragesharepricewouldimpactthisestimatebyapproximately2.6millionshares.
16. RentalExpenseandLeaseCommitments
Rentalsofspace,vehicles,manufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases
wereapproximately$375million,$313millionand$299millionin2012,2011and2010,respectively.
Theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnon-cancelable
leasetermsinexcessofoneyearatDecember30,2012are:
(DollarsinMillions)
After
2013 2014 2015 2016 2017 2017 Total
$251 192 149 115 90 128 925
Commitmentsundercapitalleasesarenotsignificant.
Johnson&Johnson2012AnnualReport • 4517. CommonStock,StockOptionPlansandStockCompensationAgreements
AtDecember30,2012,theCompanyhad4stock-basedcompensationplans.Thesharesoutstandingareforcontracts
undertheCompany’s2000StockOptionPlan,the2005Long-TermIncentivePlan,the2012Long-TermIncentivePlan,
andtheScios,Inc.StockOptionPlans.The2005Long-TermIncentivePlanexpiredApril26,2012.Alloptionsand
restrictedsharesgrantedsubsequenttothatdatewereunderthe2012Long-TermIncentivePlan.
Thecompensationcostthathasbeenchargedagainstincomefortheseplanswas$662million,$621millionand$614
millionfor2012,2011and2010,respectively.Thetotalincometaxbenefitrecognizedintheincomestatementforshare-
basedcompensationcostswas$220million,$207millionand$205millionfor2012,2011and2010,respectively.The
totalunrecognizedcompensationcostwas$565million,$562millionand$613millionfor2012,2011and2010,
respectively.Theweightedaverageperiodforthiscosttoberecognizedwas1.02years,0.97yearsand1.05yearsfor
2012,2011,and2010,respectively.Share-basedcompensationcostscapitalizedaspartofinventorywereinsignificant
inallperiods.
StockOptions
Stockoptionsexpire10yearsfromthedateofgrantandvestoverserviceperiodsthatrangefrom6monthsto4years.All
optionsaregrantedattheaverageofthehighandlowpricesoftheCompany’sCommonStockontheNewYorkStock
Exchangeonthedateofgrant.Underthe2012Long-TermIncentivePlan,theCompanymayissueupto200million
sharesofcommonstock,plusanysharescanceled,expired,forfeited,ornotissuedfromthe2005Long-TermIncentive
PlansubsequenttoApril26,2012.Sharesavailableforfuturegrantsunderthe2012Long-TermIncentivePlanwere
201.8millionattheendof2012.
TheCompanysettlesemployeestockoptionexerciseswithtreasuryshares.Previously,treasuryshareswerereplenished
throughouttheyearforthenumberofsharesusedtosettleemployeestockoptionexercises.However,pursuanttothe
acceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofSynthes,Inc.,theCompanyhasnotmade
anypurchasesofCommonStockontheopenmarketduringthefiscalthirdandfourthquartersof2012.
ThefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheBlack-Scholesoptionvaluationmodel
thatusestheassumptionsnotedinthefollowingtable.Expectedvolatilityrepresentsablendedrateof4-yeardaily
historicalaveragevolatilityrate,anda5-weekaverageimpliedvolatilityratebasedonat-the-moneytradedJohnson&
Johnsonoptionswithalifeof2years.Historicaldataisusedtodeterminetheexpectedlifeoftheoption.Therisk-freerate
wasbasedontheU.S.Treasuryyieldcurveineffectatthetimeofgrant.
Theaveragefairvalueofoptionsgrantedwas$6.39,$7.47and$8.03,in2012,2011,and2010,respectively.Thefair
valuewasestimatedbasedontheweightedaverageassumptionsof:
2012 2011 2010
Risk-freerate 1.06% 2.41% 2.78%
Expectedvolatility 18.38% 18.20% 17.40%
Expectedlife(inyears) 6.0 6.0 6.0
Dividendyield 3.60% 3.60% 3.30%
46 • Johnson&Johnson2012AnnualReportAsummaryofoptionactivityunderthePlanasofDecember30,2012,January1,2012andJanuary2,2011andchanges
duringtheyearsendingonthosedatesispresentedbelow:
Aggregate
Intrinsic
Weighted Value
Outstanding Average (Dollarsin
(SharesinThousands) Shares ExercisePrice Millions)
SharesatJanuary3,2010 212,719 $58.66 $1,310
Optionsgranted 13,996 62.62
Optionsexercised (25,020) 51.84
Optionscanceled/forfeited (8,005) 62.36
SharesatJanuary2,2011 193,690 59.68 648
Optionsgranted 9,530 62.21
Optionsexercised (20,160) 56.65
Optionscanceled/forfeited (3,601) 62.38
SharesatJanuary1,2012 179,459 60.10 1,004
Optionsgranted 8,661 65.36
Optionsexercised (49,388) 56.73
Optionscanceled/forfeited (4,381) 62.97
SharesatDecember30,2012 134,351 $61.58 $1,061
Thetotalintrinsicvalueofoptionsexercisedwas$547million,$167millionand$278millionin2012,2011and2010,
respectively.
ThefollowingtablesummarizesstockoptionsoutstandingandexercisableatDecember30,2012:
(SharesinThousands) Outstanding Exercisable
Average Average
Average Exercise Exercise
ExercisePriceRange Options Life(1) Price Options Price
$49.66-$53.77 3,600 0.1 $52.19 3,599 $52.19
$53.93-$58.33 29,134 3.6 $56.13 28,076 $56.04
$58.34-$61.75 29,604 4.0 $60.01 29,556 $60.01
$61.86-65.37 28,817 7.8 $63.29 464 $63.88
$65.62-$68.37 43,196 2.9 $65.97 43,165 $65.97
134,351 4.3 $61.58 104,860 $61.15
(1) Averagecontractualliferemaininginyears.
StockoptionsexercisableatJanuary1,2012andJanuary2,2011were138,126atanaveragepriceof$59.94andan
averagelifeof4.2yearsand141,275atanaveragepriceof$59.25andanaveragelifeof4.7years,respectively.
RestrictedShareUnitsandPerformance ShareUnits
TheCompanygrantsrestrictedshareunitswithavestingperiodofthreeyears.TheCompanyalsograntsperformance
shareunits,whicharepaidinsharesofJohnson&JohnsonCommonStockaftertheendofathree-yearperformance
period.Whetheranyperformanceshareunitsvest,andtheamountthatdoesvest,istiedtotheachievement,overathree-
yearperiod,ofthreeequally-weightedgoalsthatdirectlyalignwithorhelpdrivelong-termtotalshareholderreturn:sales,
adjustedoperationalearningspershare,andrelativetotalshareholderreturn.Thenumberofsharesactuallyearnedatthe
endofthethree-yearperiodwillvary,basedonlyonactualperformance,from0%to200%ofthetargetnumberof
performanceshareunitsgranted.
TheCompanysettlesemployeestockissuanceswithtreasuryshares.Previously,treasuryshareswerereplenished
throughouttheyearforthenumberofsharesusedtosettleemployeestockissuances.However,pursuanttothe
acceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofSynthes,Inc.,theCompanyhasnotmade
anypurchasesofCommonStockontheopenmarketduringthefiscalthirdandfourthquartersof2012.
Johnson&Johnson2012AnnualReport • 47AsummaryoftherestrictedshareunitsandperformanceshareunitsactivityunderthePlansasofDecember30,2012is
presentedbelow:
Outstanding Outstanding
Restricted Performance
(SharesinThousands) ShareUnits ShareUnits
SharesatJanuary3,2010 26,324
Granted 12,003
Issued (6,297)
Canceled/forfeited (2,296)
SharesatJanuary2,2011 29,734
Granted 11,478
Issued (8,300)
Canceled/forfeited (1,886)
SharesatJanuary1,2012 31,026 –
Granted 12,197 327
Issued (9,278) –
Canceled/forfeited (2,111) (42)
SharesatDecember30,2012 31,834 285
Theaveragefairvalueoftherestrictedshareunitsgrantedwas$58.93,$55.90and$56.69in2012,2011and2010,
respectively,usingthefairmarketvalueatthedateofgrant.Thefairvalueofrestrictedshareunitswasdiscountedfor
dividends,whicharenotpaidontherestrictedshareunitsduringthevestingperiod.Thefairvalueofrestrictedshareunits
settledwas$483.2million,$458.9millionand$375.0millionin2012,2011and2010,respectively.
Theweightedaveragefairvalueoftheperformanceshareunitswas$55.01in2012,calculatedusingtheweighted
averagefairmarketvalueforeachofthethreecomponentgoalsatthedateofgrant.
Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof
grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividends,whicharenotpaidonthe
performanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeach
performanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.Noperformanceshare
unitswereissuedin2012.
18. SegmentsofBusinessandGeographicAreas
SalestoCustomers
(DollarsinMillions) 2012 2011 2010
Consumer–
UnitedStates $5,046 5,151 5,519
International 9,401 9,732 9,071
Total 14,447 14,883 14,590
Pharmaceutical–
UnitedStates 12,421 12,386 12,519
International 12,930 11,982 9,877
Total 25,351 24,368 22,396
MedicalDevicesandDiagnostics–
UnitedStates 12,363 11,371 11,412
International 15,063 14,408 13,189
Total 27,426 25,779 24,601
Worldwidetotal $67,224 65,030 61,587
48 • Johnson&Johnson2012AnnualReportPre-TaxProfit IdentifiableAssets
(DollarsinMillions) 2012(3) 2011(4) 2010(5) 2012 2011 2010
Consumer $1,693 2,096 2,342 $24,131 24,210 23,753
Pharmaceutical 6,075 6,406 7,086 23,219 23,747 19,961
MedicalDevicesandDiagnostics 7,187 5,263 8,272 42,926 23,609 23,277
Total 14,955 13,765 17,700 90,276 71,566 66,991
Less:Expensenotallocatedtosegments(1) 1,180 1,404 753
Generalcorporate(2) 31,071 42,078 35,917
Worldwidetotal $13,775 12,361 16,947 $121,347 113,644 102,908
AdditionstoProperty, Depreciationand
Plant&Equipment Amortization
(DollarsinMillions) 2012 2011 2010 2012 2011 2010
Consumer $468 670 526 $575 631 532
Pharmaceutical 737 729 508 1,010 958 912
MedicalDevicesandDiagnostics 1,230 1,095 1,113 1,857 1,331 1,270
Segmentstotal 2,435 2,494 2,147 3,442 2,920 2,714
Generalcorporate 499 399 237 224 238 225
Worldwidetotal $2,934 2,893 2,384 $3,666 3,158 2,939
SalestoCustomers Long-LivedAssets(6)
(DollarsinMillions) 2012 2011 2010 2012 2011 2010
UnitedStates $29,830 28,908 29,450 $35,115 23,529 23,315
Europe 16,945 17,129 15,510 25,261 19,056 16,791
WesternHemisphereexcludingU.S. 7,207 6,418 5,550 3,636 3,517 3,653
Asia-Pacific,Africa 13,242 12,575 11,077 2,362 2,163 2,089
Segmentstotal 67,224 65,030 61,587 66,374 48,265 45,848
Generalcorporate 899 750 715
Othernonlong-livedassets 54,074 64,629 56,345
Worldwidetotal $67,224 65,030 61,587 $121,347 113,644 102,908
SeeNote1foradescriptionofthesegmentsinwhichtheCompanyoperates.
Exportsalesarenotsignificant.In2012,2011and2010,theCompanydidnothaveacustomerthatrepresented10%oftotalrevenues.
(1) Amountsnotallocatedtosegmentsincludeinterest(income)expense,noncontrollinginterestsandgeneralcorporate(income)
expense.Includesexpenseof$0.2billionand$0.5billionofcurrencyrelatedexpenserelatedtotheacquisitionofSynthes,Inc.in
2012and2011,respectively.
(2) Generalcorporateincludescashandmarketablesecurities.
(3) Includes$1,218millionofnetlitigationexpense,whichincludesproductliability,comprisedof$658millionand$560millioninthe
PharmaceuticalandMedicalDevicesandDiagnosticssegments,respectively.Includes$1,163millionofin-processresearchand
developmentexpense,comprisedof$1,111millionand$52millioninthePharmaceuticalandMedicalDevicesandDiagnostics
segments,respectively.Includes$795millionofSynthesintegration/transactioncostsintheMedicalDevicesandDiagnostics
segment.Includes$909millionofassetwrite-downsandotheradjustments,comprisedof$499million,$264millionand$146
millioninthePharmaceutical,ConsumerandMedicalDevicesandDiagnosticssegments,respectively.TheMedicalDevicesand
Diagnosticssegmentalsoincludes$110millionexpenseforthecostassociatedwiththeDePuyASR™Hipprogram.
(4) Includes$3,310millionofnetlitigationexpense,whichincludesproductliability,comprisedof$1,741millionand$1,569millionin
thePharmaceuticalandMedicalDevicesandDiagnosticssegments,respectively.Includes$656millionofnetrestructuringexpense,
comprisedof$676millionexpenseintheMedicalDevicesandDiagnosticssegmentandagainof$20millioninthePharmaceutical
segment.TheMedicalDevicesandDiagnosticssegmentalsoincludes$521millionexpenseforthecostassociatedwiththeDePuy
ASR™Hipprogram.
(5) Includes$397millionofnetlitigationgain,whichincludesproductliabilityexpense,comprisedof$447millionexpenseinthe
Pharmaceuticalsegmentandagainof$844millionintheMedicalDevicesandDiagnosticssegment.TheMedicalDevicesand
Diagnosticssegmentalsoincludes$280millionexpenseforthecostassociatedwiththeDePuyASR™Hipprogram.
(6) Long-livedassetsincludeproperty,plantandequipment,netfor2012,2011and2010of$16,097,$14,739and$14,553,
respectively,andintangibleassetsandgoodwill,netfor2012,2011and2010of$51,176,$34,276and$32,010,respectively.
Johnson&Johnson2012AnnualReport • 4919. SelectedQuarterlyFinancialData(unaudited)
Selectedunauditedquarterlyfinancialdatafortheyears2012and2011aresummarizedbelow:
2012 2011
(DollarsinMillionsExceptPerShare First Second Third Fourth First Second Third Fourth
Data) Quarter(1) Quarter(2) Quarter(3) Quarter(4) Quarter(5) Quarter(6) Quarter(7) Quarter(8)
Segmentsalestocustomers
Consumer $3,595 3,619 3,581 3,652 3,682 3,793 3,740 3,668
Pharmaceutical 6,133 6,291 6,402 6,525 6,059 6,233 5,982 6,094
MedDevices&Diagnostics 6,411 6,565 7,069 7,381 6,432 6,571 6,283 6,493
Totalsales 16,139 16,475 17,052 17,558 16,173 16,597 16,005 16,255
Grossprofit 11,224 11,332 11,455 11,555 11,395 11,425 10,933 10,917
Earningsbeforeprovisionfortaxeson
income 5,045 2,035 3,595 3,100 4,510 3,422 4,111 318
NetearningsattributabletoJohnson&
Johnson 3,910 1,408 2,968 2,567 3,476 2,776 3,202 218
Basicnetearningspershareattributable
toJohnson&Johnson $1.43 0.51 1.08 0.93 1.27 1.01 1.17 0.08
Dilutednetearningspershare
attributabletoJohnson&Johnson $1.41 0.50 1.05 0.91 1.25 1.00 1.15 0.08
(1) Thefirstquarterof2012includesanafter-taxgainof$106millionfromcurrencyandcostsassociatedwiththeacquisitionof
Synthes,Inc.
(2) Thesecondquarterof2012includesafter-taxchargesof$717millionforassetwrite-downs,$611millionfromnetlitigation,$564
millionassociatedwiththeacquisitionofSynthes,Inc.and$344millionfromimpairmentofin-processresearchanddevelopment.
(3) Thethirdquarterof2012includesafter-taxchargesof$135millionassociatedwiththeacquisitionofSynthes,Inc.,$340million
fromimpairmentofin-processresearchanddevelopment,$70millionassociatedwithlitigation,includingproductliability,and$24
millionassociatedwiththeDePuyASR™Hipprogram.
(4) Thefourthquarterof2012includesafter-taxchargesof$371millionfromnetlitigation,includingproductliability,$306million
associatedwiththeacquisitionofSynthes,Inc.,$73millionassociatedwiththeDePuyASR™Hipprogramand$59millionfrom
impairmentofin-processresearchanddevelopment.
(5) Thefirstquarterof2011includesanafter-taxchargeof$271millionfromnetlitigation,includingproductliability,andtheDePuy
ASR™Hipprogram.
(6) Thesecondquarterof2011includesafter-taxchargesof$549millionforrestructuring,$325millionfromlitigation,includingproduct
liability,andtheDePuyASR™Hipprogram,partiallyoffsetbya$102millionafter-taxgainassociatedwithanadjustmenttothevalue
ofthecurrencyoptionrelatedtotheacquisitionofSynthes,Inc.
(7) Thethirdquarterof2011includesa$241millionafter-taxchargeassociatedwithanadjustmenttothevalueofthecurrencyoption
anddealcostsrelatedtotheacquisitionofSynthes,Inc.
(8) Thefourthquarterof2011includesafter-taxchargesof$2,239millionfromnetlitigation,includingproductliability,$336millionfor
thecostassociatedwiththeDePuyASR™Hipprogramand$338millionassociatedwithanadjustmenttothevalueofthecurrency
optionanddealcostsrelatedtotheacquisitionofSynthes,Inc.
20. BusinessCombinationsandDivestitures
Certainbusinesseswereacquiredfor$17,821millionincashandstockand$1,204millionofliabilitiesassumedduring
2012.Theseacquisitionswereaccountedforbythepurchasemethodand,accordingly,resultsofoperationshavebeen
includedinthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2012acquisitionsincluded:Synthes,Inc.,aglobaldeveloperandmanufactureroforthopaedicsdevices;Guangzhou
BiosealBiotechCo.Ltd,adeveloperofbiologiccombinationsaddressingmoderatetoseverehemostasis;Angiotech
Pharmaceuticals,Inc.,intellectualpropertyandknowhowrelatedtotheQuill™KnotlessTissue-ClosureDevice;Corlmmun
Inc.,adeveloperofaphaseIItreatmentforCHF;CalibraMedical,Inc.,developerofaunique,wearablethree-dayinsulin
patchforconvenientanddiscreetmealtimedosingforpeoplewithdiabeteswhotakemultipledailyinjectionsofinsulin;
SpectrumVisionLLC,afullservicedistributorofcontactlensesservingRussiawithfacilitiesintheUkraineand
Kazakhstan;marketingauthorizations,trademarks,andpatentsextendingZYRTEC®relatedmarketrightsinAustraliaand
Canada.
50 • Johnson&Johnson2012AnnualReportTheexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$15,785millionand
hasbeenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately
$208millionhasbeenidentifiedasthevalueofIPR&DassociatedwiththeacquisitionsofCorlmmunInc.and
Synthes,Inc.
TheIPR&DrelatedtotheacquisitionofSynthes,Inc.of$63millionisassociatedwithorthopaedicdevices,andtheIPR&D
associatedwithCorlmmunof$145millionisrelatedtoaCHFtreatment.TheseIPR&Dvalueswerecalculatedusingthe
cashflowprojectionsdiscountedfortheriskinherentinsuchprojects.Synthes,Inc.hadaprobabilityofsuccessfactorof
100%,discountedusinga14%rate.Corlmmunhadaprobabilityofsuccessfactorof38%,discountedusinga25%rate.
Duringthefiscalsecondquarter,theCompanycompletedtheacquisitionofSynthes,Inc.,aglobaldeveloperand
manufactureroforthopaedicsdevices,forapurchasepriceof$20.2billionincashandstock.Thenetacquisitioncostof
thetransactionis$17.5billionbasedoncashonhandatclosingof$2.7billion.
Underthetermsoftheagreement,eachshareofSynthes,Inc.commonstockwasexchangedforCHF55.65incashand
1.717sharesofJohnson&Johnsoncommonstock,basedonthecalculatedexchangeratio.Theexchangeratiowas
calculatedonJune12,2012andbasedontherelevantexchangerateandclosingpriceofJohnson&Johnsoncommon
stockonthatdate,thetotalfairvalueofconsiderationtransferredwas$19.7billion.Whentheacquisitionwascompleted
onJune14,2012,basedontherelevantexchangerateandclosingpriceofJohnson&Johnsoncommonstockonthat
date,thetotalfairvalueoftheconsiderationtransferredwas$20.2billion.JanssenPharmaceutical,acompanyorganized
underthelawsofIrelandandawholly-ownedsubsidiaryofJohnson&Johnson,usedcashonhandtosatisfythecash
portionofthemergerconsideration.
ThestockportionofthemergerconsiderationconsistedofsharesofJohnson&Johnsoncommonstockpurchasedby
JanssenPharmaceutical,fromtwobanks,pursuanttotwoacceleratedsharerepurchase(ASR)agreementsdated
June12,2012.OnJune13,2012,JanssenPharmaceuticalpurchasedanaggregateofapproximately203.7millionshares
ofJohnson&Johnsoncommonstockataninitialpurchasepriceof$12.9billionundertheASRagreements,withallofthe
sharesdeliveredtoJanssenPharmaceuticalonJune13,2012.FinalsettlementofthetransactionsundereachASR
agreementisexpectedtooccurinthefirsthalfof2013,andmayoccurearlierattheoptionofthetwobanks,as
applicable,orlaterundercertaincircumstances.BasedonthetheoreticalsettlementoftheASRagreements,anadditional
19.3millionshareswouldbeissuedtosettletheASRagreementsasofDecember30,2012.
Inaddition,whiletheCompanybelievesthatthetransactionsundereachASRagreementandaseriesofrelatedinternal
transactionswereconsummatedinataxefficientmannerinaccordancewithapplicablelaw,itispossiblethattheInternal
RevenueServicecouldassertoneormorecontrarypositionstochallengethetransactionsfromataxperspective.If
challenged,anamountuptothetotalpurchasepricefortheSynthessharescouldbetreatedassubjecttoapplicableU.S.
taxatapproximatelythestatutoryratetotheCompany,plusinterest.
ThefollowingtablesummarizestheconsiderationtransferredtoacquireSynthes,Inc.valuedontheacquisitiondateof
June14,2012:
(DollarsinMillions)
Cash(multiply55.65CHFbysharesofSynthescommonstockoutstandingbytheexchangerate)(A) $6,902
CommonStock(multiply1.717bysharesofSynthescommonstockoutstandingbyJ&Jstockprice)(B) $13,335
Totalfairvalueofconsiderationtransferred $20,237
(A) Synthescommonstockoutstandingof118.7millionsharesasoftheacquisitiondateandCHF/USDexchangerateof.95674
(B) Johnson&JohnsonclosingstockpriceontheNewYorkStockExchangeasofacquisitiondateof$65.45pershare.
TheCompanyisstillfinalizingtheallocationofthepurchasepricetotheindividualassetsacquiredandliabilitiesassumed.
Theallocationofthepurchasepriceincludedinthecurrentperiodbalancesheetisbasedonthebestestimateof
management.Toassistmanagementintheallocation,theCompanyengagedvaluationspecialiststoprepareindependent
appraisals.Certainestimatedvaluessurroundinglitigationlosscontingenciesarenotyetfinalizedandaresubjectto
change.Wewillfinalizetheamountsrecognizedasweobtaintheinformationnecessarytocompletetheanalysis.We
expecttofinalizetheseamountsassoonaspossiblebutnolaterthanoneyearfromtheacquisitiondate.
Johnson&Johnson2012AnnualReport • 51Thefollowingtablepresentstheamountsrecognizedforassetsacquiredandliabilitiesassumedasoftheacquisitiondate,
aswellastheadjustmentsmadeuptoDecember30,2012:
(DollarsinMillions) June14,2012 December30,2012
Cash&Cashequivalents $2,749 2,749
Inventory 889 1,194
AccountsReceivable,net 738 738
Othercurrentassets 249 238
Property,plantandequipment 1,253 1,253
Goodwill 5,371 6,011
Intangibleassets 12,929 12,861
Othernon-currentassets 46 46
TotalAssetsAcquired 24,224 25,090
Currentliabilities 825 1,053
DeferredTaxes 2,731 3,471
Othernon-currentliabilities 431 329
TotalLiabilitiesAssumed 3,987 4,853
NetAssetsAcquired $20,237 20,237
Theadjustmentsmadesincethedateofacquisitionweretoaccountforchangestoinventory,basedontheresultsofthe
physicalinventorycountsanddeferredtaxes,toreflectthestatutorytaxratethatisbeingappliedtotheintangibleassets.
TherevisionstothepurchasepriceallocationwerenotmaterialtotheStatementsofConsolidatedEarningsfortheprior
fiscalquartersof2012.
TheassetsacquiredarerecordedintheMedicalDevicesandDiagnosticssegment.TheacquisitionofSynthes,Inc.
resultedin$6.0billionofgoodwill.Thegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromtheacquisition
ofSynthes,Inc.Thegoodwillisnotexpectedtobedeductiblefortaxpurposes.
ThepurchasepriceallocationtotheidentifiableintangibleassetsincludedintheJune14,2012andDecember30,2012
balancesheetswereasfollows:
(DollarsinMillions) June14,2012 December30,2012
Intangibleassetswithdefinitelives:
Customerrelationships $9,950 9,870
Patentsandtechnology 1,495 1,508
Totalamortizableintangibles 11,445 11,378
TrademarkandTradename 1,420 1,420
In-processresearchanddevelopment 64 63
Totalintangibleassets $12,929 12,861
Theweightedaveragelifeforthe$11.4billionoftotalamortizableintangiblesisapproximately21years.
Thetradenameassetvaluesweredeterminedtohaveanindefinitelifebasedonanumberoffactors,includingtradename
history,thecompetitiveenvironment,marketshareandfutureoperatingplans.Theintangibleassetswithdefiniteliveswere
assignedassetlivesrangingfrom7to22years.
Themajorityoftheintangibleassetvaluationrelatestocustomerrelationships,patentsandtechnologyandtradename
intangibleassetsintheCompany’strauma,craniomaxillofacial,spineandpowertoolsbusinesslines.Additionally,in-
processresearchanddevelopmentintangibleassetswerevaluedfortechnologyprogramsforunapprovedproducts.
ThevalueoftheIPR&Dwascalculatedusingcashflowprojectionsdiscountedfortheriskinherentinsuchprojects.The
discountrateappliedwas14%.
TheCompanyisintheprocessofexecutingtheintegrationplanstocombinebusinesses,salesorganizations,systems
andlocationsasaresultofwhichtheCompanyhasandwillcontinuetoincurintegrationcosts.
52 • Johnson&Johnson2012AnnualReportTheoperatingresultsofSyntheswerereportedintheCompany’sfinancialstatementsbeginningonJune14,2012.Total
salesandnetearningsforSynthesforthefiscalyearendedDecember30,2012were$2,159millionand$324million,
respectively.
ThefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendedDecember30,2012andJanuary1,
2012,asifSynthes,Inc.hadbeenacquiredasofJanuary3,2011.Theproformaresultsincludetheeffectofdivestitures
andcertainpurchaseaccountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseon
theacquiredtangibleandintangibleassets.However,proformaresultsdonotincludeanyanticipatedcostsavingsor
othereffectsoftheintegrationofSynthes,Inc.Accordingly,suchamountsarenotnecessarilyindicativeoftheresultsifthe
acquisitionhadoccurredonthedatesindicatedorwhichmayoccurinthefuture.
UnauditedProforma
consolidatedresults
(DollarsinMillionsExceptPerShareAmounts) 2012 2011
NetSales $68,894 68,741
NetEarningsattributabletoJohnson&Johnson $11,564 9,427
DilutedNetEarningspershareattributabletoJohnson&Johnson $4.11 3.40
In2012,theCompanyrecordedacquisitionrelatedcostsof$1,028millionbeforetax,whichwererecordedinCostof
productssoldandOther(income)expense.
InconnectionwiththeSynthesacquisition,DePuyOrthopaedics,Inc.agreedtodivestcertainrightsandassetsrelatedto
itstraumabusinesstoBiomet,Inc.andcompletedtheinitialclosingforthistransactioninthefiscalsecondquarterof
2012,includingthosecountriesthatrepresentedthemajorityofsales.AsofDecember30,2012,thetransactionhad
closedworldwide.
Certainbusinesseswereacquiredfor$2,797millionincashand$228millionofliabilitiesassumedduring2011.These
acquisitionswereaccountedforbythepurchasemethodand,accordingly,resultsofoperationshavebeenincludedinthe
financialstatementsfromtheirrespectivedatesofacquisition.
The2011acquisitionsincluded:CrucellN.V.,aglobalbiopharmaceuticalcompanyfocusedontheresearch&
development,productionandmarketingofvaccinesandantibodiesagainstinfectiousdiseaseworldwide;theover-the-
counterbrandsofJ.B.Chemicals&PharmaceuticalsLimited,includingRINZA®,Russia’sleadingmulti-symptomcough
andcoldbrand,andDOKTORMOM®,Russia’snumbertwosellingcoughbrand,aswellasseveralotherbrands;full
ownershipoftheJohnson&Johnson-MerckConsumerPharmaceuticalsCo.jointventureintheU.S.fromMerckSharp&
DohmeCorp;andSterilMed,Inc.,aleaderinthereprocessingandremanufacturingofmedicaldevicesintheU.S.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$2,657millionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately$982
millionhasbeenidentifiedasthevalueofIPR&DassociatedwiththeacquisitionofCrucellN.V.
TheIPR&DrelatedtotheacquisitionofCrucellN.V.of$982millionisassociatedwithvaccinesandantibodiesthat
preventand/ortreatinfectiousdiseases.ThevalueoftheIPR&Dwascalculatedusingcashflowprojectionsdiscounted
fortheriskinherentinsuchprojects.Probabilityofsuccessfactorsrangingfrom14–81%wereusedtoreflectinherent
clinicalandregulatoryrisk.Thediscountrateappliedwas16%.Duringthefiscalsecondquarterof2012,theCompany
recordedachargeof$0.5billionfortheintangibleassetwrite-downand$0.4billionfortheimpairmentofthein-process
researchanddevelopmentrelatedtotheCrucellbusiness.
Certainbusinesseswereacquiredfor$1,269millionincashand$52millionofliabilitiesassumedduring2010.These
acquisitionswereaccountedforbythepurchasemethodand,accordingly,resultsofoperationshavebeenincludedinthe
financialstatementsfromtheirrespectivedatesofacquisition.
The2010acquisitionsincluded:Acclarent,Inc.,aprivatelyheldmedicaltechnologycompanydedicatedtodesigning,
developingandcommercializingdevicesthataddressconditionsaffectingtheear,noseandthroat(ENT);RespiVertLtd.,a
privatelyhelddrugdiscoverycompanyfocusedondevelopingsmall-molecule,inhaledtherapiesforthetreatmentof
pulmonarydiseases;andMicrusEndovascularLLC,aglobaldeveloperandmanufacturerofminimallyinvasivedevicesfor
hemorrhagicandischemicstroke.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$1,185millionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately$213
millionhasbeenidentifiedasthevalueofIPR&DassociatedwiththeacquisitionsofAcclarent,Inc.,RespiVertLtd.and
MicrusEndovascularLLC.
Johnson&Johnson2012AnnualReport • 53TheIPR&DrelatedtotheacquisitionofAcclarent,Inc.was$75millionandisassociatedwithnovel,endoscopic,catheter-
baseddevicestomeettheneedsofENTpatients.ThevalueoftheIPR&Dwascalculatedusingcashflowprojections
discountedfortheriskinherentinsuchprojects.Probabilityofsuccessfactorsrangingfrom50–53%wereusedto
reflectinherentclinicalandregulatoryrisk.Thediscountrateappliedwas16%.
TheIPR&DrelatedtotheacquisitionofRespiVertLtd.was$100millionandisassociatedwithnarrowspectrumkinase
inhibitorswithauniqueprofileofanti-inflammatoryactivitiesastreatmentsformoderatetosevereasthma,Chronic
ObstructivePulmonaryDisease(COPD)andCysticFibrosis(CF).ThevalueoftheIPR&Dwascalculatedusingcashflow
projectionsdiscountedfortheriskinherentinsuchprojects.Probabilityofsuccessfactorsrangingfrom10–12%were
usedtoreflectinherentclinicalandregulatoryrisk.Thediscountrateappliedwas17%.
TheIPR&DrelatedtotheacquisitionofMicrusEndovascularLLCwas$38millionandisassociatedwithischemicand
flowdivertertechnologies.ThevalueoftheIPR&Dwascalculatedusingcashflowprojectionsdiscountedfortherisk
inherentinsuchprojects.Probabilityofsuccessfactorsrangingfrom50–75%wereusedtoreflectinherentclinicaland
regulatoryrisk.Thediscountrateappliedwas14%.
WiththeexceptionoftheSynthes,Inc.acquisition,supplementalproformainformationfor2012,2011and2010in
accordancewithU.S.GAAPstandardsrelatedtobusinesscombinations,andgoodwillandotherintangibleassets,isnot
provided,astheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectontheCompany’sresultsof
operations,cashflowsorfinancialposition.
During2012,theCompanydivestituresincluded:BYSTOLIC®(nebivolol)IPrightstoForestLaboratories,Inc.;thetrauma
businessofDePuyOrthopaedics,Inc.toBiomet,Inc.;theTherakosbusinesstoanaffiliateofGoresCapitalPartnersIII,
L.P.;thesaleofcertainconsumerbrandsandtheRhoGAM®business.In2012,thegainsonthedivestituresof
businesseswere$0.9billion.During2011,theCompanydivestituresincluded,theAnimalHealthBusinesstoElanco,a
DivisionofEliLilly,MONISTAT®inCanada,theU.S.anditsterritories(includingPuertoRico),assetsoftheOrtho
DermatologicsdivisionintheU.S.tosubsidiariesofValeantPharmaceuticalsInternational,Inc.andtheSurgical
InstrumentsBusinessofCodman&Shurtleff,Inc.In2011,thegainsonthedivestituresofbusinesseswere$1.0billion.
During2010,theCompanydivestituresincludedtheBreastCareBusinessofEthiconEndo-Surgery,Inc.Thegainson
thesedivestitureswererecognizedinOther(income)/expense,net.
21. LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseoftheirbusiness.
TheCompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount
ofthelosscanbereasonablyestimated.AsofDecember30,2012,theCompanyhasdeterminedthattheliabilities
associatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.TheCompanyhasaccruedfor
thesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther
developmentsinaccordancewithASC450-20-25.Fortheseandotherlitigationandregulatorymatterscurrently
disclosedforwhichalossisprobableorreasonablypossible,theCompanyisunabletodetermineanestimateofthe
possiblelossorrangeoflossbeyondtheamountsalreadyaccrued.Thesematterscanbeaffectedbyvariousfactors,
includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscovery
hasnotcommencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;thereare
significantfactsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutioninanyreportingperiodofone
ormoreofthesematters,eitheraloneorintheaggregate,mayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
54 • Johnson&Johnson2012AnnualReportPRODUCTLIABILITY
CertainsubsidiariesofJohnson&Johnsonareinvolvedinnumerousproductliabilitycases.Thedamagesclaimedare
substantial,andwhilethesesubsidiariesareconfidentoftheadequacyofthewarningsandinstructionsforusethat
accompanytheproductsatissue,itisnotfeasibletopredicttheultimateoutcomeoflitigation.TheCompanyhas
establishedproductliabilityaccrualsincompliancewithASC450-20basedoncurrentlyavailableinformation,whichin
somecasesmaybelimited.Changestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes
available.
MultipleproductsofJohnson&Johnsonsubsidiariesaresubjecttoproductliabilityclaimsandlawsuitsinwhichclaimants
seeksubstantialcompensatoryand,whereavailable,punitivedamages,includingLEVAQUIN®,theASR™XLAcetabular
SystemandDePuyASR™HipResurfacingSystem,thePINNACLE®AcetabularCupSystem,RISPERDAL®,pelvic
meshes,DURAGESIC®/fentanylpatchesandTOPAMAX®.AsofDecember30,2012,intheU.S.therewere
approximately2,100plaintiffswithdirectclaimsinpendinglawsuitsregardinginjuriesallegedlyduetoLEVAQUIN®,
10,750withrespecttotheASR™XLAcetabularSystemandDePuyASR™HipResurfacingSystem,3,300withrespectto
thePINNACLE®AcetabularCupSystem,425withrespecttoRISPERDAL®,4,000withrespecttopelvicmeshes,30
withrespecttoDURAGESIC®/fentanylpatchesand75withrespecttoTOPAMAX®.
InAugust2010,DePuyOrthopaedics,Inc.(DePuy)announcedaworldwidevoluntaryrecallofitsASR™XLAcetabular
SystemandDePuyASR™HipResurfacingSystemusedinhipreplacementsurgery.Claimsforpersonalinjuryhavebeen
madeagainstDePuyandJohnson&Johnson,andthenumberofpendinglawsuitscontinuestoincrease.Casesfiledin
FederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfor
theNorthernDistrictofOhio.LitigationhasalsobeenfiledincountriesoutsideoftheUnitedStates,primarilyintheUnited
Kingdom,CanadaandAustralia.TheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsassociated
withthisrecall.Duringthefiscalthirdandfourthquartersof2012,theCompanyincreaseditsaccrualsfortheDePuy
ASR™HiprecallprogramandrelatedproductliabilityaftertheCompanycompletedananalysisofnewinformation,
includingthenumberofexpectedclaims,recentlyupdatedrevisionratesoftherecalledproductsandproductliability
expensepercase.Changestotheseaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavealsobeenmadeagainstDePuyandJohnson&JohnsonrelatingtoDePuy’sPINNACLE®
AcetabularCupSystem.Thenumberofpendingproductliabilitylawsuitscontinuestoincrease,andtheCompany
continuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcases.Casesfiledin
FederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfor
theNorthernDistrictofTexas.TheCompanyhasestablishedaproductliabilityaccrualinanticipationofproductliability
litigationassociatedwithDePuy’sPINNACLE®AcetabularCupSystem.Changestothisaccrualmayberequiredinthe
futureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andJohnson&JohnsonarisingoutofEthicon’s
pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapse.Thenumberofpendingproduct
liabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcosts
andtheanticipatednumberofcases.CasesfiledinFederalcourtsintheUnitedStateshavebeenorganizedasamulti-
districtlitigationintheUnitedStatesDistrictCourtfortheSouthernDistrictofWestVirginia.Inaddition,aclassaction
andseveralindividualpersonalinjurycaseshavebeencommencedinCanadaandAustraliaseekingdamagesforalleged
injuryresultingfromEthicon’spelvicmeshdevices.TheCompanyhasestablishedaproductliabilityaccrualinanticipation
ofproductliabilitylitigationassociatedwithEthicon’spelvicmeshproducts.Changestothisaccrualmayberequiredin
thefutureasadditionalinformationbecomesavailable.
TheCompanybelievesthattheultimateresolutionofthesemattersbasedonhistoricalandreasonablylikelyfuturetrends
isnotexpectedtohaveamaterialadverseeffectontheCompany’sfinancialposition,annualresultsofoperationsand
cashflows.TheresolutioninanyinterimreportingperiodcouldhaveamaterialimpactontheCompany’sresultsof
operationsandcashflowsforthatperiod.
Johnson&Johnson2012AnnualReport • 55INTELLECTUALPROPERTY
CertainsubsidiariesofJohnson&Johnsonaresubject,fromtimetotime,tolegalproceedingsandclaimsrelatedto
patent,trademarkandotherintellectualpropertymattersarisingoutoftheirbusiness.Themostsignificantofthesematters
aredescribedbelow.
PATENTINFRINGEMENT
CertainsubsidiariesofJohnson&Johnsonareinvolvedinlawsuitschallengingthecoverageand/orvalidityofthepatents
ontheirproducts.Althoughthesesubsidiariesbelievethattheyhavesubstantialdefensestothesechallengeswithrespect
toallmaterialpatents,therecanbenoassuranceastotheoutcomeofthesematters,andalossinanyofthesecases
couldpotentiallyadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts,orrequirethepaymentofpast
damagesandfutureroyalties.
MedicalDevicesandDiagnostics
InOctober2004,TycoHealthcareGroup,LP(Tyco)andU.S.SurgicalCorporationfiledalawsuitagainstEthiconEndo-
Surgery,Inc.(EES)intheUnitedStatesDistrictCourtfortheDistrictofConnecticutallegingthatseveralfeaturesof
EES’sHARMONIC®ScalpelinfringedfourTycopatents.InOctober2007,onmotionsforsummaryjudgmentpriortothe
initialtrial,anumberofclaimswerefoundinvalidandanumberwerefoundinfringed.However,noclaimwasfoundboth
validandinfringed.TrialcommencedinDecember2007,andtheCourtdismissedthecasewithoutprejudiceongrounds
thatTycodidnotownthepatentsinsuit.Thedismissalwithoutprejudicewasaffirmedonappeal.InJanuary2010,Tyco
filedanothercomplaintintheUnitedStatesDistrictCourtfortheDistrictofConnecticutassertinginfringementofthreeof
thefourpatentsfromthepreviouslawsuitandaddingnewproducts.Tycoisseekingmonetarydamagesandinjunctive
relief.ThecasewastriedinJuly2012,andthepartiesareawaitingadecisionfromtheCourt.
InOctober2007,BruceSaffran(Saffran)filedapatentinfringementlawsuitagainstJohnson&JohnsonandCordis
Corporation(Cordis)intheUnitedStatesDistrictCourtfortheEasternDistrictofTexasalleginginfringementonU.S.
PatentNo.5,653,760.InJanuary2011,ajuryreturnedaverdictfindingthatCordis’ssalesofitsCYPHER®Stentwillfully
infringedthe‘760patent.ThejuryawardedSaffran$482million.InMarch2011,theCourtenteredjudgmentagainst
Cordisintheamountof$593million,representingthejuryverdict,plus$111millioninpre-judgmentinterest.Cordishas
appealedthejudgment.OralargumentwasheardinDecember2012,andadecisionfromtheCourtofAppealsis
pending.BecausetheCompanybelievesthatthepotentialforanunfavorableoutcomeisnotprobable,ithasnot
establishedanaccrualwithrespecttothecase.
InNovember2007,RocheDiagnosticsOperations,Inc.,etal.(Roche)filedapatentinfringementlawsuitagainstLifeScan,
Inc.(LifeScan)intheUnitedStatesDistrictCourtfortheDistrictofDelaware,accusingLifeScan’sentireOneTouch®line
ofbloodglucosemonitoringsystemsofinfringementoftwopatentsrelatedtotheuseofmicroelectrodesensors.In
September2009,LifeScanobtainedafavorablerulingonclaimconstructionthatprecludedafindingofinfringement.The
CourtenteredjudgmentagainstRocheinJuly2010andRocheappealed.TheCourtofAppealsreversedtheDistrict
Court’srulingonclaimconstructionandremandedthecasetotheDistrictCourtfornewfindingsontheissue.Theparties
areawaitingarulingonclaimconstruction.Rocheisseekingmonetarydamagesandinjunctiverelief.
InJune2009,RembrandtVisionTechnologies,L.P.(Rembrandt)filedapatentinfringementlawsuitagainstJohnson&
JohnsonVisionCare,Inc.(JJVC)intheUnitedStatesDistrictCourtfortheEasternDistrictofTexasallegingthatJJVC’s
manufactureandsaleofitsACUVUE®ADVANCE®andACUVUE®OASYS®HydrogelContactLensesinfringetheirU.S.
PatentNo.5,712,327(theChangpatent).Rembrandtisseekingmonetaryrelief.ThecasewastransferredtotheUnited
StatesDistrictCourtfortheMiddleDistrictofFlorida.InMay2012,thejuryreturnedaverdictholdingthatneitherofthe
accusedlensesinfringethe‘327patent.RembrandthasfiledanappealwiththeUnitedStatesCourtofAppealsforthe
FederalCircuit.
InNovember2011,HowmedicaOsteonicsCorp.(Howmedica)andStrykerIrelandLtd.(Stryker)filedapatent
infringementlawsuitagainstDePuyOrthopaedics,Inc.(DePuy)intheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyalleginginfringementbyDePuy’sPINNACLE®AcetabularCupSystemandDURALOC®AcetabularCupSystemof
apatentrelatingtoadual-lockingmechanismfeatureinanacetabularcupsystem.HowmedicaandStrykerareseeking
monetarydamagesandinjunctiverelief.DePuyfileditsanswerinFebruary2012andfiledacounterclaimassertingthat
Stryker’sTridentAcetabularHipSysteminfringesDePuy’sU.S.PatentNo.6,610,097.DePuyisseekingdamagesand
injunctiverelieffromHowmedicaandStryker.
56 • Johnson&Johnson2012AnnualReportInMay2012,MedtronicMinimed,Inc.,MedtronicPuertoRicoOperationsCo.andMiniMedDistributionCorp.(collectively,
MedtronicMinimed)filedapatentinfringementlawsuitagainstAnimasCorporationintheUnitedStatesDistrictCourtfor
theCentralDistrictofCaliforniaallegingthatAnimas’OneTouch®Ping®GlucoseManagementSysteminfringesnineof
theirpatents.MedtronicMinimedisseekingmonetarydamagesandinjunctiverelief.
InJune2012,DePuyOrthopaedics,Inc.(DePuy)filedadeclaratoryjudgmentactionagainstOrthopaedicHospital(OH)in
theUnitedStatesDistrictCourtfortheNorthernDistrictofIndianaseekingadeclarationoftheparties’rightsand
obligationsunderaPatentRightsandLicenseAgreementbetweenthepartiesrelatedtodevelopmentofapolyethylene
material.OHhasclaimedthatDePuyowesroyaltiesonproductsmadewithanti-oxidantpolyethylene.DePuydisputesthat
itowessuchroyaltiestoOHandisthusseekingadeclarationfromtheCourtondisputedcontractualprovisions.After
DePuyfiledthedeclaratoryjudgmentaction,OHfiledaseparatesuitonthesamesubjectmatterintheUnitedStates
DistrictCourtfortheCentralDistrictofCalifornia,andmovedforconsolidationwiththeCaliforniacase.
Pharmaceutical
InMay2009,AbbottBiotechnologyLtd.(Abbott)filedapatentinfringementlawsuitagainstCentocor,Inc.(Centocor)
(nowJanssenBiotech,Inc.(JBI))intheUnitedStatesDistrictCourtfortheDistrictofMassachusettsallegingthat
SIMPONI®infringesAbbott’sU.S.PatentNos.7,223,394and7,541,031(theSalfeldpatents).Abbottisseeking
monetarydamagesandinjunctiverelief.InApril2012,thepartiesparticipatedinanarbitrationontheissueofJBI’s
defensethatAbbottisequitablyestoppedfromassertingthepatents.InMay2012,thearbitratorrejectedJBI’sdefense.
ThecasehasbeenreinstatedintheDistrictCourtandfactdiscoveryisongoing.
InAugust2009,AbbottGmbH&Co.(AbbottGmbH)andAbbottBioresearchCenterfiledapatentinfringementlawsuit
againstCentocor(nowJBI)intheUnitedStatesDistrictCourtfortheDistrictofMassachusettsallegingthatSTELARA®
infringestwoUnitedStatespatentsassignedtoAbbottGmbH.JBIfiledacomplaintintheUnitedStatesDistrictCourtfor
theDistrictofColumbiaforadeclaratoryjudgmentofnon-infringementandinvalidityoftheAbbottGmbHpatents,aswell
asaComplaintforReviewofaPatentInterferenceDecisionthatgrantedpriorityofinventionononeofthetwoasserted
patentstoAbbottGmbH.ThecaseshavebeentransferredfromtheDistrictofColumbiatotheDistrictofMassachusetts.
TrialwasheldinSeptember2012withajuryverdictinfavorofCentocor,invalidatingAbbott’spatentclaims.Post-trial
briefinghasbeencompletedandthepartiesareawaitingadecision.AlsoinAugust2009,AbbottGmbHandAbbott
LaboratoriesLimitedbroughtapatentinfringementlawsuitinTheFederalCourtofCanadaallegingthatSTELARA®
infringesAbbottGmbH’sCanadianpatent.AtrialisscheduledforDecember2013intheCanadianCase.Inadditionto
theU.S.andCanadianlitigations,inAugust2012,AbbottfiledpatentinfringementlawsuitsintheNetherlands,
SwitzerlandandGermany.Ineachoftheabovecases,Abbottisseekingmonetarydamagesandinjunctiverelief.
LITIGATIONAGAINSTFILERSOFABBREVIATEDNEWDRUGAPPLICATIONS(ANDAs)
ThefollowingsummarizeslawsuitspendingagainstgenericcompaniesthatfiledAbbreviatedNewDrugApplications
(ANDAs)seekingtomarketgenericformsofproductssoldbyvarioussubsidiariesofJohnson&Johnsonpriortoexpiration
oftheapplicablepatentscoveringthoseproducts.TheseANDAstypicallyincludeallegationsofnon-infringement,
invalidityandunenforceabilityofthesepatents.Intheeventthesubsidiariesarenotsuccessfulintheseactions,orthe
statutory30-monthstaysexpirebeforetheUnitedStatesDistrictCourtrulingsareobtained,thethird-partycompanies
involvedwillhavetheability,uponapprovaloftheUnitedStatesFoodandDrugAdministration(FDA),tointroducegeneric
versionsoftheproductsatissue,resultinginverysubstantialmarketshareandrevenuelossesforthoseproducts.
CONCERTA®
AnumberofgenericcompanieshavefiledANDAsseekingapprovaltomarketgenericversionsofCONCERTA®.In
September2011,asettlementagreementwasenteredintowithKremers-Urban,LLCandKUDCOIreland,Ltd.
(collectively,KUDCO)pursuanttowhichKUDCOwasgrantedalicenseunderthepatent-in-suittomarketitsgeneric
versionofCONCERTA®startingonJuly1,2012,ifandwhenKUDCOobtainsFDAapproval.
InNovember2010,ALZACorporation(ALZA)andOrtho-McNeil-JanssenPharmaceuticals,Inc.(OMJPI)(nowJanssen
Pharmaceuticals,Inc.(JPI))filedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
DelawareagainstImpaxLaboratories,Inc.(Impax),TevaPharmaceuticalsUSA,Inc.,andTevaPharmaceuticalIndustries
Ltd.(collectively,Teva)inresponsetoImpaxandTeva’sfilingofamajoramendmenttoitsANDAseekingapprovalto
marketagenericversionofCONCERTA®beforetheexpirationofALZAandJPI’spatentrelatingtoCONCERTA®.Impax
Johnson&Johnson2012AnnualReport • 57andTevafiledcounterclaimsallegingnon-infringementandinvalidity.InMay2011,ALZAandJPIfiledasecondlawsuit
againstTevainresponsetoTeva’sfilingofasecondmajoramendmenttoitsANDAseekingapprovaltomarketadditional
dosagestrengthsofitsgenericCONCERTA®productbeforetheexpirationofALZAandJPI’spatentrelatingto
CONCERTA®.Ineachoftheabovecases,ALZAandJPIsoughtanOrderenjoiningthedefendantsfrommarketingits
genericversionofCONCERTA®priortotheexpirationofALZAandJPI’sCONCERTA®patent.InSeptember2012,a
settlementagreementwasenteredintowithImpaxandTevapursuanttowhichthosepartiesweregrantedalicenseunder
thepatent-in-suittomarkettheirgenericversionofCONCERTA®startingJuly14,2013(orearlierundercertain
circumstances),ifandwhentheyobtainFDAapproval.
ORTHOTRI-CYCLEN®LO
AnumberofgenericcompanieshavefiledANDAsseekingapprovaltomarketgenericversionsofORTHOTRI-CYCLEN®
LO.InFebruary2012,JPIandWatsonLaboratories,Inc.andWatsonPharmaceuticals,Inc.(collectively,Watson)entered
intoasettlementagreement.Pursuanttothesettlementagreement,thepartiesenteredintoasupplyagreementwhereby
JPIwillsupplytoWatsonacombinationaloralcontraceptivecontainingcertainspecifiedcompoundsfromDecember31,
2015(orearlierundercertaincircumstances)throughtheexpirationofthe‘815patentonDecember6,2019.Inaddition,
intheeventWatsondoesnotwishtoexerciseitsrightsunderthesupplyagreement,JPIhasgrantedWatsonalicenseto
marketWatson’sANDAproductfromDecember31,2015(orearlierundercertaincircumstances)throughDecember6,
2019.
InJanuary2010,OMJPI(nowJPI)filedapatentinfringementlawsuitagainstLupinLtd.andLupinPharmaceuticals,Inc.
(collectively,Lupin)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoLupin’sANDAseeking
approvaltomarketagenericversionofORTHOTRI-CYCLEN®LOpriortotheexpirationofJPI’spatentrelatingto
ORTHOTRI-CYCLEN®LO(theOTCLOpatent).Lupinfiledacounterclaimalleginginvalidityofthepatent.Trial
concludedinJune2012,andinSeptember2012,theCourtissuedadecisioninfavorofJPI.Inparticular,theCourt
orderedthattheeffectivedateoftheapprovalofLupin’sANDA(whichhadpreviouslybeenapproved)benotearlierthan
theexpirationoftheOTCLOpatent.LupinhasappealedthedecisiontotheCourtofAppealsfortheFederalCircuit.Oral
argumentwasheardinFebruary2013,andtheCourt’sdecisionispending.
InNovember2010,OMJPI(nowJPI)filedapatentinfringementlawsuitagainstMylanInc.andMylanPharmaceuticals,Inc.
(collectively,Mylan),andFamyCare,Ltd.(FamyCare)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyin
responsetoFamyCare’sANDAseekingapprovaltomarketagenericversionofORTHOTRI-CYCLEN®LOpriortothe
expirationoftheOTCLOpatent.MylanandFamyCarefiledcounterclaimsalleginginvalidityofthepatent.InNovember
2012,JPIandMylanenteredintoasettlementagreementpursuanttowhichMylanwasgrantedalicenseunderthe
OTCLOpatenttomarketitsgenericversionofORTHOTRI-CYCLEN®LOstartingDecember31,2015(orearlierunder
certaincircumstances),ifandwhentheyobtainFDAapproval.
InOctober2011,JPIfiledapatentinfringementlawsuitagainstSunPharmaGlobalFZEandSunPharmaceutical
Industries(collectively,Sun)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoSun’sANDA
seekingapprovaltomarketagenericversionofORTHOTRI-CYCLEN®LOpriortotheexpirationoftheOTCLOpatent.
InMay2012,JPIfiledapatentinfringementlawsuitagainstHauptPharma,Inc.,RanbaxyLaboratoriesLimitedand
RanbaxyInc.(collectively,Haupt)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoHaupt’s
ANDAseekingapprovaltomarketagenericversionofORTHOTRI-CYCLEN®LOpriortotheexpirationoftheOTCLO
patent.InDecember2012,JPIandHauptenteredintoasettlementagreementpursuanttowhichHauptwasgranteda
licenseundertheOTCLOpatenttomarketitsgenericversionofORTHOTRI-CYCLEN®LOstartingDecember31,2015
(orearlierundercertaincircumstances),ifandwhentheyobtainFDAapproval.
InAugust2012,JPIfiledapatentinfringementlawsuitagainstGlenmarkGenericsLtd.andGlenmarkGenericsInc.,USA
(collectively,Glenmark)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoGlenmark’sANDA
seekingapprovaltomarketagenericversionofORTHOTRI-CYCLEN®LOpriortotheexpirationoftheOTCLOpatent.
InNovember2012,asettlementagreementwasenteredintowithGlenmarkpursuanttowhichGlenmarkwasgranteda
licenseundertheOTCLOpatenttomarketitsgenericversionofORTHOTRI-CYCLEN®LOstartingDecember31,2015
(orearlierundercertaincircumstances),ifandwhentheyobtainFDAapproval.
Ineachoftheabovecases,JPIsoughtorisseekinganOrderenjoiningthedefendantsfrommarketingtheirgeneric
versionsofORTHOTRI-CYLCEN®LObeforetheexpirationoftheOTCLOpatent.
58 • Johnson&Johnson2012AnnualReportPREZISTA®
AnumberofgenericcompanieshavefiledANDAsseekingapprovaltomarketgenericversionsofPREZISTA®.In
November2010,Tibotec,Inc.(nowTibotec,LLC)andTibotecPharmaceuticals(nowJanssenR&DIreland)(collectively,
Tibotec)filedapatentinfringementlawsuitagainstLupin,Ltd.,LupinPharmaceuticals,Inc.(collectively,Lupin),Mylan,Inc.
andMylanPharmaceuticals,Inc.(collectively,Mylan)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyin
responsetoLupin’sandMylan’srespectiveANDAsseekingapprovaltomarketgenericversionsofTibotec’sPREZISTA®
productbeforetheexpirationofTibotec’spatentrelatingtoPREZISTA®.LupinandMylaneachfiledcounterclaims
allegingnon-infringementandinvalidity.InJuly2011,TibotecfiledanotherpatentinfringementlawsuitagainstLupininthe
UnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoLupin’ssupplementtoitsANDAtoaddnew
dosagestrengthsforitsproposedproduct.InAugust2011,TibotecandG.D.Searle&Company(G.D.Searle)fileda
patentinfringementlawsuitagainstLupinandMylaninresponsetotheirnoticelettersadvisingthattheirANDAsare
seekingapprovaltomarketgenericversionsofTibotec’sPREZISTA®productbeforetheexpirationoftwopatentsrelating
toPREZISTA®thatTibotecexclusivelylicensesfromG.D.Searle.
InMarch2011,TibotecandG.D.SearlefiledapatentinfringementlawsuitagainstTevaPharmaceuticalsUSA,Inc.and
TevaPharmaceuticals,Ltd.(collectively,Teva)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponse
toTeva’sANDAseekingapprovaltomarketagenericversionofPREZISTA®beforetheexpirationofcertainpatents
relatingtoPREZISTA®thatTiboteceitherownsorexclusivelylicensesfromG.D.Searle.
InMarch2011,TibotecfiledapatentinfringementlawsuitagainstHeteroDrugs,Ltd.UnitIIIandHeteroUSAInc.
(collectively,Hetero)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoHetero’sANDA
seekingapprovaltomarketagenericversionofPREZISTA®beforetheexpirationofcertainpatentsrelatingto
PREZISTA®thatTibotecexclusivelylicensesfromG.D.Searle.InJuly2011,uponagreementbytheparties,theCourt
enteredastayofthelawsuitpendingafinaldecisioninthelawsuitagainstTevawithrespecttothevalidityand/or
enforceabilityofthepatentsthatTiboteclicensesfromG.D.Searle,withHeteroagreeingtobeboundbysuchfinal
decision.
InSeptember2011,theCourtconsolidatedtheabovelawsuits,aswellaslawsuitsbroughtbytheUnitedStates
GovernmentagainsteachofthedefendantsforinfringementofaUnitedStatesGovernment-ownedpatentrelatingto
PREZISTA®,forpurposesofpre-trialdiscoveryandtrial,withtheprovisothatafterdiscoveryiscompleted,anypartycan
movetohavethecasesde-consolidatedfortrial.
InMayandJune2012,JanssenProducts,LPandJanssenR&DIreland(collectively,Janssen)andG.D.Searlefileda
patentinfringementlawsuitagainstLupin,TevaandMylanintheUnitedStatesDistrictCourtfortheDistrictofNewJersey,
alleginginfringementofnewlyissuedUnitedStatesReissuePatentNo.Re42,889,whichJanssenexclusivelylicenses
fromG.D.Searle.InAugust2012,JanssenandG.D.SearlefiledapatentinfringementlawsuitagainstLupin,Tevaand
MylanintheUnitedStatesDistrictCourtfortheDistrictofNewJersey,alleginginfringementofnewlyissuedUnitedStates
ReissuePatentNo.Re43,596,whichJanssenexclusivelylicensesfromG.D.Searle.Thesecaseshavebeenconsolidated
withtheabovelawsuits.InOctober2012,JanssenfiledamotiontofileaSupplementalComplaintagainstLupin,Tevaand
MylanintheUnitedStatesDistrictCourtfortheDistrictofNewJersey,alleginginfringementofUnitedStatesPatentNos.
7,772,411(Mylanonly),7,126,015(LupinandTevaonly)and7,595,408(LupinandTevaonly).InJanuary2013,the
Courtpermittedthesethreeadditionalpatentstobeaddedtotheconsolidatedaction.
Ineachoftheabovelawsuits,TibotecandJanssenareseekinganOrderenjoiningthedefendantsfrommarketingtheir
genericversionsofPREZISTA®beforetheexpirationoftherelevantpatents.
OTHERINTELLECTUALPROPERTYMATTERS
InSeptember2009,CentocorOrthoBiotechProducts,L.P.(nowJanssenProducts,LP(JPLP))intervenedinan
inventorshiplawsuitfiledbytheUniversityofKansasCenterforResearch,Inc.(KUCR)againsttheUnitedStatesof
America(USA)intheUnitedStatesDistrictCourtfortheDistrictofKansas.KUCRallegesthattwoKUCRscientists
shouldbeaddedasinventorsontwoUSA-ownedpatentsrelatingtoVELCADE®.TheUSAlicensedthepatents(and
theirforeigncounterparts)toMillenniumPharmaceuticals,Inc.(MPI),whointurnsublicensedthepatents(andtheirforeign
counterparts)toJPLPforcommercialmarketingoutsidetheUnitedStates.InJuly2010,thepartiesreachedasettlement
agreementtoresolvethedisputesinthiscaseandsubmittedtheinventorshipissuetoarbitration,theoutcomeofwhich
woulddeterminewhetherpre-specifiedpaymentswouldbemadetoKUCR,butwillnotaffectJPLP’srighttomarket
VELCADE®.ThearbitrationtookplaceinDecember2011andadecisioninfavorofKUCRwasissuedinMarch2012.As
aresult,JPLPwillberequiredtomaketheaforementionedpre-specifiedpaymentstoKUCR.
Johnson&Johnson2012AnnualReport • 59InDecember2009,theStateofIsraelfiledalawsuitintheDistrictCourtinTelAvivJaffaagainstOmrix
Biopharmaceuticals,Inc.andvariousaffiliates(Omrix).Inthelawsuit,theStateclaimsthatanemployeeofagovernment-
ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe
wasagovernmentemployee.TheStateclaimsthathehadnorighttotransferanyintellectualpropertytoOmrixbecauseit
belongstotheState.TheStateisseekingdamagesplusroyaltiesonQUIXIL™andEVICEL™products,oralternatively,
transferofthepatentstotheState.
InJanuary2011,Genentech,Inc.(Genentech)initiatedanarbitrationagainstUCBCelltech(Celltech)seekingdamagesfor
allegedlycooperatingwithCentocor,Inc.(nowJanssenBiotech,Inc.(JBI))toimproperlyterminateaprioragreementin
whichJBIwassublicensedunderGenentech’sCabillypatentstosellREMICADE®.JBIhasanindemnityagreementwith
Celltech,andCelltechassertedthatJBIwouldbeliableforanydamagesCelltechmayberequiredtopayGenentechinthat
arbitration.FollowinganarbitrationhearinginJune2012,thearbitratorsissuedadecisionfindingnoliabilityforCelltech,
andtherefore,JBIisnotliableforanypotentialindemnityclaim.JBIhasmovedtorecoveritsattorney’sfees,costsand
expenses.
InMarch2012,Noramco,Inc.(Noramco)movedtointerveneinthreepatentinfringementlawsuitsfiledintheUnited
StatesDistrictCourtfortheSouthernDistrictofNewYork(SDNY)byPurduePharmaL.P.andothers(Purdue)against
Noramcooxycodonecustomers,ImpaxLaboratories,Inc.(Impax),TevaPharmaceuticalsUSA,Inc.(Teva)andAmneal
Pharmaceuticals,LLC(Amneal).InFebruary2013,NoramcoappearedonbehalfofNoramcocustomersWatson
Laboratories,Inc.–FloridaandAndrxLabs,LLC(collectively,Watson/Andrx)inasimilarlawsuitfiledbyPurdueinthe
SDNY.Thelawsuitsareinresponsetothedefendants’respectiveANDAsseekingapprovaltomarketgenericextended
releaseoxycodoneproductsbeforetheexpirationofcertainPurduepatents.Threeoftheassertedpatentsrelateto
oxycodoneandprocessesformakingoxycodone,andNoramcohasagreedtodefendthelawsuitsonbehalfofImpax,
Teva,AmnealandWatson/Andrx.AlthoughNoramcodidnotparticipate,inNovember2012,atrialinalawsuitbroughtby
PurdueagainstanotherNoramcocustomer,ActavisElizabeth,LLC(Actavis),tookplace.Becausetheactiveingredientat
issueintheActavislawsuitisthesameastheactiveingredientatissueintheabovelawsuits,theDistrictCourt’sdecision
intheActaviscasemayaffectthoselawsuits.AdecisionfromtheDistrictCourtintheActaviscaseispending.
InAugust2012,Dr.JamesM.Swanson(Swanson)filedalawsuitagainstALZACorporation(ALZA)intheNorthern
DistrictofCaliforniaseekingtobeaddedasaninventorontwoALZA-ownedpatentsrelatingto
CONCERTA®.Alternatively,Dr.Swansonhasallegedthatthepatents-in-suitareinvalidand/orunenforceableasaresult
ofALZA’sallegedomissionofDr.Swansonasanamedinventoronthepatents.Dr.Swansonisseekingdamagesandan
awardofunjustenrichment.ALZAfiledamotiontodismissSwanson’sclaimsandoralargumentisscheduledforFebruary
2013.
GOVERNMENTPROCEEDINGS
Likeothercompaniesinthepharmaceuticalandmedicaldevicesanddiagnosticsindustries,Johnson&Johnsonand
certainofitssubsidiariesaresubjecttoextensiveregulationbynational,stateandlocalgovernmentagenciesintheUnited
Statesandothercountriesinwhichtheyoperate.Asaresult,interactionwithgovernmentagenciesisongoing.Themost
significantlitigationbroughtby,andinvestigationsconductedby,governmentagenciesarelistedbelow.Itispossiblethat
criminalchargesandsubstantialfinesand/orcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsor
litigation.
AVERAGEWHOLESALEPRICE(AWP)LITIGATION
Johnson&Johnsonandseveralofitspharmaceuticalsubsidiaries(theJ&JAWPDefendants),alongwithnumerousother
pharmaceuticalcompanies,aredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe
pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct
because,amongotherthings,thecompaniesallegedlyreportedaninflatedAverageWholesalePrice(AWP)forthedrugs
atissue.PayorsallegedthattheyusedthoseAWPsincalculatingproviderreimbursementlevels.Manyofthesecases,
bothfederalactionsandstateactionsremovedtofederalcourt,wereconsolidatedforpre-trialpurposesinaMulti-District
Litigation(MDL)intheUnitedStatesDistrictCourtfortheDistrictofMassachusetts.
Theplaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchase
ofthedrugsatissuebasedonAWP,andstategovernmententitiesthatmadeMedicaidpaymentsforthedrugsatissue
basedonAWP.InJune2007,afteratrialonthemerits,theMDLCourtdismissedtheclaimsoftwooftheplaintiffclasses
againsttheJ&JAWPDefendants.InMarch2011,theCourtdismissedtheclaimsofthethirdclassagainsttheJ&JAWP
Defendantswithoutprejudice.
60 • Johnson&Johnson2012AnnualReportAWPcasesbroughtbyvariousAttorneysGeneralhaveproceededtotrialagainstothermanufacturers.Severalstate
casesagainstcertainsubsidiariesofJohnson&Johnsonhavebeensettled,includingKentucky,whichhadbeensetfor
trialinJanuary2012andKansaswhichhadbeensetfortrialinMarch2013.LouisianaandMississippiaresetfortrialin
October2013,IllinoisissetfortrialinMay2014,andAlaskaissetfortrialinJuly2014.Otherstatecasesarelikelytobe
setfortrialinduecourse.Inaddition,anAWPcaseagainsttheJ&JAWPDefendantsbroughtbytheCommonwealthof
PennsylvaniawastriedinCommonwealthCourtinOctoberandNovember2010.TheCourtfoundinthe
Commonwealth’sfavorwithregardtocertainofitsclaimsunderthePennsylvaniaUnfairTradePracticesandConsumer
ProtectionLaw(UTPL),enteredaninjunction,andawarded$45millioninrestitutionand$6.5millionincivilpenalties.The
CourtfoundintheJ&JAWPDefendants’favorontheCommonwealth’sclaimsofunjustenrichment,misrepresentation/
fraud,civilconspiracy,andoncertainoftheCommonwealth’sclaimsundertheUTPL.TheJ&JAWPDefendantshave
appealedtheCommonwealthCourt’sUTPLrulingtothePennsylvaniaSupremeCourt.TheCompanybelievesthattheJ&J
AWPDefendantshavestrongargumentssupportingtheirappeal.BecausetheCompanybelievesthatthepotentialforan
unfavorableoutcomeisnotprobable,ithasnotestablishedanaccrualwithrespecttotheverdict.
RISPERDAL®
InJanuary2004,JanssenPharmaceuticaInc.(JanssenPharmaceutica)(nowJanssenPharmaceuticals,Inc.(JPI))received
asubpoenafromtheOfficeoftheInspectorGeneraloftheUnitedStatesOfficeofPersonnelManagementseeking
documentsconcerningsalesandmarketingof,anyandallpaymentstophysiciansinconnectionwithsalesandmarketing
of,andclinicaltrialsfor,RISPERDAL®from1997to2002.Documentssubsequentto2002havealsobeenrequestedby
theDepartmentofJustice.Anadditionalsubpoenaseekinginformationaboutmarketingof,andadversereactionsto,
RISPERDAL®wasreceivedfromtheUnitedStatesAttorney’sOfficefortheEasternDistrictofPennsylvaniain
November2005.Numeroussubpoenasseekingtestimonyfromvariouswitnessesbeforeagrandjurywerealsoreceived.
JPIcooperatedinrespondingtotheserequestsfordocumentsandwitnesses.TheUnitedStatesDepartmentofJustice
andtheUnitedStatesAttorney’sOfficefortheEasternDistrictofPennsylvania(theGovernment)arecontinuingtoactively
pursuebothcriminalandcivilactions.InFebruary2010,theGovernmentservedCivilInvestigativeDemandsseeking
additionalinformationrelatingtosalesandmarketingofRISPERDAL®andsalesandmarketingofINVEGA®.Thefocusof
thesemattersistheallegedpromotionofRISPERDAL®andINVEGA®foroff-labeluses.TheGovernmenthasnotifiedJPI
thattherearealsopendingquitamactionsallegingoff-labelpromotionofRISPERDAL®.TheGovernmentinformedJPI
thatitwillinterveneinthesequitamactionsandfileasupersedingcomplaint.
In2011,discussionstoresolvecriminalpenaltiesundertheFoodDrugandCosmeticActrelatedtothepromotionof
RISPERDAL®resultedinanagreementinprinciplewiththeUnitedStatesAttorney’sOfficefortheEasternDistrictof
Pennsylvaniaonkeyissuesrelevanttoadispositionofcriminalchargespursuanttoasinglemisdemeanorviolationofthe
FoodDrugandCosmeticAct,butcertainissuesremainopenbeforeasettlementcanbefinalized.During2011,the
Companyaccruedamountstocoverthefinancialcomponentoftheproposedcriminalsettlement.
In2012,theCompanyalsoreachedanagreementinprinciplewiththeUnitedStatesDepartmentofJusticetosettlethree
pendingcivilFalseClaimsActmattersthatarependingin(1)theEasternDistrictofPennsylvaniaconcerningsalesand
marketingofRISPERDAL®andINVEGA®;(2)theNorthernDistrictofCaliforniaregardingthesalesandmarketingof
NATRECOR®,discussedseparatelybelow;and(3)theDistrictofMassachusettsallegingthatthedefendantsprovided
theOmnicare,Inc.(Omnicare)long-termcarepharmacywithrebatesandotherpaymentsregardingRISPERDAL®and
otherproducts,discussedseparatelybelow.Assumingtheseagreementsarefinalized,theywillresolvethefederal
government’sclaimsundertheFederalFalseClaimsAct,resolveallpendingstateandfederalgovernmentlitigation
regardingOmnicareandNATRECOR®,andsettletheRISPERDAL®Medicaid-relatedclaimsforthosestatesthatoptinto
thesettlement.Withthetentativesettlementagreementsdescribedabove,issuesremainopenthatmustberesolved
beforethesettlementscanbefinalized.
TheCompanyhasaccruedamounts,includinganadditionalaccrualmadeinthesecondquarterof2012,tocoverthese
tentativesettlementagreements.However,thesettlementswillnotresolveallpendingstatelitigationmattersregarding
RISPERDAL®,andsomestatesmayelecttooptoutofthesettlements.Totheextentanystatehasaclaimandhasorwill
electtooptoutofthesesettlements,theCompanyhasaccruedanamountequaltowhatthatstatewouldreceiveifitwas
participatinginthesettlements.Amongotherstates,Arkansas,LouisianaandSouthCarolinaarenotexpectedto
participateinthesettlements(asdiscussedbelow).BecausetheCompanybelievestherearestrongargumentsonappeal
inthosecases,theCompanyhasonlyaccruedanamountequaltowhatthesestateswouldreceiveiftheyparticipatedin
thesettlements.
Inaddition,theAttorneysGeneralofmultiplestates,includingAlaska,Arkansas,Louisiana,Massachusetts,Mississippi,
Montana,NewMexico,SouthCarolinaandUtah,havependingactionsagainstJanssenPharmaceutica(nowJPI)seeking
Johnson&Johnson2012AnnualReport • 61oneormoreofthefollowingremedies:reimbursementofMedicaidorotherpublicfundsforRISPERDAL®prescriptions
writtenforoff-labeluse,compensationfortreatingtheircitizensforallegedadversereactionstoRISPERDAL®,civilfines
orpenalties,damagesfor“overpayments”bythestateandothers,violationsofstateconsumerfraudstatutes,punitive
damagesorotherreliefrelatingtoallegedunfairbusinesspractices.Certainoftheseactionsalsoseekinjunctiverelief
relatingtothepromotionofRISPERDAL®.InJanuary2012,JPIsettledalawsuitfiledbytheAttorneyGeneralofTexas.In
April2012,inthelawsuitbroughtbytheAttorneyGeneralofArkansas,thejuryfoundagainstbothJPIandJohnson&
Johnson,andtheCourtimposedpenaltiesintheamountofapproximately$1.2billion.JPIandJohnson&Johnsonhave
filedanappealandbelievethattheyhavestrongargumentssupportingtheappeal.InJanuary2013,thesamecourt
awardedattorneyfeesofapproximately$180million.Thisjudgmentwillalsobeappealed.
TheAttorneyGeneralofWestVirginiacommencedsuitin2004againstJanssenPharmaceutica(nowJPI)basedon
claimsofallegedconsumerfraudastoDURAGESIC®,aswellasRISPERDAL®.JPIwasfoundliableanddamageswere
assessedat$4.5million.JPIfiledanappeal,andinNovember2010,theWestVirginiaSupremeCourtreversedthetrial
court’sdecision.InDecember2010,theAttorneyGeneralofWestVirginiadismissedthecaseasitrelatedto
RISPERDAL®withoutanypayment.Thereafter,JPIsettledthecaseinsofarasitrelatedtoDURAGESIC®.
In2004,theAttorneyGeneralofLouisianafiledamulti-countComplaintagainstJanssenPharmaceutica(nowJPI).
Johnson&Johnsonwaslateraddedasadefendant.ThecasewastriedinOctober2010.Theissuetriedtothejurywas
whetherJohnson&JohnsonorJPIhadviolatedtheState’sMedicaidFraudAct(theAct)throughmisrepresentations
allegedlymadeinthemailingofaNovember2003DearHealthCareProfessionalletterregardingRISPERDAL®.Thejury
returnedaverdictthatJPIandJohnson&JohnsonhadviolatedtheActandawarded$257.7millionindamages.Thetrial
judgesubsequentlyawardedtheAttorneyGeneralcounselfeesandexpensesintheamountof$73million.InAugust
2012,aninterlocutoryappellatecourtaffirmedthejudgment.InJanuary2013,theLouisianaSupremeCourtaccepted
Johnson&JohnsonandJPI’srequestforappeal.OralargumentontheappealhasbeensetforMarch2013.
In2007,theOfficeofGeneralCounseloftheCommonwealthofPennsylvaniafiledalawsuitagainstJanssen
Pharmaceutica(nowJPI)onamulti-CountComplaintrelatedtoJanssenPharmaceutica’ssaleofRISPERDAL®tothe
Commonwealth’sMedicaidprogram.ThetrialoccurredinJune2010.Thetrialjudgedismissedthecaseafterthecloseof
theplaintiff’sevidence.TheCommonwealthfiledanappealinApril2011,andinJuly2012,thePennsylvaniaAppeals
CourtupheldthedismissaloftheCommonwealth’scase.
In2007,theAttorneyGeneralofSouthCarolinafiledalawsuitagainstJohnson&JohnsonandJanssenPharmaceutica
(nowJPI)onseveralcounts.InMarch2011,thematterwastriedonliabilityonly,atwhichtimethelawsuitwaslimitedto
claimsofviolationoftheSouthCarolinaUnfairTradePracticeAct,including,amongothers,questionsofwhether
Johnson&JohnsonorJPIengagedinunfairordeceptiveactsorpracticesintheconductofanytradeorcommerceby
distributingtheNovember2003DearHealthCareProfessionalletterregardingRISPERDAL®orintheiruseofthe
product’sFDA-approvedlabel.ThejuryfoundinfavorofJohnson&JohnsonandagainstJPI.InJune2011,theCourt
awardedcivilpenaltiesofapproximately$327.1million.JPIhasappealedthisjudgmentandtheCompanybelievesithas
strongargumentssupportingtheappeal.OralargumentontheappealhasbeensetbeforetheSouthCarolinaSupreme
CourtforMarch2013.
TheAttorneysGeneralofapproximately40otherstatesandtheDistrictofColumbiaindicatedaninterestinpursuing
similarlitigationagainstJPI,andobtainedatollingagreementstayingtherunningofthestatuteoflimitationswhilethey
pursuedaninvestigationofJPIregardingpotentialconsumerfraudactionsinconnectionwiththemarketingof
RISPERDAL®.InSeptember2012,JPIsettledwith36ofthestatesandtheDistrictofColumbianon-Medicaidclaimsin
connectionwiththesalesandmarketingofRISPERDAL®andINVEGA®foratotalofapproximately$181million,an
amountwhichhadbeenpreviouslyaccrued.
IntheCompany’sopinion,theultimateresolutionofanyoftheaboveRISPERDAL®mattersisnotexpectedtohavea
materialadverseeffectontheCompany’sfinancialposition,althoughtheresolutioninanyreportingperiodcouldhavea
materialimpactontheCompany’sresultsofoperationsandcashflowsforthatperiod.
OMNICARE
InSeptember2005,Johnson&JohnsonreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusetts,seekingdocumentsrelatedtothesalesandmarketingofeightdrugstoOmnicare,Inc.(Omnicare),a
managerofpharmaceuticalbenefitsforlong-termcarefacilities.InApril2009,Johnson&Johnsonandcertainofits
pharmaceuticalsubsidiarieswereservedintwocivilquitamcasesassertingclaimsundertheFederalFalseClaimsAct
andrelatedstatelawclaimsallegingthatthedefendantsprovidedOmnicarewithrebatesandotherallegedkickbacks,
causingOmnicaretofilefalseclaimswithMedicaidandothergovernmentprograms.InJanuary2010,thegovernment
62 • Johnson&Johnson2012AnnualReportintervenedinbothofthesecases,namingJohnson&Johnson,Ortho-McNeil-JanssenPharmaceuticals,Inc.(nowJanssen
Pharmaceuticals,Inc.(JPI)),andJohnson&JohnsonHealthCareSystemsInc.asdefendants.Subsequently,the
CommonwealthofMassachusetts,Virginia,andKentucky,andtheStatesofCaliforniaandIndianaintervenedinthe
action.InFebruary2011,theUnitedStatesDistrictCourtfortheDistrictofMassachusettsdismissedonequitamcase
entirelyanddismissedtheothercaseinpart,rejectingallegationsthatthedefendantshadviolatedtheirobligationto
reportits“bestprice”tohealthcareprogramofficials.TheclaimsoftheUnitedStatesandindividualstatesremain
pending.InJune2012,thepartiesweregrantedtheirjointmotiontostaythecasependingresolutionofthepotential
settlementdiscussedintheRISPERDAL®sectionabove.
InNovember2005,alawsuitwasfiledbyScottBartz,aformeremployee,intheUnitedStatesDistrictCourtforthe
EasternDistrictofPennsylvaniaagainstJohnson&Johnsonandcertainofitspharmaceuticalsubsidiaries(theJ&J
Defendants),alongwithco-defendantsMcKessonCorporation(McKesson)andOmnicare,Inc.InFebruary2011,the
plaintifffiledanamendedcomplaint.Thereafter,ontheJ&JDefendants’motion,thecasewastransferredtotheUnited
StatesDistrictCourtfortheDistrictofMassachusetts,whereitiscurrentlypending.Theamendedcomplaintallegesa
varietyofcausesofactionundertheFederalFalseClaimsActandcorrespondingstateandlocalstatutes,includingthat
theJ&JDefendantsengagedinvariousimpropertransactionsthatwereallegedlydesignedtoreportfalseprescription
drugpricestothefederalgovernmentinordertoreducetheJ&JDefendants’Medicaidrebateobligations.Thecomplaint
furtherallegesthattheJ&JDefendantsimproperlyretaliatedagainsttheplaintiffforhavingraisedtheseallegations
internally.Bartzseeksmultipleformsofrelief,includingdamagesandreinstatementtoapositionwiththesameseniority
status.TheJ&JDefendantssubsequentlymovedtodismissthecomplaintinMay2011.InMarch2012,theDistrictCourt
dismissedBartz’sclaimsundertheFederalFalseClaimsAct,anddeclinedtoexercisesupplementaljurisdictionover
numerousrelatedclaimsunderstatefalseclaimsactstatutes.TheDistrictCourt,however,deniedthedismissalmotion
withregardtoBartz’sclaimsthathewasretaliatedagainstinviolationoftheFederalFalseClaimsActandinviolationof
NewJersey’sConscientiousEmployeeProtectionAct.InFebruary2013,thepartiesenteredintoasettlementagreement
toresolveallofBartz’sclaimsandfiledajointmotiontodismissthelawsuit,withprejudice;theDistrictCourtgrantedthe
motiontodismissallclaims.
MCNEILCONSUMERHEALTHCARE
StartinginJune2010,McNeilConsumerHealthcareDivisionofMcNEIL-PPC,Inc.(McNeilConsumerHealthcare)and
certainaffiliates,includingJohnson&Johnson(theCompanies),receivedgrandjurysubpoenasfromtheUnitedStates
Attorney’sOfficefortheEasternDistrictofPennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvarious
productsofMcNeilConsumerHealthcare,andtheFDAinspectionsoftheFortWashington,PennsylvaniaandLancaster,
Pennsylvaniamanufacturingfacilities,aswellascertaindocumentsrelatingtorecallsofasmallnumberofproductsof
othersubsidiaries.Inaddition,inFebruary2011,thegovernmentservedMcNEIL-PPC,Inc.(McNEIL-PPC)withaCivil
InvestigativeDemandseekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationoftheFederalFalse
ClaimsAct.TheCompaniesarecooperatingwiththeUnitedStatesAttorney’sOfficeinrespondingtothesesubpoenas.
TheCompanieshavealsoreceivedCivilInvestigativeDemandsfrommultipleStateAttorneysGeneralOfficesbroadly
relatingtotheMcNeilrecallissues.TheCompaniescontinuetocooperatewiththeseinquiries.InJanuary2011,the
OregonAttorneyGeneralfiledacivilcomplaintagainstJohnson&Johnson,McNEIL-PPCandMcNeilHealthcareLLCin
statecourtallegingcivilviolationsoftheOregonUnlawfulTradePracticesActrelatingtoanearlierrecallofaMcNeilOTC
product.InNovember2012,thestatecourtgrantedamotionbytheCompaniestodismissOregon’scomplaintinits
entirety,withprejudice.InDecember2012,OregonfiledaNoticeofAppealintheCourtofAppealsoftheStateof
Oregon.
InMarch2011,theUnitedStatesfiledacomplaintforinjunctivereliefintheUnitedStatesDistrictCourtfortheEastern
DistrictofPennsylvaniaagainstMcNEIL-PPCandtwoofitsemployees,allegingthatMcNEIL-PPCisinviolationofFDA
regulationsregardingthemanufactureofdrugsatthefacilitiesitoperatesinLancaster,Pennsylvania,FortWashington,
Pennsylvania,andLasPiedras,PuertoRico.Onthesameday,thepartiesfiledaconsentdecreeofpermanentinjunction
resolvingtheclaimssetforthinthecomplaint.TheCourtapprovedandenteredtheconsentdecreeonMarch16,2011.
Theconsentdecree,whichissubjecttoongoingenforcementbytheCourt,requiresMcNEIL-PPCtotakeenhanced
measurestoremediatethethreefacilities.TheFortWashingtonfacility,whichwasvoluntarilyshutdowninApril2010,will
remainshutdownuntilathird-partyconsultantcertifiesthatitsoperationswillbeincompliancewithapplicablelaw,and
theFDAconcurswiththethird-partycertification.TheLancasterandLasPiedrasfacilitiesmaycontinuetomanufacture
anddistributedrugs,providedthatathirdpartyreviewsmanufacturingrecordsforselectedbatchesofdrugsreleased
Johnson&Johnson2012AnnualReport • 63fromthefacilities,andcertifiesthatanydeviationsrevieweddonotadverselyaffectthequalityoftheselectedbatches.
McNEIL-PPCsubmittedaworkplantotheFDAforremediationoftheLancasterandLasPiedrasfacilities,andthatplan
wasapprovedbytheFDAinOctober2012.Third-partybatchrecordreviewmayceaseiftheFDAhasstatedthatthe
facilitiesappeartobeincompliancewithapplicablelaw.Eachfacilityissubjecttoafive-yearauditperiodbyathirdparty
afterthefacilityhasbeendeemedbytheFDAtobeinapparentcompliancewithapplicablelaw.
OTHER
InJuly2005,SciosInc.(Scios)receivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusetts,seekingdocumentsrelatedtothesalesandmarketingofNATRECOR®.InAugust2005,Scioswas
advisedthattheinvestigationwouldbehandledbytheUnitedStatesAttorney’sOfficefortheNorthernDistrictof
CaliforniainSanFrancisco.InFebruary2009,twoquitamcomplaintswereunsealedintheUnitedStatesDistrictCourt
fortheNorthernDistrictofCalifornia,alleging,amongotherthings,improperactivitiesinthepromotionofNATRECOR®.In
June2009,theUnitedStatesgovernmentintervenedinoneofthequitamactions,andfiledacomplaintagainstSciosand
Johnson&JohnsonseekingreliefundertheFederalFalseClaimsActandassertingaclaimofunjustenrichment.In
October2011,thecriminalmatterwasresolved.Thecivilcasehasbeenstayedpendingresolutionofthepotential
settlementdiscussedintheRISPERDAL®sectionabove.
InJune2008,Johnson&JohnsonreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsrelatingtothemarketingofbiliarystentsbyCordisCorporation(Cordis).InFebruary2012,the
governmentinformedCordisthatitwasclosingitsinvestigation.Inaddition,inJanuary2010,acomplaintwasunsealedin
theUnitedStatesDistrictCourtfortheNorthernDistrictofTexas,filedbyKevinColquitt,seekingdamagesagainstCordis
andotherpartiesforallegedviolationsoftheFederalFalseClaimsActandseveralsimilarstatelawsinconnectionwiththe
marketingofbiliarystents.TheUnitedStatesDepartmentofJusticeandseveralstatesdeclinedtointervene.InJanuary
2013,theCourtgrantedCordis’smotiontodismisstheclaimsagainstCordis,withprejudice.Plaintiffhasappealed.
InSeptember2011,Synthes,Inc.(Synthes)receivedaCivilInvestigativeDemandissuedpursuanttotheFalseClaimsAct
fromtheUnitedStatesAttorney’sOfficefortheEasternDistrictofPennsylvania.TheDemandsoughtinformation
regardingallegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproducts.
SyntheshasproduceddocumentsandinformationinresponsetotheDemandandiscooperatingwiththeinquiry.
InOctober2011,theEuropeanCommission(EC)announcedthatitopenedaninvestigationconcerninganagreement
betweenJanssen-CilagB.V.(Janssen-Cilag)andSandozB.V.relatingtothesupplyoffentanylpatchesinTheNetherlands
andwhethertheagreementinfringesEuropeancompetitionlaw.InJanuary2013,theECissuedaStatementof
ObjectionssettingoutfactsregardingapotentialviolationofEUantitrustlaws.Janssen-Cilagispreparingaresponseto
theStatementofObjections.
InApril2012,JanssenPharmaceuticals,Inc.(JPI)receivedaletterrequestingcertaindocumentsfromtheUnitedStates
DepartmentofJusticerelatingtothemarketingandpromotionofDORIBAX®.JPIhasprovideddocumentsandcontinues
tocooperatewiththisgovernmentinquiry.
InMay2012,Acclarent,Inc.(Acclarent)receivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusettsrequestingdocumentsbroadlyrelatingtothesales,marketingandpromotionbyAcclarentofRELIEVA
STRATUS™MicroFlowSpacerproducts.AcclarentiscooperatingwiththeUnitedStatesAttorney’sOfficeinresponding
tothesubpoena.
InAugust2012,DePuyOrthopaedics,Inc.,DePuy,Inc.(nowDePuySynthes,Inc.(DePuySynthes)),andJohnson&
JohnsonServices,Inc.receivedaninformalrequestfromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsandtheCivilDivisionoftheUnitedStatesDepartmentofJusticefortheproductionofmaterialsrelatingto
theASR™XLHipdevice.Thegovernmenthassincemadeadditionalinformalrequestsfortheproductionofdocumentsas
tothedevice.Thegovernmentisinvestigatingwhetheranypersonorentitysubmittedorcausedtobesubmittedfalse
claimsorfalsestatementsaffectingfederalhealthcareprogramsinconnectionwiththemarketinganduseoftheASR™XL
Hipdevice.DePuyOrthopaedics,Inc.,DePuySynthes,andJohnson&JohnsonServices,Inc.havevoluntarilyproduced
documentsinresponsetothegovernment’sinformalrequestsandarefullycooperatingwiththegovernment’scivil
investigation.
InOctober2012,Johnson&JohnsonwascontactedbytheCaliforniaAttorneyGeneral’sofficeregardingamulti-state
AttorneyGeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby
Johnson&Johnsonsubsidiaries.Johnson&Johnsonanditssubsidiarieshavesinceenteredintoatollingagreementwith
the42statesparticipatinginthemulti-stateinvestigation.
64 • Johnson&Johnson2012AnnualReportInDecember2012,Therakos,Inc.(Therakos),formerlyasubsidiaryofJohnson&JohnsonandpartoftheOrtho-Clinical
Diagnostics,Inc.(OCD)franchise,receivedaletterfromthecivildivisionoftheUnitedStatesAttorney’sOfficeforthe
EasternDistrictofPennsylvaniainformingTherakosthattheUnitedStatesAttorney’sOfficewasinvestigatingthesales
andmarketingofUVADEX®(methoxsalen)andtheUVARXTS®Systemduringtheperiod2000tothepresent.The
UnitedStatesAttorney’sOfficerequestedthatOCDandJohnson&Johnsonpreservedocumentsthatcouldrelatetothe
investigation.TherakoswassubsequentlyacquiredbyanaffiliateofGoresCapitalPartnersIII,L.P.OCDandJohnson&
JohnsonretaincertainliabilitiesthatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleofTherakos,
andhavetakenappropriatestepstoretainpotentiallyrelevantdocumentsandwillcooperatewiththeUnitedStates
Attorney’sOffice’sinvestigationwithrespecttosuchactivity.
Inrecentyears,Johnson&JohnsonhasreceivednumerousrequestsfromavarietyofUnitedStatesCongressional
Committeestoproduceinformationrelevanttoongoingcongressionalinquiries.ItisthepolicyofJohnson&Johnsonto
cooperatewiththeseinquiriesbyproducingtherequestedinformation.
GENERALLITIGATION
StartinginJuly2006,fivelawsuitswerefiledinUnitedStatesDistrictCourtfortheDistrictofNewJerseybyvarious
employersandemployeebenefitplansandfundsseekingtorecoveramountstheypaidforRISPERDAL®forplan
participants.Ingeneral,PlaintiffsallegethatJohnson&Johnsonandcertainofitspharmaceuticalsubsidiariesengagedin
off-labelmarketingofRISPERDAL®inviolationofthefederalandNewJerseyRICOstatutes.Inaddition,Plaintiffs
assertedvariousstatelawclaims.Allofthecaseswereconsolidatedintoonecaseseekingclassactionstatus,butshortly
thereafter,oneactionwasvoluntarilydismissed.InDecember2008,theCourtdismissedtheactionsofthefourremaining
plaintiffs.InApril2010,thoseplaintiffsfiledanewconsolidatedclassactionagainstJohnson&JohnsonandJanssen,L.P.
(nowJanssenPharmaceuticals,Inc.);andinMarch2011,thatactionwasdismissed.InApril2011,oneofthoseplaintiffs
filedanoticeofappealwiththeUnitedStatesCourtofAppealsfortheThirdCircuit.ThatappealwasdismissedinJuly
2011.
InApril2009,Ortho-ClinicalDiagnostics,Inc.(OCD)receivedagrandjurysubpoenafromtheUnitedStatesDepartment
ofJustice,AntitrustDivision,requestingdocumentsandinformationfortheperiodbeginningSeptember1,2000through
thepresent,pertainingtoaninvestigationofallegedviolationsoftheantitrustlawsinthebloodreagentsindustry.OCD
compliedwiththesubpoena.InFebruary2011,OCDreceivedaletterfromtheAntitrustDivisionindicatingthatithad
closeditsinvestigationinNovember2010.InJune2009,followingthepublicannouncementthatOCDhadreceiveda
grandjurysubpoena,multipleclassactioncomplaintswerefiledagainstOCDbydirectpurchasersseekingdamagesfor
allegedpricefixing.Thevariouscaseswereconsolidatedforpre-trialpurposesintheUnitedStatesDistrictCourtforthe
EasternDistrictofPennsylvaniaasInreBloodReagentAntitrustLitigation.InAugust2012,theDistrictCourtgranteda
motionfiledbyPlaintiffsforclasscertification.OCDrequestedinterlocutoryreviewoftheclasscertificationdecision,and
inOctober2012,theAppellateCourtgrantedOCD’spetitionforinterlocutoryreview.
InApril2010,aputativeclassactionlawsuitwasfiledintheUnitedStatesDistrictCourtfortheNorthernDistrictof
CaliforniabyrepresentativesofnursinghomeresidentsortheirestatesagainstJohnson&Johnson,Omnicare,Inc.
(Omnicare),andotherunidentifiedcompaniesorindividuals.InFebruary2011,Plaintiffsfiledasecondamendedcomplaint
assertingthatcertainrebateagreementsbetweenJohnson&JohnsonandOmnicareincreasedtheamountofmoneyspent
onpharmaceuticalsbythenursinghomeresidentsandviolatedtheShermanActandtheCaliforniaBusiness&Professions
Code.Thesecondamendedcomplaintalsoassertedaclaimofunjustenrichment.Plaintiffssoughtmultipleformsof
monetaryandinjunctiverelief.Johnson&JohnsonmovedtodismissthesecondamendedcomplaintinMarch2011.The
CourtgrantedthemotioninitsentiretyinAugust2011,dismissingallclaimsassertedbyPlaintiffs.InOctober2011,the
Courtdismissedtheactionwithprejudice.TheplaintiffsfiledanoticeofappealtotheUnitedStatesCourtofAppealsfor
theNinthCircuitinNovember2011.InFebruary2012,Plaintiffsstipulatedtoavoluntarydismissalofthematter,with
prejudice.Pursuanttothetermsofthestipulation,theNinthCircuitdismissedthecaseinitsentiretyinMarch2012.
StartinginMay2010,multiplecomplaintsseekingclassactioncertificationrelatedtotheMcNeilrecallshavebeenfiled
againstMcNeilConsumerHealthcareandcertainaffiliates,includingJohnson&Johnson,intheUnitedStatesDistrictCourt
fortheEasternDistrictofPennsylvania,theNorthernDistrictofIllinois,theCentralDistrictofCalifornia,theSouthernDistrict
ofOhioandtheEasternDistrictofMissouri.TheseconsumercomplaintsallegegenerallythatpurchasersofvariousMcNeil
medicinesareowedmonetarydamagesandpenaltiesbecausetheypaidpremiumpricesfordefectivemedicationsrather
thanlessexpensivealternativemedications.Allbutonecomplaintseekscertificationofanation-wideclassofpurchasersof
thesemedicines,whereasonecomplaint,theHarveycase,seekscertificationofaclassofMOTRIN®IBpurchasersin
Missouri.InOctober2010,theJudicialPanelonMultidistrictLitigationconsolidatedalloftheconsumercomplaints,except
fortheHarveycase,whichwasconsolidatedinMarch2011,intoonelawsuit:Inre:McNeilConsumerHealthcare,etal.,
Johnson&Johnson2012AnnualReport • 65MarketingandSalesPracticesLitigation,forpretrialproceedingsintheUnitedStatesDistrictCourtfortheEasternDistrict
ofPennsylvania.InJanuary2011,theplaintiffsinallofthecasesexcepttheHarveycasefiledaConsolidatedAmendedCivil
ConsumerClassActionComplaint(CAC)namingadditionalpartiesandclaims.InJuly2011,theCourtgrantedamotionby
Johnson&JohnsontodismisstheCACwithoutprejudice,butpermittedtheplaintiffstofileanamendedcomplaintwithin
thirtydaysofthedismissalorder.InAugust2011,theplaintiffsfiledaSecondAmendedCivilConsumerClassAction
Complaint(SAC).InJuly2012,theCourtgrantedJohnson&Johnson’smotiontodismisstheSACwithprejudice.
Separately,inSeptember2011,Johnson&Johnson,Johnson&JohnsonInc.andMcNeilConsumerHealthcareDivisionof
Johnson&JohnsonInc.receivedaNoticeofCivilClaimfiledbyNickFieldintheSupremeCourtofBritishColumbia,
Canada(theBCCivilClaim).TheBCCivilClaimisaputativeclassactionbroughtonbehalfofpersonswhoresidein
BritishColumbiaandwhopurchasedduringtheperiodbetweenSeptember20,2001andthepresentoneormore
variousMcNeilinfants’orchildren’sover-the-countermedicinesthatweremanufacturedattheFortWashingtonfacility.
TheBCCivilClaimallegesthatthedefendantsviolatedtheBCBusinessPracticesandConsumerProtectionAct,and
otherCanadianstatutesandcommonlaws,bysellingmedicinesthatwereallegedlynotsafeand/oreffectiveordidnot
complywithCanadianGoodManufacturingPractices.TheBCplaintiffservedtheiraffidavitsinsupportofclass
certificationinApril2012.ThedefendantsrespondingaffidavitswereservedinJune2012.Thedateforhearingofthe
certificationapplicationhasnotyetbeenscheduled.
InSeptember2010,ashareholder,RonaldMonk,filedalawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyseekingclasscertificationandallegingthatJohnson&Johnsonandcertainindividuals,includingexecutiveofficers
andemployeesofJohnson&Johnson,failedtodisclosethatanumberofmanufacturingfacilitiesfailedtomaintaincurrent
goodmanufacturingpractices,andthatasaresult,thepriceoftheCompany’sstockdeclinedsignificantly.Plaintiffseeks
topursueremediesundertheSecuritiesExchangeActof1934torecoverhisallegedeconomiclosses.InDecember
2011,amotionbyJohnson&Johnsontodismisswasgrantedinpartanddeniedinpart.PlaintiffmovedtheCourtto
reconsiderpartoftheDecember2011ruling.DefendantsfiledanswerstotheremainingclaimsoftheAmended
ComplaintinFebruary2012andthecaseisproceedingtodiscovery.InMay2012,theCourtdeniedPlaintiff’smotionfor
reconsideration.InSeptember2012,PlaintifffiledaSecondAmendedComplaintandJohnson&Johnsonhasmovedto
dismissPlaintiff’sSecondAmendedComplaintinpart.
InApril2011,OMJPharmaceuticals,Inc.(OMJPR)filedalawsuitagainsttheUnitedStatesinUnitedStatesDistrictCourt
fortheDistrictofPuertoRicoallegingoverpaymentoffederalincometaxesforthetaxyearsendedNovember30,1999
andNovember30,2000.OMJPRallegesthattheInternalRevenueServiceerroneouslycalculatedOMJPR’staxcredits
underSection936oftheTaxCode.OMJPRfiledamotionforsummaryjudgment,andtheUnitedStatesfiledacross
motionforsummaryjudgment.InOctober2012,theCourtgrantedtheUnitedStates’motionforsummaryjudgmentand
deniedOMJPR’smotionforsummaryjudgment.OMJPRappealedthisdecision.IfOMJPRlosesthislawsuit,itmayface
liabilityforsubsequenttaxyears.
InAugust2011,anarbitrationpanelruledthatMitsubishiTanabePharmaCorporation(Tanabe),JanssenBiotech,Inc.‘s
(JBI’s)distributorofREMICADE®inJapan,couldseektomodifytheproportionofnetsalesrevenuethatTanabemust
remittoJBIinexchangefordistributionrightsandcommercialsupplyofREMICADE®(theSupplyPrice).Tanabe
commencedthearbitrationagainstCentocorOrthoBiotech,Inc.(nowJBI)in2009pursuanttotheparties’distribution
agreement,whichgrantsTanabetherighttodistributeREMICADE®inJapanandcertainotherpartsofAsia.JBIhas
counterclaimedforanincreaseintheSupplyPrice.AhearingwasheldinNovember2011todeterminetheappropriate
splitofrevenueandthepartiesareawaitingadecision.
Johnson&JohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtundertheComprehensive
EnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,andcomparablestate,localor
foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
SHAREHOLDERDERIVATIVEACTIONS
StartinginApril2010,anumberofshareholderderivativelawsuitswerefiledintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseyagainstcertaincurrentandformerdirectorsandofficersofJohnson&Johnson.Johnson&Johnson
isnamedasanominaldefendant.TheseactionswereconsolidatedinAugust2010intoonelawsuit:InreJohnson&
JohnsonDerivativeLitigation.Additionally,inSeptember2010,anothershareholderderivativelawsuitwasfiledbyMichael
WolininNewJerseySuperiorCourtagainstcertaincurrentandformerdirectorsandofficersofJohnson&Johnson.
Johnson&Johnsonisnamedasanominaldefendantinthisactionaswell.Thepartiestothisactionhavestipulatedthatit
shallbestayeduntiltheInreJohnson&JohnsonDerivativeLitigationiscompletelyresolved.
66 • Johnson&Johnson2012AnnualReportTheseshareholderderivativeactionsaresimilarintheirclaimsandcollectivelytheyassertavarietyofallegedbreachesof
fiduciaryduties,including,amongotherthings,thatthedefendantsallegedlyengagedin,approvedof,orfailedtoremedy
orpreventdefectivemedicaldevices,improperpharmaceuticalrebates,improperoff-labelmarketingofpharmaceutical
andmedicaldeviceproducts,violationsofcurrentgoodmanufacturingpracticeregulationsthatresultedinproductrecalls,
andthattheyfailedtodisclosetheaforementionedallegedmisconductintheCompany’sfilingsundertheSecurities
ExchangeActof1934.Eachcomplaintseeksavarietyofrelief,includingmonetarydamagesandcorporategovernance
reforms.Johnson&Johnsonmovedtodismisstheseactionsonthegrounds,interalia,thattheplaintiffsfailedtomakea
demandupontheBoardofDirectors.InSeptember2011,InreJohnson&JohnsonDerivativeLitigationwasdismissed
withoutprejudiceandwithleavetofileanamendedcomplaint.
Johnson&JohnsonfiledareportintheInreJohnson&JohnsonDerivativeLitigationmatterinJuly2011,preparedbya
SpecialCommitteeoftheBoardofDirectors,whichinvestigatedtheallegationscontainedinthederivativeactionsandin
anumberofshareholderdemandlettersthattheBoardreceivedin2010raisingsimilarissues.TheSpecialCommittee
wasassistedinitsinvestigationbyindependentcounsel.TheSpecialCommittee’sreportrecommended:i)thatJohnson&
Johnsonrejecttheshareholderdemandsandtakewhateverstepsarenecessaryorappropriatetosecuredismissalofthe
derivativelitigationandii)thattheBoardofDirectorscreateanewRegulatoryandComplianceCommitteechargedwith
responsibilityformonitoringandoversightoftheCompany’sHealthCareComplianceandQuality&Compliancesystems
andissues.TheBoardofDirectorsofJohnson&JohnsonunanimouslyadoptedtheSpecialCommittee’s
recommendations,andinApril2012,theBoardofDirectorscreatedtheRegulatory,Compliance&GovernmentAffairs
Committee.
InAugust2011,twoshareholderswhohadsubmittedshareholderdemandlettersin2010filedshareholderderivative
lawsuitsintheUnitedStatesDistrictCourtfortheDistrictofNewJerseynamingvariouscurrentandformerofficersand
directorsasdefendantsandchallengingtheBoard’srejectionoftheirdemands.InNovember2011,theCourt
consolidatedthesetwocasesintoCopelandv.Prince.Johnson&Johnsonsecuredanextensionoftimetorespondtothe
complaint.
TwoadditionalshareholderderivativelawsuitswerefiledinMay2011intheUnitedStatesDistrictCourtfortheDistrictof
NewJersey,andtwoothershareholderderivativelawsuitswerefiledinNewJerseySuperiorCourtinMay2011and
August2011,allnamingcurrentdirectorsofJohnson&JohnsonasdefendantsandJohnson&Johnsonasthenominal
defendant.ThecomplaintsallegebreachesoffiduciarydutiesrelatedtotheCompany’scompliancewiththeForeign
CorruptPracticesActandparticipationintheUnitedNationsIraqOilForFoodProgram,thattheCompanyhassuffered
damagesasaresultofthoseallegedbreaches,andthatthedefendantsfailedtodisclosetheallegedmisconductinthe
Company’sfilingsundertheSecuritiesExchangeActof1934.Plaintiffsseekmonetarydamages,andthestatecourt
plaintiffsalsoseekcorporategovernancereforms.ThefederallawsuitswereconsolidatedinJuly2011intoInreJ&J
FCPADerivativeShareholderLitigation,andanamendedconsolidatedcomplaintwasfiledinAugust2011.InOctober
2011,Johnson&Johnsonmovedtodismisstheconsolidatedfederallawsuitonthegroundsthattheplaintiffsfailedto
makeademandupontheBoardofDirectors.Theplaintiffssecuredanextensionoftimetorespondtothemotion.The
statelawsuitswereconsolidatedinNovember2011intoInreJ&JShareholderDerivativeLitigation,andaconsolidated
complaintwasfiledinDecember2011.InJanuary2012,Johnson&Johnsonmovedtodismissorstaythestatelawsuits
pendingresolutionofthefederallawsuitandmovedtodismissonthegroundthattheplaintiffsfailedtomakeademandon
theBoardofDirectors.InMay2012,theCourtgrantedamotionbyJohnson&Johnsontostaythestatelawsuitspending
resolutionofInreJ&JFCPADerivativeShareholderLitigation.
InJuly2012,thepartiesineachoftheshareholderderivativecasespendinginfederalcourtdiscussedabove(specifically,
InreJohnson&JohnsonDerivativeLitigation,Copelandv.Prince,andInreJ&JFCPADerivativeShareholderLitigation)
filedaStipulationofSettlementtopermanentlyresolvealloftheactionsintheirentirety.InOctober2012,thesettlement
wasapprovedbytheCourt.InNovember2012,anoticeofappealwasfiledintheUnitedStatesCourtofAppealsforthe
ThirdCircuitbyashareholderwhoobjectedtotheapprovalofthesettlementintheDistrictCourtonthegroundsthatthe
lawsuitandthesettlementdidnotprovideanybenefittotheCompany,andthatplaintiffs’counselhadrequestedan
excessivefeeaward.
InJune2012,twoothershareholderswhohadsubmittedashareholderdemandletterinMarch2010,theNewJersey
BuildingLaborersAnnuityandtheNewJerseyBuildingLaborersPensionFunds,filedanadditionalshareholderderivative
lawsuitinNewJerseySuperiorCourtnamingvariouscurrentandformerofficersanddirectorsasdefendantsandalso
challengingtheBoard’srejectionoftheirdemands.Thisshareholderderivativelawsuitpurportstoallegethesameclaims
thatarethesubjectofthesettlementdescribedabove.Thepartiestothisactionhadenteredintoaconsentorderstaying
theactionpendingfinalapprovalofthesettlementdiscussedabove.InNovember2012,theplaintiffsagreedtovoluntarily
dismisstheaction.
Johnson&Johnson2012AnnualReport • 67InSeptember2011,twoadditionalshareholderderivativelawsuitswerefiledintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseybyDonovanSpamerandTheGeorgeLeonFamilyTrustnamingcurrentdirectorsandoneformer
directorofJohnson&JohnsonasdefendantsandJohnson&Johnsonasthenominaldefendant.Theselawsuitsallegethat
thedefendantsbreachedtheirfiduciarydutiesintheirdecisionswithrespecttothecompensationoftheChiefExecutive
Officerduringtheperiodfrom2008through2011,andthatthedefendantsmademisleadingstatementsinthe
Company’sannualproxystatements.Bothoftheselawsuitshavebeenvoluntarilydismissedwithoutprejudice,buta
similarlawsuitonbehalfofTheGeorgeLeonFamilyTrustwasrefiledinJuly2012.Thatlawsuitseeksavarietyofrelief,
includingmonetarydamages,injunctiverelief,andcorporategovernancereforms.Theabovesettlementdoesnotresolve
thesepotentialclaims.TheBoardofDirectors’evaluationoftheseallegationsisongoing.
22. Restructuring
In2011,CordisCorporation,asubsidiaryofJohnson&Johnson,announcedthediscontinuationofitsclinicaldevelopment
programfortheNEVO™Sirolimus-ElutingCoronaryStentandcessationofthemanufactureandmarketingofCYPHER®
andCYPHERSELECT®PlusSirolimus-ElutingCoronaryStentsbytheendof2011.TheCompanywillfocusonother
cardiovasculartherapieswheresignificantpatientneedsexist.
AsaresultoftheabovementionedrestructuringplanannouncedbyCordisCorporation,theCompanyrecorded$676
millioninrelatedpre-taxcharges,ofwhichapproximately$164millionofthepre-taxrestructuringchargesrequirecash
payments.The$676millionofrestructuringchargesconsistsofassetwrite-offsof$512millionand$164millionrelated
toleaseholdandcontractobligationsandotherexpenses.The$512millionofassetwrite-offsrelatetoproperty,plantand
equipmentof$265million,intangibleassetsof$160millionandinventoryof$87million(recordedincostofproducts
sold).TheCordisrestructuringprogramhasbeensubstantiallycompleted.Therestructuringchargewasrecordedinthe
MedicalDevicesandDiagnosticssegment.
68 • Johnson&Johnson2012AnnualReportReport of Independent Registered Public
Accounting Firm
TotheShareholdersandBoardofDirectorsofJohnson&Johnson:
Inouropinion,theaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearnings,
statementsofcomprehensiveincome,statementsofequity,andstatementsofcashflowspresentfairly,inallmaterial
respects,thefinancialpositionofJohnson&JohnsonanditssubsidiariesatDecember30,2012andJanuary1,2012,and
theresultsoftheiroperationsandtheircashflowsforeachofthethreeyearsintheperiodendedDecember30,2012in
conformitywithaccountingprinciplesgenerallyacceptedintheUnitedStatesofAmerica.Alsoinouropinion,the
Companymaintained,inallmaterialrespects,effectiveinternalcontroloverfinancialreportingasofDecember30,2012,
basedoncriteriaestablishedinInternalControl–IntegratedFrameworkissuedbytheCommitteeofSponsoring
OrganizationsoftheTreadwayCommission(COSO).TheCompany’smanagementisresponsibleforthesefinancial
statements,formaintainingeffectiveinternalcontroloverfinancialreportingandforitsassessmentoftheeffectivenessof
internalcontroloverfinancialreporting,includedintheaccompanying“Management’sReportonInternalControlover
FinancialReporting.”OurresponsibilityistoexpressopinionsonthesefinancialstatementsandontheCompany’sinternal
controloverfinancialreportingbasedonourintegratedaudits.Weconductedourauditsinaccordancewiththestandards
ofthePublicCompanyAccountingOversightBoard(UnitedStates).Thosestandardsrequirethatweplanandperform
theauditstoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementand
whethereffectiveinternalcontroloverfinancialreportingwasmaintainedinallmaterialrespects.Ourauditsofthefinancial
statementsincludedexamining,onatestbasis,evidencesupportingtheamountsanddisclosuresinthefinancial
statements,assessingtheaccountingprinciplesusedandsignificantestimatesmadebymanagement,andevaluatingthe
overallfinancialstatementpresentation.Ourauditofinternalcontroloverfinancialreportingincludedobtainingan
understandingofinternalcontroloverfinancialreporting,assessingtheriskthatamaterialweaknessexists,andtesting
andevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassessedrisk.Ourauditsalso
includedperformingsuchotherproceduresasweconsiderednecessaryinthecircumstances.Webelievethatouraudits
provideareasonablebasisforouropinions.
Acompany’sinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe
reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith
generallyacceptedaccountingprinciples.Acompany’sinternalcontroloverfinancialreportingincludesthosepoliciesand
proceduresthat(i)pertaintothemaintenanceofrecordsthat,inreasonabledetail,accuratelyandfairlyreflectthe
transactionsanddispositionsoftheassetsofthecompany;(ii)providereasonableassurancethattransactionsare
recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting
principles,andthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof
managementanddirectorsofthecompany;and(iii)providereasonableassuranceregardingpreventionortimelydetection
ofunauthorizedacquisition,use,ordispositionofthecompany’sassetsthatcouldhaveamaterialeffectonthefinancial
statements.
Becauseofitsinherentlimitations,internalcontroloverfinancialreportingmaynotpreventordetectmisstatements.Also,
projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate
becauseofchangesinconditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
Asdescribedin“Management’sReportonInternalControloverFinancialReporting,”managementhasexcludedSynthes,
Inc.fromitsassessmentofinternalcontroloverfinancialreportingasofDecember30,2012,becauseitwasacquiredby
theCompanyinapurchasebusinesscombinationduring2012.WehavealsoexcludedSynthes,Inc.fromourauditof
internalcontroloverfinancialreporting.Synthes,Inc.isawholly-ownedsubsidiarywhosetotalassetsandtotalrevenues
representapproximately17%and3%,respectively,oftherelatedconsolidatedfinancialstatementamountsasofandfor
theyearendedDecember30,2012.
PricewaterhouseCoopersLLP
NewYork,NewYork
February21,2013
Johnson&Johnson2012AnnualReport • 69Management’s Report on Internal Control
Over Financial Reporting
UnderSection404oftheSarbanes-OxleyActof2002,managementisrequiredtoassesstheeffectivenessofthe
Company’sinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreport,basedonthatassessment,
whethertheCompany’sinternalcontroloverfinancialreportingiseffective.
ManagementoftheCompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial
reporting.TheCompany’sinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe
reliabilityoftheCompany’sfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith
generallyacceptedaccountingprinciples.
Internalcontrolsoverfinancialreporting,nomatterhowwelldesigned,haveinherentlimitations.Therefore,internalcontrol
overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial
statementpreparationandmaynotpreventordetectallmisstatements.Moreover,projectionsofanyevaluationof
effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin
conditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
TheCompany’smanagementhasassessedtheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingas
ofDecember30,2012.Inmakingthisassessment,theCompanyusedthecriteriaestablishedbytheCommitteeof
SponsoringOrganizationsoftheTreadwayCommission(COSO)in“InternalControl-IntegratedFramework”.These
criteriaareintheareasofcontrolenvironment,riskassessment,controlactivities,informationandcommunicationand
monitoring.TheCompany’sassessmentincludedextensivedocumenting,evaluatingandtestingthedesignandoperating
effectivenessofitsinternalcontrolsoverfinancialreporting.
TheCompanyacquiredSynthes,Inc.,anditsconsolidatedsubsidiaries(Synthes)inJune2012.Synthestotalassets,
whichwereprimarilyintangibleassetsandgoodwill,andtotalrevenuesrepresentedapproximately17%and3%,
respectively,oftherelatedconsolidatedfinancialstatementsasofandfortheperiodendedDecember30,2012.Asthe
acquisitionoccurredinJune2012andSyntheswaspreviouslynotsubjecttotherequirementsunderSection404ofthe
Sarbanes-OxleyActof2002,thescopeoftheCompany’sassessmentofthedesignandeffectivenessofinternalcontrol
overfinancialreportingforthefiscalyear2012excludedSynthes.ThisexclusionisinaccordancewiththeSEC’sgeneral
guidancethatanassessmentofarecentlyacquiredbusinessmaybeomittedfromthescopeintheyearofacquisition.
BasedontheCompany’sprocessesandassessment,asdescribedabove,managementhasconcludedthat,asof
December30,2012,theCompany’sinternalcontroloverfinancialreportingwaseffective.
TheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingasofDecember30,2012hasbeenauditedby
PricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,asstatedintheirreport,whichappears
herein.
AlexGorsky DominicJ.Caruso
Chairman,BoardofDirectors VicePresident,Finance
ChiefExecutiveOfficer ChiefFinancialOfficer
70 • Johnson&Johnson2012AnnualReportSummary of Operations and Statistical Data
2002-2012
(DollarsinMillionsExceptPerShare
Amounts) 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Salestocustomers—U.S. $29,830 28,908 29,450 30,889 32,309 32,444 29,775 28,377 27,770 25,274 22,455
Salestocustomers—International 37,394 36,122 32,137 31,008 31,438 28,651 23,549 22,137 19,578 16,588 13,843
Totalsales 67,224 65,030 61,587 61,897 63,747 61,095 53,324 50,514 47,348 41,862 36,298
Costofproductssold 21,658 20,360 18,792 18,447 18,511 17,751 15,057 14,010 13,474 12,231 10,498
Selling,marketingandadministrativeexpenses 20,869 20,969 19,424 19,801 21,490 20,451 17,433 17,211 16,174 14,463 12,520
Researchanddevelopmentexpense 7,665 7,548 6,844 6,986 7,577 7,680 7,125 6,462 5,344 4,834 4,094
In-processresearchanddevelopment 1,163 – – – 181 807 559 362 18 918 189
Interestincome (64) (91) (107) (90) (361) (452) (829) (487) (195) (177) (256)
Interestexpense,netofportioncapitalized 532 571 455 451 435 296 63 54 187 207 160
Other(income)expense,net 1,626 2,743 (768) (526) (1,015) 534 (671) (214) 15 (385) 294
Restructuring – 569 – 1,073 – 745 – – – – –
53,449 52,669 44,640 46,142 46,818 47,812 38,737 37,398 35,017 32,091 27,499
Earningsbeforeprovisionfortaxesonincome $13,775 12,361 16,947 15,755 16,929 13,283 14,587 13,116 12,331 9,771 8,799
Provisionfortaxesonincome 3,261 2,689 3,613 3,489 3,980 2,707 3,534 3,056 4,151 2,923 2,522
Netearnings 10,514 9,672 13,334 12,266 12,949 10,576 11,053 10,060 8,180 6,848 6,277
Add:Netlossattributabletononcontrollinginterest 339 – – – – – – – – – –
Netearningsattributableto
Johnson&Johnson 10,853 9,672 13,334 12,266 12,949 10,576 11,053 10,060 8,180 6,848 6,277
Percentofsalestocustomers 16.1% 14.9 21.7 19.8 20.3 17.3 20.7 19.9 17.3 16.4 17.3
Dilutednetearningspershareofcommonstock(1) $3.86 3.49 4.78 4.40 4.57 3.63 3.73 3.35 2.74 2.29 2.06
Percentreturnonaverageshareholders’equity 17.8% 17.0 24.9 26.4 30.2 25.6 28.3 28.2 27.3 27.1 26.4
Percentincrease(decrease)over
previousyear:
Salestocustomers 3.4% 5.6 (0.5) (2.9) 4.3 14.6 5.6 6.7 13.1 15.3 12.3
Dilutednetearningspershare 10.6% (27.0) 8.6 (3.7) 25.9 (2.7) 11.3 22.3 19.7 11.2 17.7
Supplementarybalancesheetdata:
Property,plantandequipment,net 16,097 14,739 14,553 14,759 14,365 14,185 13,044 10,830 10,436 9,846 8,710
Additionstoproperty,plantandequipment 2,934 2,893 2,384 2,365 3,066 2,942 2,666 2,632 2,175 2,262 2,099
Totalassets 121,347 113,644 102,908 94,682 84,912 80,954 70,556 58,864 54,039 48,858 40,984
Long-termdebt 11,489 12,969 9,156 8,223 8,120 7,074 2,014 2,017 2,565 2,955 2,022
Operatingcashflow 15,396 14,298 16,385 16,571 14,972 15,022 14,248 11,799 11,089 10,571 8,135
Commonstockinformation
Dividendspaidpershare $2.400 2.250 2.110 1.930 1.795 1.620 1.455 1.275 1.095 0.925 0.795
Shareholders’equitypershare 23.33 20.95 20.66 18.37 15.35 15.25 13.59 13.01 10.95 9.25 7.79
Marketpricepershare(year-endclose) $69.48 65.58 61.85 64.41 58.56 67.38 66.02 60.10 63.42 50.62 53.11
Averagesharesoutstanding(millions)
–basic 2,753.3 2,736.0 2,751.4 2,759.5 2,802.5 2,882.9 2,936.4 2,973.9 2,968.4 2,968.1 2,998.3
–diluted 2,812.6 2,775.3 2,788.8 2,789.1 2,835.6 2,910.7 2,961.0 3,002.8 2,992.7 2,995.1 3,049.1
Employees(thousands) 127.6 117.9 114.0 115.5 118.7 119.2 122.2 115.6 109.9 110.6 108.3
(1) AttributabletoJohnson&Johnson.
Johnson&Johnson2012AnnualReport • 71Shareholder Return Performance Graphs
SetforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnontheCompany’sCommonStockfor
periodsoffiveyearsandtenyearsendingDecember31,2012,againstthecumulativetotalreturnoftheStandard&
Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexandtheStandard&Poor’sHealthCareEquipment
Index.Thegraphsandtablesassumethat$100wasinvestedonDecember31,2007andDecember31,2002ineachof
theCompany’sCommonStock,theStandard&Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexand
theStandard&Poor’sHealthCareEquipmentIndexandthatalldividendswerereinvested.
5-Year Cumulative Total
Shareholder Return
$135
Johnson & Johnson
S&P 500 Index
$110
S&P Pharmaceu(cid:2)cal Index
S&P Healthcare Equipment
Index
$85
5-Year CAGR
J&J 4.4%
S&P 500 1.7%
S&P Pharm 5.7%
$60
S&P H/C Equip 1.1% 2007 2008 2009 2010 2011 2012
2007 2008 2009 2010 2011 2012
Johnson&Johnson $100.00 $92.23 $102.63 $102.03 $112.13 $124.24
S&P500Index $100.00 $63.00 $79.67 $91.68 $93.61 $108.59
S&P500PharmaceuticalIndex $100.00 $81.80 $97.03 $97.78 $115.14 $131.75
S&P500HealthcareEquipmentIndex $100.00 $72.36 $93.18 $90.66 $89.93 $105.46
10-Year Cumulative Total
Shareholder Return
$210
Johnson & Johnson
S&P 500 Index $180
S&P Pharmaceu(cid:2)cal Index
$150
S&P Healthcare Equipment
Index
10-Year CAGR
$120
J&J 5.5%
S&P 500 7.1%
S&P Pharm 4.5%
$90
S&P H/C Equip 5.6% 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Johnson&Johnson $100.00 $97.89 $122.52 $118.41 $133.14 $137.95 $127.23 $141.58 $140.75 $154.68 $171.38
S&P500Index $100.00 $128.68 $142.68 $149.69 $173.33 $182.85 $115.20 $145.69 $167.63 $171.17 $198.57
S&P500PharmaceuticalIndex $100.00 $108.78 $100.70 $97.31 $112.74 $117.98 $96.51 $114.48 $115.36 $135.85 $155.45
S&P500HealthcareEquipmentIndex $100.00 $132.04 $148.70 $148.78 $154.92 $162.86 $117.84 $151.76 $147.65 $146.47 $171.76
72 • Johnson&Johnson2012AnnualReportBoard of Directors Senior Management
ALEXGORSKY ALEXGORSKY
Chairman,BoardofDirectors ChiefExecutiveOfficer
Chairman,ExecutiveCommittee
MARYSUECOLEMAN
CHARLESE.AUSTIN
President,UniversityofMichigan
VicePresident,GlobalSupplyChain
JAMESG.CULLEN
DOMINICJ.CARUSO
RetiredPresidentandChiefOperatingOfficer,
VicePresident,Finance
BellAtlanticCorporation
ChiefFinancialOfficer
IANE.L.DAVIS Member,ExecutiveCommittee
SeniorAdvisor,ApaxPartners;FormerChairmanand
DOUGLASK.CHIA
WorldwideManagingDirector,McKinsey&Company
CorporateSecretary
AssistantGeneralCounsel
MICHAELM.E.JOHNS
Professor,EmorySchoolofMedicineandRollins STEPHENJ.COSGROVE
SchoolofPublicHealth;ChancellorandExecutive CorporateController
VicePresidentofHealthAffairsEmeritus,Emory ChiefAccountingOfficer
University
JOAQUINDUATO
SUSANL.LINDQUIST WorldwideChairman,PharmaceuticalsGroup
MemberandFormerDirector,WhiteheadInstitutefor
PETERM.FASOLO
BiomedicalResearch;ProfessorofBiology,
VicePresident,GlobalHumanResources
MassachusettsInstituteofTechnology
Member,ExecutiveCommittee
ANNEM.MULCAHY
KARENA.LICITRA
FormerChairmanandChiefExecutiveOfficer,
WorldwideChairman,GlobalMedicalSolutionsGroup
XeroxCorporation
MICHELORSINGER
LEOF.MULLIN
WorldwideChairman,GlobalOrthopaedicsGroup
RetiredChairmanandChiefExecutiveOfficer,
DeltaAirLines,Inc. JOHNA.PAPA
Treasurer
WILLIAMD.PEREZ
SeniorAdvisor,Greenhill&Co.,Inc.;RetiredPresident SANDRAE.PETERSON
andChiefExecutiveOfficer,Wm.WrigleyJr.Company GroupWorldwideChairman
Member,ExecutiveCommittee
CHARLESPRINCE
RetiredChairmanandChiefExecutiveOfficer, GARYJ.PRUDEN
CitigroupInc. WorldwideChairman,GlobalSurgeryGroup
MICHAELE.SNEED
DAVIDSATCHER
VicePresident,GlobalCorporateAffairs
Director,CenterofExcellenceonHealthDisparities;
Director,SatcherHealthLeadershipInstituteand PAULUSSTOFFELS
Poussaint-Satcher-CosbyChairinMentalHealth,
ChiefScientificOfficer
MorehouseSchoolofMedicine
WorldwideChairman,PharmaceuticalsGroup
Member,ExecutiveCommittee
A.EUGENEWASHINGTON
ViceChancellorofHealthSciences,DeanoftheDavid MICHAELH.ULLMANN
GeffenSchoolofMedicineattheUniversityofCalifornia, VicePresident,GeneralCounsel
LosAngeles(UCLA);ChiefExecutiveOfficerofthe Member,ExecutiveCommittee
UCLAHealthSystem
JESSEJ.WU
RONALDA.WILLIAMS WorldwideChairman,ConsumerGroup
FormerChairmanandChiefExecutiveOfficer,
AetnaInc.PRINCIPALOFFICE COMMONSTOCK JOHNSON&JOHNSONONTHEWEB
OneJohnson&JohnsonPlaza ListedonNewYorkStockExchange
Ourwebsite:www.jnj.com
NewBrunswick,NewJersey08933 StockSymbol:JNJ
(732)524-0400
SHAREHOLDERRELATIONSCONTACT Ourcompanyblog:www.jnjbtw.com
ANNUALMEETING DouglasK.Chia
TheAnnualMeetingofShareholderswilltake CorporateSecretary
Ourhistoryblog:www.kilmerhouse.com
placeonThursday,April25,2013,atthe (732)524-2455
HyattRegencyHotel,TwoAlbanyStreet,New
INVESTORRELATIONSCONTACT www.facebook.com/jnj
Brunswick,NewJersey.Themeetingwill
conveneat10a.m.Allshareholdersasofthe LouiseMehrotra
recorddateofFebruary26,2013arecordially VicePresident,InvestorRelations www.twitter.com/JNJCares
invitedtoattend.AformalNoticeofAnnual (800)950-5089 www.twitter.com/JNJNews
Meeting,ProxyStatementandProxyhave (732)524-6492
www.youtube.com/user/JNJhealth
beensenttoshareholders.
TRANSFERAGENTANDREGISTRAR www.youtube.com/user/jnjenntv
CORPORATEGOVERNANCE Questionsregardingstockholdings,certificate www.linkedin.com/company/
Copiesofour2012AnnualReporton replacement/transfer,dividendsandaddress johnson-&-johnson
Form10-K,QuarterlyReportsonForm10-Q, changesshouldbedirectedto:
andCurrentReportsonForm8-Ktothe ComputershareTrustCompany,N.A.
SecuritiesandExchangeCommission,Proxy 250RoyallStreet Toviewthe2012Johnson&JohnsonAnnualReport,
Statement,andthisAnnualReportare Canton,MA02021 pleasegotowww.2012annualreport.jnj.com
availableonlineatwww.investor.jnj.com/ (800)328-9033or orscanthisQRcode.
sec-filings.cfm,ortoshareholderswithout (781)575-2718(outsidetheU.S.)
charge,uponwrittenrequesttotheSecretary www.computershare.com
atourprincipaladdress,orbycalling
DIVIDENDREINVESTMENTPLAN
(800)950-5089.
ThePlanallowsforfullorpartialdividend
Inaddition,ontheCorporateGovernance reinvestmentandadditionalmonthlycash
sectionofourwebsite,www.investor.jnj.com, investmentsupto$50,000peryearin
shareholderscanviewourRestatedCertificate Johnson&JohnsonCommonStockwithout
ofIncorporation;By-Laws;Principlesof brokeragecommissionsorservicechargeson
CorporateGovernance;ChartersoftheAudit stockpurchases.Ifyouareinterestedin
Committee,Compensation&Benefits participatinginthePlanandneedan
Committee,Nominating&Corporate authorizationformand/ormoreinformation,
GovernanceCommittee,Regulatory, pleasecallComputershareTrustCompany,
Compliance&GovernmentAffairs N.A.at(800)328-9033or(781)575-2718
Committee,andScience,Technology& (outsidetheU.S.).
SustainabilityCommittee;PolicyonBusiness
Conduct(foremployees);CodeofBusiness HEARINGIMPAIRED
Conduct&EthicsforMembersoftheBoard Shareholderswhohaveinquiriesregarding
ofDirectorsandExecutiveOfficers;andother stock-relatedmatterscancommunicate
corporategovernancematerials.Copiesof directlywithComputershareTrustCompany,
thesedocumentsareavailabletoshareholders N.A.viaatelecommunicationsdevice(TDD).
withoutchargeuponwrittenrequesttothe Thetelephonenumberforthisserviceis
Secretaryatourprincipaladdress. (800)952-9245or(781)575-2692(outsidethe
U.S.).
UnderSection302oftheSarbanes-OxleyAct,
wearerequiredtofilecertificationssignedby ELECTRONICDELIVERYNOTIFICATION
theChiefExecutiveOfficerandtheChief TheProxyStatementandour2012Annual
FinancialOfficerasExhibitstoourForm10-K Reportareavailableonourwebsiteat
orForm10-Qforeachfiscalyearorquarter. www.investor.jnj.com/annual-reports.cfm.
Inaddition,wearerequiredtosubmita Insteadofreceivingpapercopiesofnextyear’s
certificationsignedbytheChiefExecutive ProxyStatementandAnnualReportbymail,
OfficertotheNewYorkStockExchange youcanelecttoreceiveane-mailmessagethat
within30daysfollowingtheAnnualMeeting willprovidealinktothosedocumentsonthe
ofShareholders.Copiesofthecertifications Internet.Shareholderswhoholdtheirshares
filedforpreviousyearsarepostedonthe intheirownnamemayenrollintheelectronic
CorporateGovernancesectionofourwebsite, proxyandAnnualReportaccessservicefor
andfuturecertificationswillbeposted futureAnnualMeetingsofShareholders
promptlyuponfiling. onlineat:www.computershare-na.com/green.
Shareholdersthatholdtheirsharesin“street
name”(thatis,inthenameofabank,broker TheJohnson&JohnsonAnnualReportcontainsmanyof
orotherholderofrecord)whowishtoenroll thevaluabletrademarksandtradenamesownedandused
forelectronicaccessmayregisterforonline bytheJohnson&JohnsonFamilyofCompaniesinthe
deliveryofmaterialsbygoingto: UnitedStatesandinter-nationallytodistinguishproducts
enroll.icsdeliver.com/jnj. andservicesofoutstandingquality.
©Johnson&Johnson2013
SHAREHOLDER INFORMATIONOur Credo
We believe our first responsibility istothe doctors,nurses and patients,
tomothers and fathers and all others whouse our products and
services. Inmeeting their needs everything wedo must be of high
quality. We must constantly strivetoreduce our costsin order to
maintain reasonable prices. Customers’orders must be serviced
promptly and accurately. Our suppliers and distributors must have an
opportunity tomake afair profit.
We are responsible toour employees, the men and women whowork
withusthroughout the world.Everyone must be considered asan
individual. We must respect their dignity and recognize their merit. They
must have asense of security in their jobs.Compensation must be fair
and adequate, and working conditions clean, orderly and safe.We must
be mindful of waystohelp our employees fulfill their family
responsibilities. Employees must feel free tomake suggestions and
complaints. There must be equal opportunity for employment,
development and advancement for thosequalified. We must provide
competent management, and their actions must be justand ethical.
We are responsible tothe communities in which welive and workand
tothe world community aswell. We must be good citizens — support
good worksand charities and bear our fair share of taxes.We must
encourage civic improvements and better health and education. We
must maintain in good order the property weare privileged touse,
protecting the environment and natural resources.
Our final responsibility istoour stockholders. Businessmust make a
sound profit. We must experiment withnew ideas. Research must be
carried on,innovative programs developed and mistakes paid for.New
equipment must be purchased, new facilities provided and new
products launched. Reserves must be created toprovide for adverse
times.When weoperate according tothese principles, the
stockholders should realize afair return.
OneJohnson&JohnsonPlaza,NewBrunswick,NewJersey08933